text
stringlengths 65
123k
| url
stringlengths 25
420
| crawl_date
timestamp[us, tz=UTC]date 2022-04-01 01:00:57
2022-09-19 04:34:04
|
|---|---|---|
USF now stands at No. 42 among all public universities and continues to be America's fastest-rising university
TAMPA, Fla., Sept. 12, 2022 /PRNewswire/ -- The University of South Florida has hit an all-time high on U.S. News & World Report's (U.S. News) annual ranking of the best colleges in America. In the new rankings released today, USF sits at No. 42 among all public universities and No. 97 among all universities public or private. This marks the fourth consecutive year that USF has ranked in the top 50 public universities and the first time USF has broken into the top 100 among all universities.
USF continues to hold the distinction of being the fastest-rising university in America, as no university in the country has risen higher in the rankings over the past 10 years than USF. In that time USF has jumped a remarkable 52 spots among public universities, from No. 94 to No. 42, and 73 spots among all universities, from No. 170 to No. 97.
"The University of South Florida is proud to achieve our highest-ever position in U.S. News & World Report's rankings and to once again be recognized as America's fastest-rising university," USF President Rhea Law said. "USF's standing in the rankings is a testament to the hard work and success of our faculty, staff and students, who make an impact in our communities every day. We will continue to help shape the future for our society as we pursue our goal of becoming a top-25 public university."
The U.S. News methodology combines a host of factors, including student graduation and retention rates, class size, student debt, faculty excellence and academic reputation. USF ranks ahead of, or is tied with, six public institutions in the prestigious Association of American Universities, the top 65 research universities in North America that USF aspires to be eligible for future membership.
Reaching its highest position ever in U.S. News rankings continues a historic stretch of achievements for USF. The university recently welcomed its largest-ever class of first-year students and received the most applications from prospective students in history, announced a record-breaking fundraising year and experienced a transformational state budget.
The University of South Florida, a high-impact global research university dedicated to student success, generates an annual economic impact of more than $6 billion. Over the past 10 years, no other public university in the country has risen faster in U.S. News and World Report's national university rankings than USF. Serving more than 50,000 students on campuses in Tampa, St. Petersburg and Sarasota-Manatee, USF is designated as a Preeminent State Research University by the Florida Board of Governors, placing it in the most elite category among the state's 12 public universities. USF has earned widespread national recognition for its success graduating under-represented minority and limited-income students at rates equal to or higher than white and higher income students. USF is a member of the American Athletic Conference. Learn more at www.usf.edu.
View original content to download multimedia:
SOURCE University of South Florida
|
https://www.whsv.com/prnewswire/2022/09/12/university-south-florida-rises-its-highest-position-ever-us-news-amp-world-report-rankings/
| 2022-09-12T05:02:54Z
|
The newest edition ranks 1,500 colleges and universities across the country.
WASHINGTON, Sept. 12, 2022 /PRNewswire/ -- U.S. News & World Report, the global authority in education rankings, today announced the 2022-2023 Best Colleges. Serving as a guide for prospective students and their families, the rankings evaluate 1,500 colleges and universities on up to 17 measures of academic quality.
"For nearly 40 years, the Best Colleges methodology has continuously evolved to reflect changes in the higher education landscape and the interests of prospective students," said Kim Castro, editor and chief content officer at U.S. News. "Guiding that evolution is U.S. News' mission of providing useful data and information to help with one of life's biggest decisions."
This year's rankings include:
- Update to SAT/ACT calculation: In previous editions, SAT/ACT scores were, in effect, reduced if too few students submitted scores. For this edition, U.S. News discontinued this practice. For schools that reported SAT/ACT scores for less than 50% of new entrants in consecutive years, U.S. News did not use those scores to calculate the school's rank. Instead, U.S. News increased the weights of two other ranking factors: high school class standing and average graduation rate. This change was made due to the pandemic's effects on testing in 2020, when the supply and demand for taking the SAT/ACT plummeted, particularly among students from low-income backgrounds.
- More comprehensive measure of faculty resources: The percent of faculty with a terminal degree now includes the share of part-time faculty with a terminal degree. Previously, this metric assessed only full-time faculty. This is a more comprehensive measurement that now includes highly credentialed faculty regardless of their employment contract. This change reflects the growing number of part-time instructors at schools.
- Updates to the ranking categories: About 10% of ranked schools moved into different categories this year. For example, a school ranked previously as a Regional University may now be ranked as a National University. This is due to the "2021 update" from the Carnegie Classification of Institutions of Higher Education, which U.S. News has used since the first Best Colleges rankings in 1983 to compare schools with similar missions.
To calculate the rankings, U.S. News focuses on academic quality and places emphasis on outcome measures – including graduation rates, retention rates, graduate indebtedness and social mobility. Outcomes are the most highly weighted ranking factor, contributing 40% to each school's overall score.
Visit USNews.com/colleges for more information, and share what makes your school the best fit for you on Facebook and Twitter.
2022-2023 U.S. News & World Report Best Colleges
1. Princeton University (NJ)
2. Massachusetts Institute of Technology
3. Harvard University (MA) (tie)
3. Stanford University (CA) (tie)
3. Yale University (CT) (tie)
National Liberal Arts Colleges – Top 3
1. Williams College (MA)
2. Amherst College (MA)
3. Pomona College (CA)
Top Public Schools
National Universities – Top 3
1. University of California, Berkeley (tie)
1. University of California, Los Angeles (tie)
3. University of Michigan – Ann Arbor (tie)
3. University of Virginia (tie)
National Liberal Arts Colleges – Top 3
1. United States Naval Academy
2. United States Military Academy at West Point
3. United States Air Force Academy
Top Performers on Social Mobility
National Universities – Top 3
1. Keiser University (FL)
2. University of California, Riverside
3. California State University – Long Beach
National Liberal Arts Colleges – Top 3
1. Salem College (NC)
2. Lake Forest College (IL)
3. Tougaloo College (MS)
Alongside the rankings, U.S. News publishes editorial content related to the college selection experience. This includes advice on topics such as how parents should approach college visits, when to submit your college application, how to choose a major and more.
On Sept. 21, U.S. News will host a free webinar on the new edition of Best Colleges, with presentations from the lead ranking analysts. Those interested in attending can register here.
To learn more about the U.S. News College Compass, which provides access to the most complete rankings and data, or to order a copy of the "Best Colleges 2023" guidebook (ISBN 979-8-9864591-0-3), visit the online U.S. News store.
U.S. News Academic Insights is a higher education analytical tool that provides instant access to U.S. News historical rankings, tracks important metrics over time, and creates a comparative analysis of peer institutions. For more information, visit ai.usnews.com.
About U.S. News & World Report
U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, Real Estate, News and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C.
View original content to download multimedia:
SOURCE U.S. News & World Report, L.P.
|
https://www.whsv.com/prnewswire/2022/09/12/us-news-announces-2022-2023-best-colleges-rankings/
| 2022-09-12T05:03:00Z
|
GRAND CANYON NATIONAL PARK, Ariz. — A 67-year-old man died after a motorboat flipped over during a Colorado River trip inside Grand Canyon National Park, officials said Sunday.
Park officials said the boat overturned shortly after 2 p.m. Saturday at Bedrock Rapid, which rafting experts say is a large rocky island that divides the river into left and right channels.
Emergency medical personnel treated four people and transported them to the South Rim, park officials said. Authorities say their injuries are not critical.
Park officials identified the deceased as Ronald Vanderlugt, but didn't immediately release his hometown. They said Vanderlugt was on the fifth day of his trip.
Members of the river trip group pulled Vanderlugt out of the water, saw he was unresponsive and began CPR, park officials said. They said park rangers were flown into the location by helicopter, but Vanderlugt could not be resuscitated.
The boat flipped in the rapid when it came up against a rock, said John Dillon, executive director of the Grand Canyon River Outfitters Association, which represents outfitters permitted in the canyon.
Dillon said some of the passengers decided against continuing the trip, operated by Western River Expeditions.
An investigation will be conducted by the National Park Service and the Coconino County Medical Examiner.
Copyright 2022 NPR. To see more, visit https://www.npr.org.
|
https://www.wyomingpublicmedia.org/2022-09-11/a-motorboat-flips-at-grand-canyon-national-park-and-leaves-1-dead
| 2022-09-12T05:47:50Z
|
Man gets 60 years for filming himself raping child
DALLAS (AP) - Authorities say a Dallas-area man was sentenced to 60 years in prison after he pleaded guilty to filming himself raping a 7-year-old girl.
The U.S. attorney’s office for the northern district of Texas said in a statement Friday that Mark Allen Miller, of Rowlett, was sentenced Thursday by a federal judge in Dallas after pleading guilty to two counts of producing child pornography.
The 35-year-old Miller was arrested on Jan. 12 after the girl’s father, with whom Miller was staying, said he walked in on Miller raping the girl, who was 9 years old at the time. The father said he and Miller had been friends for over a decade.
Prosecutors say Miller admitted to police that he had been molesting the girl for two years. They say he also admitted to producing child pornography, including at least five videos and 132 images involving the victim.
The 60 years Miller was sentenced to was the statutory maximum sentence.
Copyright 2022 The Associated Press. All rights reserved. Gray News contributed to this report.
|
https://www.whsv.com/2022/09/12/man-gets-60-years-filming-himself-raping-child/
| 2022-09-12T05:50:32Z
|
...HIGH SURF ADVISORY IN EFFECT FOR SOUTH FACING SHORES OF ALL
ISLANDS BEGINNING MONDAY MORNING...
.A south swell (190 degrees) will build tonight and bring surf
heights to advisory level for south facing shores by Monday
morning. The large surf will continue Monday night and decline
Tuesday.
...HIGH SURF ADVISORY IN EFFECT FROM 6 AM MONDAY TO 6 AM HST
TUESDAY...
* WHAT...Surf 7 to 10 feet.
* WHERE...South facing shores of all Hawaiian Islands.
* WHEN...From 6 AM Monday to 6 AM HST Tuesday.
* IMPACTS...Moderate. Expect strong breaking waves, shore break,
and strong longshore and rip currents making swimming
difficult and dangerous.
PRECAUTIONARY/PREPAREDNESS ACTIONS...
Beachgoers, swimmers, and surfers should heed all advice given by
ocean safety officials and exercise caution.
&&
KAUAI COUNTY, HAWAII (KITV4) - 30 years ago, Hurricane Iniki ravaged the island of Kauai, destroying more than 1,400 homes and leaving behind $3 billion in damage. There is still damage on the island decades later.
“I remember the big glass windows in our living room flexing and breaking. The sound of the hurricane cannot really able to be explained. There was crunching, whistling and hissing,” said Derek Kawakami, Mayor of Kauai County.
Ron Agor, who was as an architect at the time said 20% of the homes and buildings he worked with were completely destroyed – all that was left were slabs and a bathtub.
“Along the coast, we saw buildings that were obviously picked up and pushed back a couple of blocks. We saw roofs torn out and on the west side, we had winds over 200 miles an hour,” said Ron Agor, Agor Jehn Architects, LLC.
Agor is currently working on rebuilding the Coco Palms Hotel that was severely damaged by the hurricane. He said what we can learn 30 years later is knowing the basic designs of our homes and base flood elevation numbers.
Former Mayor Joann Yukimura said Kauai residents were serious about being prepared for Iniki. She said everyone was stocking up on water, food and gasoline.
“Despite being one of the strongest hurricanes in our nation’s history, I think we had a very low mortality rate because people took it seriously and they took shelter,” said former Mayor Yukimura.
Kauai officials urge the community to start planning early. That can include getting meds for kupuna and food for your pets.
Do you have a story idea? Email news tips to news@kitv.com
|
https://www.kitv.com/news/local/hurricane-iniki-left-its-damage-30-years-ago/article_64c9e438-3257-11ed-80fb-2bb838a516b7.html
| 2022-09-12T06:15:09Z
|
PARIS, Sept. 12, 2022 /PRNewswire/ -- The Brattle Group announced today that it has expanded its global reach with the launch of an office in Paris, the economic consultancy's fifth location in Europe and fourteenth across the globe.
"Paris is an important strategic location for many of our clients," said Brattle President David Hutchings. "Our new Paris office reflects Brattle's strong and growing client base in France, and the ever-expanding nature of our global work."
The Paris office will be jointly led by Principal Carlos Lapuerta, a renowned international arbitration and competition expert who has been with Brattle for more than three decades; and Principal Laurent Eymard, an expert with more than fifteen years of experience with merger, antitrust, and state aid cases before the Autorité de la concurrence, French courts, and other European jurisdictions.
"Brattle is committed to providing exceptional services to our European clients, and our ability to do so is further enhanced with a local presence in a city that is globally recognized as an important hub for arbitration," said Mr. Lapuerta, who will split his time between Paris and London.
"The Paris market is also characterized by increasingly complex mergers, antitrust investigations, and civil litigations," added Mr. Eymard, who will split his time between Paris and Brussels. "Our presence here is an ideal complement to our strong global competition team, as we continue to help clients address complex issues in France, across the EU, and worldwide."
Brattle's experts in Paris will work closely with the firm's broad network of internal experts as well as industry experts and academics from across Europe, North America, and the Asia-Pacific region. In the past three years, the firm's experts across the globe have provided oral testimony in arbitrations with an aggregate claim value of over $20 billion. Brattle's competition experts include over 100 internal and external experts specializing in jurisdictions across the world.
Learn more about Brattle's Paris office.
ABOUT BRATTLE
The Brattle Group answers complex economic, finance, and regulatory questions for corporations, law firms, and governments around the world. We are distinguished by the clarity of our insights and the credibility of our experts, which include leading international academics and industry specialists. Brattle has over 500 talented professionals across four continents. For more information, please visit brattle.com.
View original content to download multimedia:
SOURCE The Brattle Group
|
https://www.whsv.com/prnewswire/2022/09/12/brattle-group-expands-europe-with-paris-office/
| 2022-09-12T06:34:02Z
|
GOTHENBURG, Sweden, Sept. 12, 2022 /PRNewswire/ -- Castellum has met all the conditions for securing the Green Equity Designation on Nasdaq Stockholm and has now become the first large property company in the Nordics to be approved and classified as such.
Today, at 9:30 a.m. ET, Castellum's President and CEO Rutger Arnhult will participate in the bell-ringing ceremony at Nasdaq Tower in New York to highlight the green designation of the company's share on Nasdaq Stockholm.
"It is extremely gratifying that Castellum has received this designation in light of how long and how earnestly the company has worked with all kinds of sustainability issues. The company is thoroughly committed, and its goals are set high. By designating Castellum's equity as green, we clearly show the investor market that Castellum's operations are leading the way and making a difference in the greatest challenge of our time, and help investors to make sensible, sustainable decisions," says Rutger Arnhult, Chief Executive Officer of Castellum AB.
"The fact that Castellum's sustainability performance already exceeds the set requirements by a good margin does not mean in any way that going forward, we will slacken the pace in terms of reaching our own long-term goal of becoming climate-neutral by 2030 at the latest. It is natural for Castellum to always be a driving force for new long-term, climate-positive solutions even outside our own industry," says Rutger Arnhult.
The purpose of Nasdaq's Green Equity Designation is to provide increased visibility for investors who are looking for sustainable investments. To meet the criteria for a green share, at least 50 per cent of sales and 50 per cent of investments must be considered green, and less than 5 per cent of assets can be linked to fossil fuels.
Castellum has engaged the research company Cicero Shades of Green as an external party for the review of the application process. Cicero reports that 60 per cent of sales and 62 per cent of investments meet the requirements for being considered green.
"As one of the first major property companies, we are incredibly proud that our share has now received Nasdaq's Green Equity Designation and can thereby be classified as green. Interest in investing sustainably has increased markedly over the last several years, and going forward green investments will be crucial in reaching our shared sustainable development goals and achieving a climate-neutral world," says Filip Elland, Chief Sustainability Officer at Castellum AB.
For further information, please contact:
Rutger Arnhult, CEO Castellum AB, +46 704-58 24 70
Filip Elland, Chief Sustainability Officer Castellum AB, +46 70-320 63 26
About Castellum
Castellum is one of the largest listed property companies in the Nordic region that develops flexible workplaces and smart logistics solutions. As of 30 June 2022, the property value totalled approximately SEK 185 billion, including the ownership share of the Norwegian company Entra ASA. We are active in attractive Nordic growth regions. One of our sustainability goals is to become entirely climate neutral by 2030 at the latest. Castellum is the only Nordic property and construction company elected to the Dow Jones Sustainability Index (DJSI). The Castellum share is listed on Nasdaq Stockholm Large Cap.
Beyond expectations.
www.castellum.se
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Castellum
|
https://www.whsv.com/prnewswire/2022/09/12/castellums-share-receives-green-equity-designation-nasdaq/
| 2022-09-12T06:34:08Z
|
AVENTURA, Fla. and NATICK, Mass., Sept. 12, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it is presenting new preclinical data for its GPC3 Flex-NK™ cell engager antibody in combination with natural killer cells at the European Society of Medical Oncology's annual congress in Paris, France on September 12th, 2022.
The poster is available on both Cytovia and ESMO's websites and will be displayed from 9AM-5PM CET and presented from 12PM-1PM CET on Monday, September 12th, 2022 (Poster Session 13, Hall 4, Abstract 756P).
Background: GPC3 is an oncofetal antigen that is highly expressed in HCC while it is hardly expressed in adult normal tissues except placenta. CYT-303 is a multifunctional bispecific NK cell engager built on our Flex-NKTM scaffold, which engages NK cells through NKp46 and targets GPC3 expressed on tumor cells.
Conclusions:
- CYT-303 showed dose-dependent HCC tumor growth inhibition in PBNK and iNK cell injected HCC tumor models.
- Dose-dependent increases in CYT-303 concentrations in tumor and blood were observed in the PBNK injected HCC tumor model showing the potential for CYT-303 to penetrate solid tumors.
- CYT-303 treated animals showed significant decreases in blood PBNKs suggesting CYT-303 may facilitate trafficking of these cells from blood to the tumor.
- Bell shaped dose-response observed with CYT-303 monotherapy in the PBNK injected HCC tumor model is consistent with CYT-303 in vitro studies showing similar dose-responses for PBNK and HCC tumor binding and tumor cytolysis.
- The linear dose-response observed with CYT-303 combination therapy with iNK cells in the HCC tumor model is consistent with the in vitro linear dose-response observed with iNK combination for cytolysis of HCC tumors.
- CYT-303 treatment resulted in reductions in blood AFP levels in both the PBNK and iNK injected HCC tumor models showing the utility of this biomarker for CYT-303 clinical studies.
- These CYT-303 preclinical proof-of-concept studies support clinical development of CYT-303 in HCC.
About Cytovia Therapeutics
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. The company is developing three types of iPSC-derived (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology.
These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Headquartered in Aventura, FL., Cytovia has research and development laboratories in Natick, MA. The company's own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation and the University of California San Francisco (UCSF).
Cytovia has recently formed CytoLynx Therapeutics, a strategic partnership focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.
Find out more at www.cytoviatx.com and follow us on Facebook, Twitter, LinkedIn, YouTube, and Instagram.
ABOUT HCC
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of death worldwide, with 800,000 new cases diagnosed globally every year. The incidence in Asia is amongst the highest in the world (75%) with 400,000 in China alone. According to the American Cancer Society, it is estimated that there were close to 40,000 new HCC cases in the US in 2022, with almost 30,000 deaths from the disease, which continues to be on the rise. The major risk factors for HCC include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic alcohol consumption, hepatitis B, and hepatitis C.
Despite advances in immunotherapy, with current treatment options including multi-kinase inhibitors (TKI) and checkpoint inhibitors, life expectancy for patients diagnosed with HCC remains very low. The disease is often diagnosed at an advanced stage, with a median survival of approximately 6 to 20 months following diagnosis, and a 5-year survival rate below 10% in the US. Fortunately, new options including cell therapy and bispecific antibodies offer promise towards a cure for liver cancer.
View original content to download multimedia:
SOURCE Cytovia Therapeutics
|
https://www.whsv.com/prnewswire/2022/09/12/cytovia-therapeutics-presents-new-preclinical-data-its-gpc3-flex-nk-cell-engager-antibody-combination-with-natural-killer-cells-esmo-2022-paris/
| 2022-09-12T06:34:15Z
|
BALTIMORE and PALO ALTO, Calif., Sept. 12, 2022 /PRNewswire/ -- Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR.
Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their initial CT scan is negative. Delfi's technology is paired to the study objectives by measuring whether Delfi can identify individuals in Europe's screen-eligible population who are most likely to benefit from a CT scan. The collaboration, initiated and facilitated through a partnership between the Netherlands Cancer Institute ((NKI), with Dr. D. van den Broek as PI) and the institute for DiagNostic Accuracy (iDNA), includes Delfi analyzing the first 9,000 subjects enrolled through the trial in the Netherlands and France (Gustave Roussy) - generating data that can support Delfi's research and subsequent implementation within the European Union.
"One of the goals of our study is to examine how a liquid biopsy test might improve screening in a manner that is cost-effective," said prof. Matthijs Oudkerk, MD, PhD, Chief Scientific Officer at iDNA and leading the Radiology and AI readings of 4ITLR. "We are eager to explore how a low-cost liquid biopsy platform could help us screen more high-risk Europeans."
Based on the results of the NELSON trial, the European Union is expected to initiate a European lung cancer screening program for individuals at risk due to their smoking and age.
"We know that LDCT screening is effective in reducing lung cancer mortality," said Peter B. Bach, Delfi Diagnostics Chief Medical Officer. "This study should lay the groundwork for widespread, cost efficient screening of those at risk in Europe. Delfi is honored to be part of it."
Lung cancer kills more than 380,000 Europeans each year, and more than half of all new lung cancer diagnoses in Europe occur at stage IV, when 5-year survival rates can be as low as 2 percent. But screening older heavy smokers with low-dose CT could save up to 80,000 lives in Europe per year.
About Delfi Diagnostics
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi ("DNA Evaluation of Fragments for early Interception") is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
About The Netherlands Cancer Institute (NKI) and CVV (NKI Center for Early Diagnostics).
The NKI is among the world's foremost comprehensive cancer centers, combining innovative fundamental, translational, and clinical research with dedicated patient care. Our research institute gratefully acknowledges funding from the Dutch Ministry of Health, Welfare and Sport, the Dutch Cancer Society, and individual donors. The NKI Center for Early Diagnostics is an initiative of the NKI. Our Center combines innovation and scientific research to provide certainty in an early stage for risk factors or signs that may indicate cancer.
About iDNA
iDNA is a Contract Research Organization specialized in early-stage lung cancer, and researching new technologies for the early detection and treatment of lung cancer, with comorbidities in cardiovascular diseases and COPD/emphysema. Key to the early detection of lung cancer are high quality lung cancer screening programs and therefore iDNA wants to set the ''golden standard'' for worldwide lung cancer screening. iDNA works with relevant, early-stage, asymptomatic, high- to medium-risk lung cancer (sub)populations, up to a large, multi-national scale. In addition, iDNA provides several services facilitating the required validation of liquid- and imaging biomarkers and/or therapeutics, while working with KOLs and research partners worldwide. iDNA thereby provides leading pharmaceutical, biotech and AI partners with the opportunity to implement their disruptive technology much quicker and more cost-effective, fully capitalizing on the current momentum within the lung cancer screening landscape.
About Gustave Roussy
Ranked as the leading European Cancer Centre and sixth in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient's human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient's life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: a quarter of patients treated are included in clinical trials.
View original content to download multimedia:
SOURCE Delfi Diagnostics
|
https://www.whsv.com/prnewswire/2022/09/12/delfi-diagnostics-selected-liquid-biopsy-partner-4-in-the-lung-run-large-scale-european-lung-cancer-screening-study/
| 2022-09-12T06:34:22Z
|
Dental practices can use the tools as a guide to make their work more environmentally sustainable and by tracking progress they can achieve recognition awards for their efforts.
GENEVA, Sept. 12, 2022 /PRNewswire/ -- FDI World Dental Federation (FDI) today launched a Toolkit for Sustainable Dentistry, to help dental practices understand what actions they can take to ensure their work is environmentally sustainable. By providing dentists and dental teams with the tools and strategies to implement greener practices, as well as track progress, FDI hopes to contribute to reducing the environmental impact of the profession in a tangible way.
The toolkit was developed further to the release of a Consensus Statement on Environmentally Sustainable Oral Healthcare, earlier this year, which outlines the challenges and solutions to improving sustainability in dentistry. It also recognizes that the oral healthcare sector has a responsibility to provide environmentally sustainable care without compromising patient welfare.
"Dentists and dental teams can play an active role in reducing the environmental impact of dentistry, while safeguarding optimal patient care. This online Toolkit for Sustainable Dentistry is a step towards helping dental practices adopt measures to reduce their carbon footprint." said Prof. Ihsane Ben Yahya, FDI President. She continued "I hope that our work today will have a positive impact on our future generations so that they can enjoy a healthy life and planet."
The toolkit was developed as part of FDI's Sustainability in Dentistry project, and consists of an interactive platform that guides users to drive their activities towards more sustainable practices by providing them with practical solutions. Dentists and their teams can undertake different sets of challenges and subsequently earn bronze, silver, or gold recognition awards for their practice. The interactive challenges will give dental teams the tools to raise awareness, implement changes and become more environmentally sustainable. Dental organizations and practices, all around the world, are encouraged to register and make eco-friendly choices as a team to showcase their commitment to our planet.
Picture is available at AP Images (http://www.apimages.com)
Media contact
Charanjit Jagait, FDI Communications & Advocacy Director
cjagait@fdiworlddental.org | Tel.: +41 797967613
About FDI World Dental Federation
FDI World Dental Federation serves as the principal representative body for over one million dentists worldwide. Its membership includes some 200 national dental associations and specialist groups in over 130 countries. FDI has the vision of leading the world to optimal oral health. https://www.fdiworlddental.org/; facebook.com/FDIWorldDentalFederation; twitter.com/FDIWorldDental; https://www.linkedin.com/company/fdiworlddentalfederation
About the Sustainability in Dentistry project
FDI's Sustainability in Dentistry project was established to motivate and inspire commitment to reduce the collective CO2 footprint of dentistry, targeting practitioners, patients, and the supply chain itself. The project will produce a suite of tools and resources for dental practices and patients to be more environmentally sustainable. The Consensus Statement was developed through multi-stakeholder collaboration and has resulted in the development of the Online Toolkit for Sustainable Dentistry to help dental practices reduce their environmental impact. Also being developed is a Pledge for Sustainable Dentistry, which will provide guidelines and objectives for achieving a sustainable procurement and supply procedure. Co-signatories across the supply chain are encouraged to sign the pledge.
The project is supported by our founding partners: Colgate, HALEON, Dentsply Sirona, Procter & Gamble and TePe. www.fdiworlddental.org/sustainability-dentistry
SOURCE FDI World Dental Federation
|
https://www.whsv.com/prnewswire/2022/09/12/fdi-world-dental-federation-launches-toolkit-how-make-dentistry-more-sustainable/
| 2022-09-12T06:34:28Z
|
The integrated ColorVu technology and varifocal lens within the camera guarantees that image brightness and full color always remain consistent as the camera zooms in and out
HANGZHOU, China, Sept. 12, 2022 /PRNewswire/ -- Hikvision today announces new additions to its Pro series PTZ cameras, including the integration of ColorVu technology for the first time in this range. With ColorVu, Hikvision's new Pro series cameras can provide consistent image brightness and full color imaging as the camera zooms in and out. This ensures crystal-clear details and vivid color for distant objects at all times and in all conditions.
Revolutionary "ColorVu + Varifocal" integration
Traditional PTZ cameras often struggle to ensure that images remain bright and clear when they zoom in, especially in low light conditions. This is because the lens aperture gets smaller when operators increase the focal length, reducing the light entering the lens and thereby impacting the clarity of images.
One way to solve this issue is to adjust the size of the aperture as the focal length changes , so that a consistent amount of light can enter the lens . With Hikvision ColorVu technology, a very large fixed aperture is used in the Pro series varifocal PTZ cameras, enabling consistent light and color for imaging as the camera zooms in or out at night.
The new PTZ cameras' fixed F1.2 lens aperture allows as much as 14x more light to enter the lens compared to conventional PTZ units. This same capability also ensures vivid and full-color imaging in light conditions as low as 0.0005 lux: or nearly total darkness. The result is bright and colored images, even in extremely low light conditions or at night.
The camera also has a warm supplemental LED light that further illuminates the field of vision, allowing objects and events to be captured in full color within 100-meter range.
Further increasing security capabilities with AcuSense
In addition to ColorVu, Hikvision Pro series cameras have also been equipped with AcuSense technology, which distinguishes between real security threats and harmless moving objects such as animals, falling leaves, and changing lights.
This smart classification capability means that alarms are only triggered in the event of real security threats. In such cases, the PTZ lens follows the detected threats and sends automated alerts to home or business owners, security teams, or Alarm Receiving Centers (ARCs).
The ability to detect real security threats in real time, and to reduce false alarms, means that security end users and teams can respond to security incidents quickly and effectively and minimize negative impacts. This is especially vital for protecting site perimeters, key entrances and exits, and other restricted areas.
Find out more
Hikvision's new Pro series PTZ cameras are available in 2 / 4/ 8 MP resolutions for a wide range of security needs and budgets. Specifically, the 2 MP models support 20x optical zoom, while 4 / 8 MP models support up to 12x optical zoom. They are ideal for security applications in industrial parks, factories, warehouses, schools and a wide range of other indoor and outdoor locations.
For more information about the new PTZ cameras, please visit the website or contact us today!
View original content to download multimedia:
SOURCE Hikvision
|
https://www.whsv.com/prnewswire/2022/09/12/hikvision-introduces-new-pro-series-ptz-cameras-with-colorvu/
| 2022-09-12T06:34:35Z
|
MILWAUKEE, Sept. 12, 2022 /PRNewswire/ -- Today, ManpowerGroup (NYSE: MAN) released its 2021-2022 Environmental, Social, and Governance (ESG) report—Working to Change the World—citing its reduction of operational emissions by 39%, and marking significant progress toward its 2030 goal of reducing direct emissions (Scope 1 and 2) by 60%, and its value chain emissions by 30%. ManpowerGroup was the first company in its industry to have its climate goals validated by the Science Based Target initiative (SBTi).
The company is also actively driving its social mission where it can have the most impact by addressing the growing structural skills shortage by calling on the global community to work together to accelerate impact in the areas of skills development, employability, and diversity, equity, inclusion, and belonging (DEIB). This will help workers prepare for a future of work that is more digital, more global and fast paced than ever.
An inaugural member of the World Economic Forum's Alliance for CEO Climate Leaders and a founding member of the World Employment Confederation and many others, ManpowerGroup is an active contributor and believer in collective partnership. Its Working to Change the World plan reinforces its values around people and purpose – that meaningful work has the power to change the world – and highlights the many ways the company is making progress within its main pillars:
- Planet (the E in ESG) - by reducing emissions within the company and its value chain
- People & Prosperity (the S in ESG) - by creating talent at scale and providing meaningful, sustainable work for all
- Principles of Governance - by being consistently recognized for its ethical and responsible business practices
"I am proud of the dedication of the ManpowerGroup team to be first in our industry to have our 2030 climate goals validated by SBTi, identifying the levers to reach Net-Zero by 2045 or sooner," says ManpowerGroup Chairman and CEO Jonas Prising. "What is increasingly urgent, however, is the need to make the same kind of global collective progress to address the S - and decades faster than we did on climate action. When you're dealing with people and talent, you're intimately involved in one of the most important decisions in someone's lifetime - the choice of a job, career and income. We know that global economics, current geopolitics, and other accelerating trends are exacerbating the divide between knowledge workers, skilled and unskilled workers. Unless we act now, we will see a further bifurcation of opportunity and wealth creation by gender, race, education, and skill set, which is not good for economic growth and societal well-being."
"We believe in shared ambitions to achieve Net Positive on the S and, therefore, we must take a more science-based approach," says Ruth Harper, chief sustainability and communications officer of ManpowerGroup. "For us, People and Prosperity are core to our business and foundational to our purpose. That's why we believe in Net Positive employment – so that people are better off whether they stay with us or leave. It means being people first by broadening diversity, equity, inclusion, and belonging in the workplace, increasing people's individual employability, and providing them with greater control of their prosperity and earning potential so they know more about themselves, understand their potential, and can be confident they have the skills for today and tomorrow."
Key highlights from the ManpowerGroup 2021-2022 ESG Report:
Planet
- Reduced operational emissions (Scope 1 and 2) by 39% - significant progress towards its goal of 60% reduction by 2030.
- Reported on climate to the Carbon Disclosure Project (CDP) for the 11th year, with scores higher than industry averages.
- Activated Planet teams in its 15 largest markets to align globally and deliver locally on its Climate Action Plan.
People & Prosperity
- Focused on closing the skills gap, improving employability and income prosperity, and building a more resilient, future-ready workforce.
- Transformed 182,000 lives to date through the Manpower MyPath program, providing personalized coaching and upskilling opportunities mapped to in-demand career pathways -- most notably in skilled technical, transportation and logistics as well as business professionals like those in marketing and sales roles.
- Committed to championing diversity, equity, inclusion, and belonging (DEIB) in the workplace and to setting an ambitious goal to reach 50% gender diversity at a global leadership level by 2025. For the past 10 years, ManpowerGroup has exceeded 30% gender diversity in its board of directors and its global workforce in 2021 was 60% female.
Principles of Governance
- Named as one of the World's Most Ethical Companies by Ethisphere for the 13th year in 2022 – the only company in the industry to be awarded this accolade for more than a decade.
- Included on the Dow Jones Sustainability Index for the 12th year.
- To date, achieved platinum, gold, and silver EcoVadis rankings in 24 countries and at the global level.
Find the full report at: www.manpowergroup.com/sustainability.
ABOUT MANPOWERGROUP
ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 75 countries and territories and has done so for over 70 years. We are recognized consistently for our diversity – as a best place to work for Women, Inclusion, Equality, and Disability, and in 2022 ManpowerGroup was named one of the World's Most Ethical Companies for the 13th year – all confirming our position as the brand of choice for in-demand talent.
View original content to download multimedia:
SOURCE ManpowerGroup
|
https://www.whsv.com/prnewswire/2022/09/12/manpowergroup-releases-2021-2022-working-change-world-report-citing-39-reduction-operational-emissions-calls-global-community-collective-action-s-esg/
| 2022-09-12T06:34:42Z
|
The combination of NT-I7 plus pembrolizumab enhances infiltration of PD-1+ T cells
ROCKVILLE, Md., Sept. 12, 2022 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, presented data that suggests that NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells in cold tumors, at the European Society for Medical Oncology (ESMO) Congress in Paris, France, September 9-13, 2022.
While initial results from the phase 2a study NIT-110 had showed that subjects responding to NT-I7 plus pembrolizumab had enhanced lymphocyte infiltration, NeoImmuneTech conducted a new biomarker analysis of the immune-associated changes in the tumor microenvironment (TME) after NT-I7 plus pembrolizumab. The overall goal was to continue to understand how the combination of the long-acting human IL-7 and a checkpoint inhibitor (CPI) can induce a stronger immune response, since CPIs alone are usually considered ineffective in cold tumors with low T cell infiltration.
New data presented in a poster[1] at ESMO Congress 2022 suggest that the combination of NT-I7 and pembrolizumab induces infiltration of CD8 T cells into the tumor microenvironment in more than 80% of analyzed samples. The infiltration of CD8 T cells showed an increase of over 5-fold in over 50% of on-treatment samples after only one dose of NT-I7. Treatment with NT-I7 and pembrolizumab increased the immunogenicity of the TME. The analysis also revealed that treatment-induced reduction of the tumor volume was associated with the magnitude of CD8 T cell infiltration.
Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech said: "We continue to gather evidence to demonstrate that the combination of NT-I7 and pembrolizumab has promising clinical efficacy in very cold and immunosuppressive indications. Our latest data presented at ESMO indicate that the enhanced tumor-specific CD8 T cell infiltration into the tumor microenvironment may trigger enhanced clinical efficacy. This represents an encouraging path to potentially provide one day more therapeutic options to patients with cold tumors where CPIs are usually ineffective."
About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.
About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.
Forward-looking Statements
The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the "Company") that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company's control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.
Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.
[1] Aung Naing - NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells and provides a more immunogenic tumor microenvironment. Biomarker data from the NIT-110 Study.
Poster Number: 1674P, ESMO Congress 2022
View original content:
SOURCE The NeoImmuneTech, Inc
|
https://www.whsv.com/prnewswire/2022/09/12/neoimmunetechs-nt-i7-creates-more-immunogenic-tumor-microenvironment-when-associated-with-pembrolizumab/
| 2022-09-12T06:34:48Z
|
PARIS, Sept. 12, 2022 /PRNewswire/ -- Rivada Space Networks GmbH, a global network company launching a constellation of 600 low-earth-orbit satellites (LEO) to enable secure, global connectivity for governments and enterprises, today announced it has joined the EU Secure Connectivity Programme.
The need for secure and resilient global connectivity increases with the digitization of the economy and society and increasing geopolitical and cybersecurity threats. The European Commission is proposing an ambitious plan for an EU space-based secure communication system that will ensure worldwide uninterrupted access to secure and cost-effective satellite communication services for the protection of critical infrastructures, surveillance and crisis management. It will also allow for the provisioning of commercial services by the private sector to enable advanced, reliable and fast connections for all citizens and businesses across Europe.
German company Rivada Space Networks has submitted its contribution to the Preliminary Market Consultation of the EU Secure Connectivity Programme outlining key attributes of the Rivada Space Network's laser-linked LEO constellation architecture. These include global reach, ultra-security, resilience and low latency. A firm believer in common infrastructure platforms for public use, Rivada is also proposing to use their Open Access Wireless Marketplace platform to optimize the efficient use of the multi-orbit infrastructure capacity among the member countries and stakeholders in the project.
Clemens Kaiser, Chief Programme Officer at Rivada Space Networks commented: "We reviewed the requirements and identified an absolute need to add LEO to this multi-orbit constellation approach, with Ka-band delivering the optimal solution in terms of high-throughput networking."
Rivada Space Networks Chairman Declan Ganley said: "We can ensure extra secure connectivity and the highest data sovereignty as our space network connects any two points in the world via intersatellite laser links, avoiding terrestrial or non-terrestrial infrastructures or the internet. This allows users to communicate through a single global private network running entirely over the constellation without any terrestrial touchpoint other than the user terminals or secure cloud insertion points. The physical separation at the infrastructure level significantly increases cybersecurity and data sovereignty and does so at a global scale. Furthermore, this makes our network disaster resilient since it is independent from any other infrastructure."
He further added: "Security and Open Access are two of the foundational elements of Rivada's vision of a secure and accessible digital future for all. We aim to leverage the strengths of our satellite communication system in combination with our unique, patented Open Access Wireless Market Platform to enable an efficient use of spectrum and facilitate a fair distribution of capacity to member states. We are proud to be joining the EU's multi-stakeholder Secure Connectivity Programme, mobilizing the space and technology sector to provide an independent and secure communications infrastructure for Europe."
* Rivada Space Networks Founder Declan Ganley will be outlining Rivada's game-changing connectivity network with all its advantages for enterprise and government communications at the forthcoming World Satellite Business Week event in Paris on Monday 12th September, 13:45-14:30 Busy Agenda for NGSO Constellations #WSBW 2022. To meet with Rivada, email events@rivada.com
About Rivada Space Networks
Rivada Space Networks GmbH is a disruptive new company set to establish and operate the first truly global low latency point-to-point connectivity network of LEO satellites. By connecting its satellites with lasers, Rivada Space Networks will provide resellers and B2B customers with the ability to securely connect any two points on the globe with low latency and high bandwidth. The constellation of 600 low-earth-orbit communications satellites will represent a fundamental change in the availability of secure, global, end-to-end enterprise-grade connectivity for Telecom, Enterprise, Maritime, Energy and Government Services markets. Rivada Space Networks is a wholly owned subsidiary of Rivada Networks, Inc.
About Rivada Networks, Inc.
Rivada Networks, Inc. is a U.S.-based wireless technology company focused on open access wholesale and the convergence of terrestrial and satellite communications. Founded by Declan Ganley, Rivada Networks, Inc. is active across North and South America as well as Europe. Rivada holds a multitude of patents relating to spectrum sharing, digital spectrum arbitrage, prioritized messaging, open access services and other wireless communications technologies. For more information: www.rivada.com
Follow us on:
LinkedIn: www.linkedin.com/company/rivada-networks/
Twitter: @rivadaspace
Media Contacts:
Brian Carney
Head of Corporate Communications
Rivada Networks
Tel: +1 (207) 256-0386
Email: bcarney@rivada.com
Anna Erhardt
Head of Communications
Rivada Space Networks GmbH
Tel: +49 1517 24 97 010
Email: aerhardt@rivada.com
Melanie Dickie
Director
MPD Communications
Tel: +31 6 14 22 97 62
Email: mdickie@rivada.com
View original content to download multimedia:
SOURCE Rivada Space Networks
|
https://www.whsv.com/prnewswire/2022/09/12/rivada-space-networks-joins-eu-secure-connectivity-programme-provide-ultra-secure-infrastructure-government-amp-enterprise-communications/
| 2022-09-12T06:34:54Z
|
STOCKHOLM, Sept. 12, 2022 /PRNewswire/ -- Skanska signed a contract amendment with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA. The contract amendment is worth USD 63M, about SEK 620M, which will be included in the US order bookings for the third quarter 2022.
The contract includes early site and foundation work and long lead equipment procurement. Construction is underway and completion for work under the amendment is scheduled for the end of June 2023. Work on the OHSU Hospital Expansion Project began in April 2022, and substantial completion is scheduled for 2026.
For further information please contact:
Daniela Arellano, Communications Director, Skanska USA, tel +1 (213) 317 4977
Jacob Birkeland, Head of Media Relations and Public Affairs, Skanska AB, tel +46 (0)10 449 19 57
Direct line for media, tel +46 (0)10 448 88 99
This and previous releases can also be found at www.skanska.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Skanska
|
https://www.whsv.com/prnewswire/2022/09/12/skanska-signs-additional-contract-expand-hospital-portland-oregon-usa-usd-63m-about-sek-620m/
| 2022-09-12T06:35:01Z
|
Free college-level history class for hometown veterans
ROANOKE, Va. (WDBJ) - Veterans across our hometowns are eligible to sign up for a semester of discussion and discovery.
Clemente Course in Humanities is sponsoring a free college-level course for veterans.
They are partnering with Roanoke Public Libraries, Virginia Tech, and the Virginia Museum of Fine Arts.
The class, “Democracy and Duty: Activating Service,” will explore what drives the call to service and how to repurpose that passion.
“When People ask me. I spent 28 years in the military, total. What is it that you miss the most? It’s the community. It’s the camaraderie,” said Veteran and Virginia Tech Professor Jim Dubinsky. “It’s the sense of people knowing who you are, what you do, and why you do it. And I think that’s probably the thing that this provides in addition to an opportunity to learn together.”
The class will be held Tuesdays and Thursdays online and in-person at the Williamson Road Branch Library from 6:30 until 8:30 p.m. You can register by clicking here or email questions to vtvets4humanities@gmail.com.
Copyright 2022 WDBJ. All rights reserved.
|
https://www.whsv.com/2022/09/11/free-college-level-history-class-hometown-veterans/
| 2022-09-12T08:05:22Z
|
Retired nurse saves baby’s life on flight: ‘I’m glad I was there’
ORLANDO (WESH) - A retired nurse jumped into action and saved a 3-month-old infant who had stopped breathing during a flight.
Tamara Panzino was already in vacation mode 35 minutes into her Spirit Airlines flight Thursday night from Pittsburgh to Orlando.
“I was reading my book, not paying attention, had my ear buds in, and I heard a flight attendant say, ‘We have an infant not breathing,’” Panzino said.
Soon after, an announcement came over the speaker, asking if there was a doctor on board. Panzino, a retired registered nurse, got up and ran to the back of the plane to help the 3-month-old girl.
“I didn’t know what I was dealing with. I saw an infant. The head was back and blue lips, and my heart just dropped,” Panzino said.
Even though Panzino is retired, her years of nursing experience kicked in. A round of questions revealed the infant was just lying still when she stopped breathing.
“Gave daddy the baby, held it while I did a sternal rub, kind of an aggressive shake of the chest… trying to make it cry, take a deep breath,” Panzino said.
The group then moved to the front of the plane
“The baby’s color started looking better. I was so glad, but I kept shaking it aggressively,” Panzino said.
Panzino did not have to perform CPR and calls the response a team effort.
“Spirit Airlines had everything we needed right on board, and before we knew it, within a couple minutes, we were home free. The baby was going to be good. The color came back. I heard breathing sounds, a heartbeat. Total relief,” Panzino said.
She is pushing back on being called a hero.
“It’s not a hero thing. It’s a community coming together and everyone volunteering to do what their knowledge can help them do. I’m glad I was there,” she said.
After a day to decompress, Panzino was ready for her and her husband’s Caribbean cruise out of Port Canaveral over the weekend.
Spirit Airlines released a statement thanking Panzino and the crew for their quick response.
Copyright 2022 WESH via CNN Newsource. All rights reserved.
|
https://www.whsv.com/2022/09/12/retired-nurse-saves-babys-life-flight-im-glad-i-was-there/
| 2022-09-12T08:05:28Z
|
VANCOUVER, BC, September 12, 2022 /PRNewswire/ - B2Gold Corp. (TSX: BTO) (NYSE AMERICAN: BTG) (NSX: B2G) ("B2Gold" or the "Company") is pleased to announce that its Board of Directors (the "Board") has declared a cash dividend for the third quarter of 2022 of $0.04 per common share (or an expected $0.16 per share on an annualized basis), payable on September 29, 2022, to shareholders of record as of September 21, 2022. All dollar figures are in United States Dollars unless otherwise indicated.
As part of the long-term strategy to maximize shareholder value, B2Gold expects to declare future quarterly dividends at the same level. This dividend is designated as an "eligible dividend" for the purposes of the Income Tax Act (Canada). Dividends paid by B2Gold to shareholders outside Canada (non-resident investors) will be subject to Canadian non-resident withholding taxes.
The declaration and payment of future dividends and the amount of any such dividends will be subject to the determination of the Board, in its sole and absolute discretion, taking into account, among other things, economic conditions, business performance, financial condition, growth plans, expected capital requirements, compliance with the B2Gold's constating documents, all applicable laws, including the rules and policies of any applicable stock exchange, as well as any contractual restrictions on such dividends, including any agreements entered into with lenders to the Company, and any other factors that the Board deems appropriate at the relevant time. There can be no assurance that any dividends will be paid at the intended rate or at all in the future.
B2Gold is a low-cost international senior gold producer headquartered in Vancouver, Canada. Founded in 2007, today, B2Gold has operating gold mines in Mali, Namibia and the Philippines and numerous exploration and development projects in various countries including Mali, Colombia, Finland and Uzbekistan. B2Gold forecasts total consolidated gold production of between 990,000 and 1,050,000 ounces in 2022.
"Clive T. Johnson"
President & Chief Executive Officer
For more information on B2Gold, please visit the Company website at www.b2gold.com or contact:
The Toronto Stock Exchange and NYSE American LLC neither approve nor disapprove the information contained in this news release.
Production guidance presented in this news release reflect total production at the mines B2Gold operates on a 100% project basis. Please see our Annual Information Form dated March 30, 2022 for a discussion of our ownership interest in the mines B2Gold operates.
This news release includes certain "forward-looking information" and "forward-looking statements" (collectively forward-looking statements") within the meaning of applicable Canadian and United States securities legislation, including: projections; outlook; guidance; forecasts; estimates; statements regarding future or estimated financial and operational performance, gold production and sales, revenues and cash flows, and capital costs (sustaining and non-sustaining) and operating costs, and including, without limitation: total consolidated gold production of between 990,000 and 1,050,000 ounces in 2022. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as "expect", "plan", "anticipate", "project", "target", "potential", "schedule", "forecast", "budget", "estimate", "intend" or "believe" and similar expressions or their negative connotations, or that events or conditions "will", "would", "may", "could", "should" or "might" occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made.
Forward-looking statements necessarily involve assumptions, risks and uncertainties, certain of which are beyond B2Gold's control, including risks associated with or related to: the duration and extent of the COVID-19 pandemic, the effectiveness of preventative measures and contingency plans put in place by the Company to respond to the COVID-19 pandemic, including, but not limited to, social distancing, a non-essential travel ban, business continuity plans, and efforts to mitigate supply chain disruptions; escalation of travel restrictions on people or products and reductions in the ability of the Company to transport and refine doré; the volatility of metal prices and B2Gold's common shares; changes in tax laws; the dangers inherent in exploration, development and mining activities; the uncertainty of reserve and resource estimates; not achieving production, cost or other estimates; actual production, development plans and costs differing materially from the estimates in B2Gold's feasibility and other studies; the ability to obtain and maintain any necessary permits, consents or authorizations required for mining activities; environmental regulations or hazards and compliance with complex regulations associated with mining activities; climate change and climate change regulations; the ability to replace mineral reserves and identify acquisition opportunities; the unknown liabilities of companies acquired by B2Gold; the ability to successfully integrate new acquisitions; fluctuations in exchange rates; the availability of financing; financing and debt activities, including potential restrictions imposed on B2Gold's operations as a result thereof and the ability to generate sufficient cash flows; operations in foreign and developing countries and the compliance with foreign laws, including those associated with operations in Mali, Namibia, the Philippine and Colombia and including risks related to changes in foreign laws and changing policies related to mining and local ownership requirements or resource nationalization generally, including in response to the COVID-19 outbreak; remote operations and the availability of adequate infrastructure; fluctuations in price and availability of energy and other inputs necessary for mining operations; shortages or cost increases in necessary equipment, supplies and labour; regulatory, political and country risks, including local instability or acts of terrorism and the effects thereof; the reliance upon contractors, third parties and joint venture partners; the lack of sole decision-making authority related to Filminera Resources Corporation, which owns the Masbate Project; challenges to title or surface rights; the dependence on key personnel and the ability to attract and retain skilled personnel; the risk of an uninsurable or uninsured loss; adverse climate and weather conditions; litigation risk; competition with other mining companies; community support for B2Gold's operations, including risks related to strikes and the halting of such operations from time to time; conflicts with small scale miners; failures of information systems or information security threats; the ability to maintain adequate internal controls over financial reporting as required by law, including Section 404 of the Sarbanes-Oxley Act; compliance with anti-corruption laws, and sanctions or other similar measures; social media and B2Gold's reputation; risks affecting Calibre having an impact on the value of the Company's investment in Calibre, and potential dilution of our equity interest in Calibre; as well as other factors identified and as described in more detail under the heading "Risk Factors" in B2Gold's most recent Annual Information Form, B2Gold's current Form 40-F Annual Report and B2Gold's other filings with Canadian securities regulators and the U.S. Securities and Exchange Commission (the "SEC"), which may be viewed at www.sedar.com and www.sec.gov, respectively (the "Websites"). The list is not exhaustive of the factors that may affect B2Gold's forward-looking statements
B2Gold's forward-looking statements are based on the applicable assumptions and factors management considers reasonable as of the date hereof, based on the information available to management at such time. These assumptions and factors include, but are not limited to, assumptions and factors related to B2Gold's ability to carry on current and future operations, including: the duration and effects of COVID-19 on our operations and workforce; development and exploration activities; the timing, extent, duration and economic viability of such operations, including any mineral resources or reserves identified thereby; the accuracy and reliability of estimates, projections, forecasts, studies and assessments; B2Gold's ability to meet or achieve estimates, projections and forecasts; the availability and cost of inputs; the price and market for outputs, including gold; foreign exchange rates; taxation levels; the timely receipt of necessary approvals or permits; the ability to meet current and future obligations; the ability to obtain timely financing on reasonable terms when required; the current and future social, economic and political conditions; and other assumptions and factors generally associated with the mining industry.
B2Gold's forward-looking statements are based on the opinions and estimates of management and reflect their current expectations regarding future events and operating performance and speak only as of the date hereof. B2Gold does not assume any obligation to update forward-looking statements if circumstances or management's beliefs, expectations or opinions should change other than as required by applicable law. There can be no assurance that forward-looking statements will prove to be accurate, and actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, no assurance can be given that any events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits or liabilities B2Gold will derive therefrom. For the reasons set forth above, undue reliance should not be placed on forward-looking statements.
View original content to download multimedia:
SOURCE B2Gold Corp.
|
https://www.whsv.com/prnewswire/2022/09/12/b2gold-declares-third-quarter-2022-dividend-004-per-share/
| 2022-09-12T08:05:34Z
|
NEW YORK and LONDON and COPENHAGEN, Denmark, Sept. 12, 2022 /PRNewswire/ -- In response to the growing drive for higher corporate governance standards – both globally and at a national market level - Broadridge Financial Solutions, Inc. (NYSE:BR) today announced it has commenced live operations of its new "golden copy" event notification and direct vote execution service for the Danish market. The service, delivered in collaboration with Danish central securities depositary Euronext Securities Copenhagen, enables global and domestic banks, custodians, wealth managers and local agents to streamline processes and transform operational efficiency throughout the proxy voting lifecycle in Denmark, while supporting their compliance obligations under the Shareholder Rights Directive (SRD II) and Denmark's updated Companies Act.
The Denmark service is the latest addition to the broad and rapidly expanding Direct Market Solutions (DMS) product suite, which focuses on traditional sub custody voting related activities. Firms using the service can depend on the timely and accurate receipt of meeting notifications sourced directly from Euronext, an extended voting window for underlying clients, and greater transparency through the confirmation of votes submitted and cast.
"With ESG as a central component for investors, the need for best-in-class governance and stewardship practices has never been stronger. Our collaboration with Broadridge will provide a more direct chain of proxy communications, and a higher level of service quality for all players," said Niels Hjort Rotendahl, CEO, Euronext Securities Copenhagen. "This comes at a pivotal time due to recent changes to the Danish Companies Act removing the need to present Power of Attorney documents, which we anticipate will lead to a significant rise in shareholder participation at meetings and require our combined services."
"It is our strategic priority to advance shareholder democracy and empower investors – institutional and retail - through the most efficient proxy voting ecosystem for both cross-border and local market participants," said Demi Derem, GM, International Investor Communications Solutions at Broadridge. "Through close collaboration with Euronext Securities Copenhagen, we have again demonstrated the importance of partnering with market leading infrastructure providers to deliver a best-in-class service that transforms and enhances the client experience, while reducing operating costs through our mutualised service model."
Broadridge is firmly committed to expanding its market coverage for proxy processing and extended voting windows, with more markets to follow in 2022 and 2023. This complements Broadridge's existing leading global voting solutions that already provide 100% coverage across 100+ markets.
Broadridge Financial Solutions (NYSE: BR), a global Fintech leader with $5 billion in revenues, provides the critical infrastructure that powers investing, corporate governance, and communications to enable better financial lives. We deliver technology-driven solutions that drive business transformation for banks, broker-dealers, asset and wealth managers and public companies. Broadridge's infrastructure serves as a global communications hub enabling corporate governance by linking thousands of public companies and mutual funds to tens of millions of individual and institutional investors around the world. Our technology and operations platforms underpin the daily trading of more than U.S. $9 trillion of equities, fixed income and other securities globally. A certified Great Place to Work®, Broadridge is part of the S&P 500® Index, employing over 14,000 associates in 21 countries.
For more information about us please visit broadridge.com.
Investors:
W. Edings Thibault
Investor Relations
+ 1 516-472-5129
Edings.thibault@broadridge.com
Media:
Gregg Rosenberg
Corporate Communications
+1 212-918-6966
Gregg.rosenberg@broadridge.com
View original content to download multimedia:
SOURCE Broadridge Financial Solutions, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/broadridge-euronext-collaborate-transform-proxy-voting-lifecycle-denmark/
| 2022-09-12T08:05:40Z
|
GREENLAWN, N.Y., Sept. 12, 2022 /PRNewswire/ -- Compliancy Group is the American Psychological Association's (APA) preferred provider for HIPAA Compliance Solutions.
Through the APA Member Advantage Program, APA Members will be able to automate their HIPAA compliance requirements at a special members-only rate. Compliancy Group's software, the Guard, eliminates the burden of HIPAA in a way that is simple, fast, and affordable.
"We are proud to have been selected as the APA's preferred provider for HIPAA Compliance Solutions. We know that psychology practices are extremely busy and aim to make compliance as quick and painless as possible." - Liam Degnan, Director of Strategic Initiatives, Compliancy Group.
"At APA, one of our key goals is to provide our members with the resources they need to do their work more effectively and efficiently. That is why we are excited to welcome Compliancy Group to the APA Member Advantage program. We look forward to working with them to help our members become, and stay, HIPAA compliant." - Ian King, Chief of Strategic Implementation and Membership, APA.
Managing and understanding HIPAA can be difficult, making proper compliance an onerous task for busy psychology practices. Compliancy Group couples its simplified software solution with dedicated Compliance Coaches to guide psychologists through every step of implementing an effective HIPAA compliance program. By working with a dedicated Coach, psychologists are enabled to become HIPAA compliant quickly through a few self-paced virtual meetings.
Once psychology practices have successfully completed their compliance program, their Coach verifies and validates their efforts, issuing them the HIPAA Seal of Compliance. The Seal can be displayed on a psychology practice's website, email signature, and signage, proving they are dedicated to protecting patient information and have completed the steps required to satisfy the law.
Free HIPAA Resources
HIPAA Compliance Checklist
HIPAA Recipe Book
About Compliancy Group
Compliancy Group gives psychologists confidence in their compliance plan, increasing patient loyalty, and profitability of their business while reducing risk. Find out more about Compliancy Group and HIPAA.
About the American Psychological Association
The American Psychological Association (APA) is the leading scientific and professional organization representing psychology in the United States, with more than 133,000 researchers, educators, clinicians, consultants, and students as its members. Its mission is to promote the advancement, communication, and application of psychological science and knowledge to benefit society and improve lives.
Media Contact: Liam Degnan, 855-854-4722 ext. 530, apa@compliancygroup.com
View original content to download multimedia:
SOURCE Compliancy Group
|
https://www.whsv.com/prnewswire/2022/09/12/compliancy-group-is-american-psychological-associations-preferred-provider-hipaa-compliance-solutions/
| 2022-09-12T08:05:46Z
|
Sam Gioia, a real estate and semiconductor manufacturing veteran, joins as Head of U.S. Manufacturing & Assembly
SEATTLE, Sept. 12, 2022 /PRNewswire/ -- Modulous, a Seattle and London-based construction technology company helping developers and construction firms build modular housing without capital intensive factories, has raised $11.5 million of Series A funding to further grow its physical and digital technologies. The funds were raised from investors that include SFV, the venture arm of German real estate developer Patrizia, Regal London, one of the U.K.'s best-regarded real estate developers, CEMEX Ventures, the venture arm of construction giant CEMEX, Blackhorn Ventures (U.S.), GroundBreak Ventures (Canada), Goldacre (U.K.), and Leela Capital (U.K.). The funding is a rare example of a tech firm increasing its valuation as global markets slide – a testament to growing interest in companies that help decarbonize the real estate and construction industries.
The Modulous software platform automates multifamily real estate project design, costing, and programming – meaning developers, architects, and contractors can figure out pricing and decide whether a site is viable in hours, not weeks. In addition, Modulous has developed a configurable Kit of Parts, which is a set of proprietary sub-assembles that allows developers, architects, and contractors to build modular homes without a fixed factory. The company's end-to-end platform enables 50% faster project delivery, 60% reduction in embodied carbon, and 70% reduction in construction waste.
Modulous also announced today that it has appointed Sam Gioia as Head of U.S. Manufacturing & Assembly. Gioia will oversee the successful U.S. market delivery of the company's modular Kit of Parts for the construction of residential multifamily housing. His role is to develop and manage the firm's supply chain partners that provide the Kit of Parts, and to ensure the physical product's manufacturability.
With a world-class team from the likes of Microsoft, Google, Katerra, Ramboll, 3i, WeWork, Rolls Royce, and Netflix, Modulous has developed a software platform that works in concert with the Kit of Parts to solve major pain points across the three core areas of the home-building process:
- Architecture and design – Modulous' software generates optimized designs and massing for a site and bases these on its physical Kit of Parts. This not only guarantees the technical feasibility of the design, but also provides accurate costs and schedule, all completed in hours. Architects can avoid spending weeks on speculative work, designing schemes that may turn out to not be economically viable, and instead present clients with a variety of options inside a day, upping their chances of winning work while letting them focus on more productive tasks.
- Construction – Modulous' Kit of Parts enables general contractors to deliver multi-story apartment blocks with no upfront investment. Instead of requiring complex and costly factories, Modulous' established supply chain partners deliver sub-assemblies to assembly facilities near site, increasing margin, employing local labor, and improving working capital efficiency.
- Development – The Modulous platform produces 3D visualizations and detailed cost plans, and it will provide developers a real-time analysis of return-on-investment calculations, enabling them to quickly option sites and establish land values driven by accurate data.
Modulous' supply chain partners have focused their collaboration on continuously reducing the number of components required, similarly to the approach previously taken by the automotive and aviation industries. By tracking each of these components, it will be possible to measure and calculate the accurate carbon content of a scheme, and to ensure the use of healthy, non-toxic materials.
"Building energy efficient, affordable housing without the waste and carbon footprint that accompanies traditional construction has never been more critical. Modular delivery is really the only way the housing crisis can be resolved, but, for many, the upfront capital investment has held back the industry's ability to scale. We are keen to prove that by collaborating with each other, the industry can move forward with transparency and cost certainty front and center. That's why we are delighted to have completed this Series A round in the most testing funding environment for decades. It's a testament to the potential we have to solve the housing crisis and to the amazing team we have built."
"The AEC industry is at an inflection point where we are just beginning to see the advantages of Modern Methods of Construction (MMC). The U.S. urgently needs more housing, a clear pathway to net-zero development, and an approach to home-building that enhances communities by integrating new construction seamlessly with the surrounding environment. MMC enables all three goals by standardizing processes to gain manufacturing efficiencies, and by providing modularity in the form of interchangeable variations for wall panels, flooring, and finishes. The Modulous Kit of Parts allows a housing project to be rendered in digital 3D before being manifested physically, which means that project partners can pre-emptively solve all the issues that would normally delay a construction project."
"We are very pleased to back the outstanding Modulous team, which brings together experts across design, construction, and technology. Modulous stands out for us in the way it has brought together the physical and the digital in the built environment by combining its ground-breaking 'Kit of Parts' modular solution with a digital design platform. We are excited to support the company's mission to reinvent the way homes are delivered while prioritizing better outcomes for people and planet."
"We are delighted to be participating in this funding round and entering into a strategic relationship with Modulous. We believe that Modulous is making great strides to truly disrupt the real estate industry as the sector moves towards delivering net zero developments. We are thrilled to be partnering with Modulous, bringing together Regal London's fully integrated delivery model and Modulous' technological innovation – we are excited to be part of this journey."
"Construction, an industry largely unchanged for more than 100 years, is ripe for evolution. Much like the transportation and energy industries, sector-specific innovation relies on a blend of digital and physical technologies that improve productivity and accelerate a net-zero future. Modulous' low-capex, asset-light approach has significant scalability potential, which is why Blackhorn Ventures is so excited to invest in this world-class team."
"We're taking bold steps to try and decarbonize construction and house building. Precision-engineering homes offsite is an important way to drive up quality, reduce safety problems, and cut carbon all at once. Modulous' 'asset-light' approach – that goes direct to suppliers – strips out the need for costly factories, one of the biggest barriers to making offsite manufacturing a mass-market solution. These are universal challenges, and we firmly support the approach of forging partnerships with all relevant stakeholders in the market to solve it together."
"We came on board as an early supply-chain partner because Modulous has built an inspired solution to some of the biggest pain points in construction and development. Their technology removes many of the inefficiencies which, for too long, have stifled innovation, and better promotes demonstratable decarbonized design and build. The future of construction is changing, the U.K. Government, through its purchasing power are driving Modern Methods of Construction (MMC) such as offsite / modular to help improve safety, improved productivity, quality, and sustainability. Our values."
View original content to download multimedia:
SOURCE Modulous
|
https://www.whsv.com/prnewswire/2022/09/12/construction-tech-firm-modulous-raises-115-million-help-developers-architects-general-contractors-build-net-zero-modular-homes-without-factory/
| 2022-09-12T08:05:53Z
|
HAIFA, Israel, Sept. 12, 2022 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ("Elbit Systems") announced today that its U.S. subsidiary, Elbit Systems of America LLC, ("Elbit Systems of America"), was awarded a $10 million contract by SOSSEC, Inc. to begin phase II of the development of an Advanced Low Light Level Sensor (ALLLS) that is intended to be used to support the U.S. Army's Integrated Visual Augmentation System (IVAS) 2.0 for soldiers. The contract will be executed through 2025 and the work will be conducted in Roanoke, Virginia.
SOSSEC, Inc. manages the System of Systems Consortium (SOSSEC) and the Sensors, Communications, and Electronics Consortium (SCEC) through the Other Transaction Authority project life cycle of the U.S. Department of Defense.
Under the contract, Elbit Systems of America will develop multiple prototype cameras for laboratory and field testing and experimentation by its Night Vision team. The ALLLS is a critical component to the U.S. Army's IVAS 2.0 concept that integrates next-generation situational awareness tools and high-resolution digital sensors to deliver a single operating picture. The IVAS 2.0 is intended to be a significantly enhanced head-up display dramatically improving how a soldier senses the surrounding environment and makes critical decisions in the battlefield.
Raanan Horowitz, President and CEO of Elbit Systems of America, said, "Innovation is what we do. Our workforce understands that breakthrough innovations require bold ideas and execution. We are committed, company-wide, to developing new capabilities for our customers. We're excited to focus on the ALLLS project and accomplish the U.S. Army's needs, while learning new methodologies along the way."
About Elbit Systems
Elbit Systems Ltd. is an international high technology company engaged in a wide range of defense, homeland security and commercial programs throughout the world. The Company, which includes Elbit Systems and its subsidiaries, operates in the areas of aerospace, land and naval systems, command, control, communications, computers, intelligence surveillance and reconnaissance ("C4ISR"), unmanned aircraft systems, advanced electro-optics, electro-optic space systems, EW suites, signal intelligence systems, data links and communications systems, radios, cyber-based systems and munitions. The Company also focuses on the upgrading of existing platforms, developing new technologies for defense, homeland security and commercial applications and providing a range of support services, including training and simulation systems.
For additional information, visit: https://elbitsystems.com, follow us on Twitter or visit our official Facebook, Youtube and LinkedIn Channels.
Company Contacts:
Joseph Gaspar, Senior EVP – Business Management
Tel: +972-77-2948661
j.gaspar@elbitsystems.com
Dr. Yaacov (Kobi) Kagan, EVP & Chief Financial Officer
Tel: +972-77-2946663
kobi.kagan@elbitsystems.com
Rami Myerson, Director, Investor Relations
Tel: +972-77-2948984
rami.myerson@elbitsystems.com
David Vaaknin, VP, Head of Corporate Communications
Tel: +972-77-2946691
david.vaaknin@elbitsystems.com
IR Contact:
Ehud Helft
Kenny Green
GK Investor Relations
Tel: 1-646-201-9246
elbitsystems@gkir.com
This press release may contain forward–looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Israeli Securities Law, 1968) regarding Elbit Systems Ltd. and/or its subsidiaries (collectively the Company), to the extent such statements do not relate to historical or current facts. Forward-looking statements are based on management's current expectations, estimates, projections and assumptions about future events. Forward–looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions about the Company, which are difficult to predict, including projections of the Company's future financial results, its anticipated growth strategies and anticipated trends in its business. Therefore, actual future results, performance and trends may differ materially from these forward–looking statements due to a variety of factors, including, without limitation: scope and length of customer contracts; governmental regulations and approvals; changes in governmental budgeting priorities; general market, political and economic conditions in the countries in which the Company operates or sells, including Israel and the United States among others; changes in global health and macro-economic conditions; differences in anticipated and actual program performance, including the ability to perform under long-term fixed-price contracts; changes in the competitive environment; and the outcome of legal and/or regulatory proceedings. The factors listed above are not all-inclusive, and further information is contained in Elbit Systems Ltd.'s latest annual report on Form 20-F, which is on file with the U.S. Securities and Exchange Commission. All forward–looking statements speak only as of the date of this release. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company does not undertake to update its forward-looking statements.
Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies. All other brand, product, service and process names appearing are the trademarks of their respective holders. Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of Elbit Systems Ltd. or any third party, except as expressly granted herein.
View original content:
SOURCE Elbit Systems Ltd.
|
https://www.whsv.com/prnewswire/2022/09/12/elbit-systems-america-awarded-10-million-contract-develop-advanced-night-vision-sensor/
| 2022-09-12T08:06:00Z
|
HAIFA, Israel , Sept. 12, 2022 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ("Elbit Systems") announced today that its U.S. subsidiary, Elbit Systems of America LLC, ("Elbit Systems of America"), was awarded an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract with a maximum potential value of up to approximately $49 million, to provide 120mm mortar systems for the U.S. Army. The contract will be executed in Fort Worth, Texas over a period of five years. An initial delivery order of approximately $10 million has been issued under this ID/IQ contract, to be executed over a two-year period.
The contract was awarded following the successful completion of a previous contract of this type that was awarded to the company in 2016.
Raanan Horowitz, President and CEO of Elbit Systems of America, said, "Being a trusted provider of choice for critical missions and needs is part of our vision. I am honored the U.S. Army continues to value the solutions our company provides to U.S. Soldiers and we look forward to a continued partnership."
About Elbit Systems
Elbit Systems Ltd. is an international high technology company engaged in a wide range of defense, homeland security and commercial programs throughout the world. The Company, which includes Elbit Systems and its subsidiaries, operates in the areas of aerospace, land and naval systems, command, control, communications, computers, intelligence surveillance and reconnaissance ("C4ISR"), unmanned aircraft systems, advanced electro-optics, electro-optic space systems, EW suites, signal intelligence systems, data links and communications systems, radios, cyber-based systems and munitions. The Company also focuses on the upgrading of existing platforms, developing new technologies for defense, homeland security and commercial applications and providing a range of support services, including training and simulation systems.
For additional information, visit: https://elbitsystems.com, follow us on Twitter or visit our official Facebook, YouTube and LinkedIn Channels.
Company Contacts:
Joseph Gaspar, Senior EVP – Business Management
Tel: +972-77-2948661
j.gaspar@elbitsystems.com
Dr. Yaacov (Kobi) Kagan, EVP & Chief Financial Officer
Tel: +972-77-2946663
kobi.kagan@elbitsystems.com
Rami Myerson, Director, Investor Relations
Tel: +972-77-2948984
rami.myerson@elbitsystems.com
David Vaaknin, VP, Head of Corporate Communications
Tel: +972-77-2946691
david.vaaknin@elbitsystems.com
IR Contact:
Ehud Helft
Kenny Green
GK Investor Relations
Tel: 1-646-201-9246
elbitsystems@gkir.com
This press release may contain forward–looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Israeli Securities Law, 1968) regarding Elbit Systems Ltd. and/or its subsidiaries (collectively the Company), to the extent such statements do not relate to historical or current facts. Forward-looking statements are based on management's current expectations, estimates, projections and assumptions about future events. Forward–looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions about the Company, which are difficult to predict, including projections of the Company's future financial results, its anticipated growth strategies and anticipated trends in its business. Therefore, actual future results, performance and trends may differ materially from these forward–looking statements due to a variety of factors, including, without limitation: scope and length of customer contracts; governmental regulations and approvals; changes in governmental budgeting priorities; general market, political and economic conditions in the countries in which the Company operates or sells, including Israel and the United States among others; changes in global health and macro-economic conditions; differences in anticipated and actual program performance, including the ability to perform under long-term fixed-price contracts; changes in the competitive environment; and the outcome of legal and/or regulatory proceedings. The factors listed above are not all-inclusive, and further information is contained in Elbit Systems Ltd.'s latest annual report on Form 20-F, which is on file with the U.S. Securities and Exchange Commission. All forward–looking statements speak only as of the date of this release. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company does not undertake to update its forward-looking statements.
Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies. All other brand, product, service and process names appearing are the trademarks of their respective holders. Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of Elbit Systems Ltd. or any third party, except as expressly granted herein.
View original content:
SOURCE Elbit Systems Ltd.
|
https://www.whsv.com/prnewswire/2022/09/12/elbit-systems-america-awarded-49-million-idiq-contract-supply-mortar-systems-us-army/
| 2022-09-12T08:06:06Z
|
STOCKHOLM, Sept. 12, 2022 /PRNewswire/ -- Electrolux is initiating a cost reduction program on the back of weaker-than-expected market demand and weak earnings in the third quarter. The cost measures are expected to result in a material positive earnings contribution in 2023. Ricardo Cons, currently Head of Business Area Latin America, has been appointed Head of Business Area North America.
Market demand for core appliances in Europe and the US so far in the third quarter is estimated to have decreased at a significantly accelerated pace compared with the second quarter, driven by the impact of high inflation on consumer durables purchases and low consumer confidence. High retailer inventory levels have amplified the impact of the slowdown in consumer demand.
In combination with supply chain imbalances resulting in significant production inefficiencies and increased costs, the third quarter earnings for the Group are expected to decline significantly compared to the second quarter 2022 also excluding the one-time cost to exit the Russia market. This has been driven mainly by Europe and North America. Business Area North America is expected to report an operating loss in the third quarter exceeding the loss in the second quarter.
Since market demand for 2023 is expected to continue to be weak in both regions, the Board has today decided to initiate a Group-wide cost reduction program addressing both variable and structural costs. The program, which starts immediately, will focus on reducing variable costs, with special attention to eliminating cost inefficiencies in our supply chain and production. The structural cost reductions will primarily take place in Europe and North America and include prioritization and efficiency measures leveraging recent organizational changes which took effect July 1. The measures include increasing productivity in operations as well as optimizing the R&D portfolio, administration, sales and marketing activities.
In business area North America, the strategy to strengthen and broaden our product offering with consumer experience innovations remains. However, the production transformation with two new facilities and several new product platforms, in combination with the particularly challenging supply chain conditions in the region, require additional measures to return to stability and profitability. A turnaround program will therefore be conducted under the leadership of Ricardo Cons, who has been appointed new Head of Business Area North America. Ricardo Cons has successfully led the transformation of the Electrolux business in Latin America over the last six years. He succeeds Nolan Pike, who takes up a new position continuing to report to Anna Ohlsson-Leijon. A new leader of Electrolux Latin America is anticipated to be appointed shortly.
The Group cost reduction program and the North American turnaround program are expected to result in a material positive earnings contribution from both Cost efficiency and Investments in innovation and marketing in 2023. More information on cost reduction targets for 2023, as well as a potential material restructuring cost, will be communicated in the third quarter interim report published on October 28.
The share buyback program initiated on May 2, 2022, was completed on September 2. Given the current market environment, the Board does not intend to initiate additional share buybacks before the AGM 2023.
Telephone conference
Electrolux will today hold a telephone conference at 10.00 CET, with comments from Jonas Samuelson, President and CEO, followed by a Q&A session.
- To only listen to the telephone conference, use the link:
OR
- To both listen to the telephone conference and ask questions, use the link:
This is information that AB Electrolux is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 12-09-2022 08:45 CET.
For further information, please contact:
Sophie Arnius, Investor Relations, +46 70 590 80 72
Paul Palmstedt, Corporate Communications, +46 70 593 92 83
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Electrolux
|
https://www.whsv.com/prnewswire/2022/09/12/electrolux-cost-reduction-program-management-changes/
| 2022-09-12T08:06:18Z
|
Positive clinical data presented in a mini-oral session at ESMO
Safety profile of the combination was generally similar to Libtayo monotherapy
TARRYTOWN, N.Y., Sept. 12, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive data from multiple expansion cohorts of an initial Phase 1 trial for an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo® (cemiplimab) in advanced melanoma. The results were shared in a mini-oral session at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.
"After regulatory approvals of our PD-1 inhibitor Libtayo in two advanced non-melanoma skin cancers, we are expanding our efforts in dermato-oncology to address advanced melanoma," said Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron. "Combining LAG-3 and PD-1 inhibition has shown promise in advanced melanoma but achieving response rates above 50% has been challenging. In two independent dose expansion cohorts from a Phase 1 clinical trial of patients naïve to PD-1 or PD-L1 inhibitors, our LAG-3 inhibitor fianlimab combined with Libtayo demonstrated greater than 60% response rates. Notably, the safety profile for this combination appears in line with Libtayo monotherapy. A Phase 3 trial in first-line metastatic melanoma is currently enrolling patients, and we look forward to opening additional trials with this combination in the near future."
Data presented at ESMO were from three dose expansion cohorts in advanced melanoma, including two that enrolled patients who had not previously been treated with a PD-1 or PD-L1 inhibitor (PD-1/PD-L1-naïve) and one of patients who had received prior PD-1 or PD-L1 inhibitor therapy (PD-1/PD-L1-experienced). The objective response rate (ORR) in the PD-1/PD-L1-experienced cohort was 13%. Results from the PD-1/PD-L1-naïve cohorts were as follows:
- In updated results for one cohort (n=40), a 62.5% ORR (25 of 40 patients; 6 complete reponses [CR], 19 partial responses [PR]). Median duration of response (DOR) was not reached (range: 12 months to not evaluable [NE]) and the median progression-free survival (PFS) was 24 months (95% confidence interval [CI], 4 months to NE), per Kaplan-Meier estimates.
- In a newly presented independent confirmatory cohort (n=40), a 65% ORR (26 of 40 patients; 1 CR, 25 PRs). The median DOR (range: 6 months to NE) and median PFS (95% CI, 7.5 to NE) were not reached, per Kaplan-Meier estimates.
Tumor responses were based on RECIST 1.1 criteria and per investigator assessment. AEs of any grade in the two PD-1/PD-L1-naïve cohorts (n= 80) occurred in 96% of patients, with 29% considered serious. The most common immune-mediated AEs in ≥15% patients were rash (n=19) and pruritus (n=12). AEs that were ≥grade 3 occurred in 40% of patients. The treatment discontinuation rate due to AEs was 16%, with two deaths considered possibly related to treatment (colitis and cardiac shock).
The potential use of fianlimab and Libtayo described above is investigational, and safety and efficacy of this combination have not been evaluated by any regulatory authority.
About Regeneron in Oncology
At Regeneron, we're applying more than three decades of scientific innovation with the goal of developing paradigm-changing therapies for patients with cancer. Our oncology portfolio is built around two foundational approaches – our approved PD-1 inhibitor Libtayo and investigational bispecific antibodies – which are being evaluated both as monotherapies and in combination with emerging therapeutic modalities. Together, they provide us with unique combinatorial flexibility to develop potentially synergistic treatments for a wide range of solid tumors and blood cancers.
If you are interested in learning more about our clinical trials, please contact us (clinicaltrials@regeneron.com or 844-734-6643) or visit our clinical trials website.
About fianlimab
Fianlimab is a fully human monoclonal antibody targeting the immune checkpoint receptor LAG-3 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In melanoma, LAG-3 expression on cancer cells is associated with therapeutic resistance to PD-1 inhibitors. Fianlimab is being investigated in combination with Regeneron's PD-1 inhibitor Libtayo to determine whether concurrent blockade of LAG-3 and PD-1 can help overcome this resistance and release the brakes on T cell activation.
About Libtayo
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. In the U.S. and other countries Libtayo is indicated in certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC), as well as in advanced cervical cancer in Canada and Brazil. As of July 1, 2022, Libtayo is developed and marketed globally by Regeneron.
In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. Food and Drug Administration (FDA). Outside of the U.S. the generic name of Libtayo in its approved indication is cemiplimab.
The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either conventional or novel therapeutic approaches for other solid tumors and blood cancers. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.
U.S. FDA-approved Indications Libtayo is a prescription medicine used to treat people with:
- A type of skin cancer called advanced CSCC that has spread or cannot be cured by surgery or radiation.
- A type of skin cancer called BCC:
- A type of lung cancer called NSCLC. Libtayo may be used as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high "PD-L1" and your tumor does not have an abnormal "EGFR", "ALK "or "ROS1" gene.
It is not known if Libtayo is safe and effective in children.
About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create approximately one in five of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes REGEN-COV® (casirivimab and imdevimab), Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb) and Inmazeb™ (atoltivimab, maftivimab and odesivimab-ebgn).
IMPORTANT SAFETY INFORMATION AND INDICATION FOR U.S. PATIENTS
What is the most important information I should know about Libtayo?
Libtayo is a medicine that may treat certain cancers by working with your immune system. Libtayo can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.
Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:
- Lung problems: cough, shortness of breath, or chest pain
- Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, or severe stomach area (abdomen) pain or tenderness
- Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than normal
- Hormone gland problems: headache that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, or changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
- Kidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, or loss of appetite
- Skin problems: rash, itching, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat, or genital area, fever or flu-like symptoms, or swollen lymph nodes
- Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with Libtayo. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles, confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs, double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight, persistent or severe muscle pain or weakness, muscle cramps, low red blood cells, or bruising
- Infusion reactions that can sometimes be severe. Signs and symptoms of infusion reactions may include: nausea, chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain, or facial swelling.
- Rejection of a transplanted organ. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.
- Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with Libtayo. Your healthcare provider will monitor you for these complications.
Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with Libtayo. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with Libtayo if you have severe side effects.
Before you receive Libtayo, tell your healthcare provider about all your medical conditions, including if you:
- have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome are pregnant or plan to become pregnant. Libtayo can harm your unborn baby
Females who are able to become pregnant:
- Your healthcare provider will give you a pregnancy test before you start treatment.
- You should use an effective method of birth control during your treatment and for at least 4 months after your last dose of Libtayo. Talk with your healthcare provider about birth control methods that you can use during this time.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Libtayo.
- are breastfeeding or plan to breastfeed. It is not known if Libtayo passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of Libtayo.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of Libtayo include muscle or bone pain, tiredness, rash, and diarrhea. These are not all the possible side effects of Libtayo. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals and Sanofi at
1-877-542-8296.
Please see full Prescribing Information, including Medication Guide.
About Regeneron
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.
For more information, please visit www.Regeneron.com or follow @Regeneron on Twitter.
Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators' ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without Libtayo® (cemiplimab) in combination with fianlimab; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron's Products and Regeneron's Product Candidates; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Libtayo in combination with fianlimab for the treatment of advanced melanoma; safety issues resulting from the administration of Regeneron's Products (such as Libtayo) and Regeneron's Product Candidates (such as fianlimab) in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products (such as Libtayo) from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including those discussed or referenced in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials or therapeutic applications; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection, Dupixent® (dupilumab), and Praluent® (alirocumab)), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2021 and its Form 10-Q for the quarterly period ended June 30, 2022. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
View original content:
SOURCE Regeneron Pharmaceuticals, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/fianlimab-lag-3-inhibitor-combined-with-libtayo-cemiplimab-demonstrates-greater-than-60-response-rates-two-independent-cohorts-patients-with-advanced-melanoma-nave-pd-1-or-pd-l1-inhibitors/
| 2022-09-12T08:06:25Z
|
Joining a rare subset of startup unicorns with 9-figure recurring revenues, Fireblocks performance underscores digital asset adoption at scale in the Web3 economy
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Fireblocks (www.fireblocks.com), an easy-to-use platform to create innovative products on the blockchain and manage day-to-day crypto operations, announced today that its 2022 Annual Recurring Revenue (ARR) has surpassed $100 million just four years after the company's inception and three years since Fireblocks' first product went into market. This achievement places Fireblocks among a rare subset of SaaS unicorns — including Slack and Twilio — that have reached this coveted valuation milestone in less than five years.
Founded on a mission to enable every business to easily and securely support digital assets and cryptocurrencies, Fireblocks' explosive growth runs congruent to the overwhelming interest in decentralized finance, blockchain, and Web3 technologies from the world's largest banks, consumer brands, gaming companies, fintechs, startups, and enterprises.
"For the digital asset industry, 2022 has been a year of consolidation as well as tremendous growth," said Fireblocks Co-founder and CEO, Michael Shaulov. "We saw an unprecedented volume of new market entrants, including fintechs, Web3 startups, banks, and PSPs. Because of Fireblocks' MPC custody and treasury management technology, which has become one of the most fundamental pieces of infrastructure for the digital asset ecosystem, we have seen first-hand the innovation happening among fintechs, Web3 start-ups, banks, and PSPs who are diligently bringing new digital asset products to market. We will continue growing our secure and scalable product suites to meet this market demand and support every business joining the decentralized economy."
"Fireblocks' growth is a testament to the quality of its product and the dedication of the team building it," said Michelle Bailhe, Partner at Sequoia. "As crypto becomes increasingly integrated into global financial infrastructure, Fireblocks will continue to grow in importance, enabling businesses to deliver secure crypto products for customers around the world, ranging from crypto and fintech startups to large financial institutions."
Fireblocks is the only platform that eliminates a single point of failure and insulates digital assets from cyberattacks, internal collusion, and human error using a patent-pending multi-layer security approach. As digital assets and crypto enter into mainstream consciousness, Fireblocks' MPC-CMP technology has become widely adopted by some of the world's most recognized institutions and cutting-edge start-ups such as BNP Paribas, Six Digital Exchange, ANZ Bank, FIS, Checkout.com, MoonPay, Animoca Brands, and Wirex. In 2022, over 1,500 organizations deployed Fireblocks' technology to protect customer and investor funds, strengthen digital asset security, and streamline day-to-day crypto operations.
"Essentially, businesses — from startups to enterprises — reach out to Fireblocks in order to maximize security in their technology stack so that they may focus on their core competencies: building innovative services and products for their customers while maintaining agility and the ability to react quickly to headwinds," said Idan Ofrat, Fireblocks' Chief Technology Officer and Co-founder. "As we look to the future, we are committed to delivering the same secure, easy-to-use and scalable solution for emerging market entrants and use cases such as stablecoin issuance, NFT treasury management, and crypto payments."
"Fireblocks offers critical infrastructure for a wide range of companies looking to build out digital asset operations, including games, fintechs, banks and more," said Arjun Balaji, an Investment Partner with Paradigm. "At Paradigm, we're committed to supporting organizations like Fireblocks that empower developers and ultimately make Web3 more user-friendly and secure."
Stay in the know and subscribe to Fireblocks' Weekly Newsletter, Fireblogs, here https://www.fireblocks.com/blog/.
Learn more about how Fireblocks can power your digital asset business here: https://www.fireblocks.com/.
About Fireblocks
Fireblocks is an enterprise-grade platform delivering a secure infrastructure for moving, storing, and issuing digital assets. Fireblocks enables exchanges, lending desks, custodians, banks, trading desks, and hedge funds to securely scale digital asset operations through the Fireblocks Network and MPC-based Wallet Infrastructure. Fireblocks serves over 1,500 financial institutions, has secured the transfer of over $3 trillion in digital assets, and has a unique insurance policy that covers assets in storage & transit. Some of the biggest trading desks have switched to Fireblocks because it's the only solution that CISOs and Ops Teams both love. For more information, please visit www.fireblocks.com.
View original content to download multimedia:
SOURCE Fireblocks
|
https://www.whsv.com/prnewswire/2022/09/12/fireblocks-surpasses-100-million-arr-milestone-cementing-its-status-saas-centaur/
| 2022-09-12T08:06:31Z
|
- Shasqi's lead asset, SQ3370 is designed to activate doxorubicin at the tumor site and established click chemistry in humans
- Phase 1 data presented at ESMO Congress 2022 show SQ3370 is well-tolerated among patients receiving up to approximately 12 times the standard dose of doxorubicin (Dox); dose escalation continues
- The unprecedented therapeutic index of SQ3370, the first agent that allows the administration of over 5 times conventional Dox, unlocks the opportunity to exploit the full potential of the target
- High dose levels of SQ3370 show novel immune-regulatory effects that could treat both local and metastatic lesions
SAN FRANCISCO, Sept. 12, 2022 /PRNewswire/ -- Shasqi, a clinical-stage biotechnology company developing oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC ®) platform announced today it has opened the Phase 2 of their Phase 1/2a clinical study to further assess SQ3370 in anthracycline- naïve patients. The Phase 2 study follows the company's presentation at the European Society for Medical Oncology (ESMO) Congress, held September 9-13, 2022, evaluating the safety, tolerability, maximum tolerated dose, and recommended Phase 2 dose for SQ3370 in patients with locally advanced and/or metastatic solid tumors (NCT04106492).
"We are encouraged by the promising results from our Phase 1 study and preclinical data which indicate that click chemistry in humans has the potential to revolutionize cancer care by expanding the therapeutic index of anti-cancer therapies such as doxorubicin," said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi. "We look forward to further exploring the safety and efficacy of our lead candidate SQ3370 at unprecedented dose levels in the Phase 2 study."
The Phase 1 clinical data were presented as a poster during the congress:
- Abstract Title: Phase 1 Clinical & Immunologic Data of SQ3370 in Advanced Solid Tumors
- Presentation Number: 1499P
- Poster Session Title: Phase 1 Clinical & Immunologic Data of SQ3370 in Advanced Solid Tumors
- Link to full poster details here.
Key Phase 1 study findings include:
- SQ3370 was well tolerated among 27 DLT evaluable patients receiving up to 12x (1x equals 75mg/m2/cycle of Dox molar equivalents); maximum tolerated dose has not been reached
- Among patients treated with a least one cycle of SQ3370, no protocol defined dose-limiting toxicities, including anthracycline myelosuppression and gastrointestinal (GI) toxicity, were observed and no treatment emergent adverse events (TEAEs) that led to death were considered related to SQ3370; the most frequent Grade ≥3 TEAE was anemia
- The highest doses tested of SQ3370 led to immune activation in soft tissue sarcomas which are considered immunologically cold tumors, validating preclinical findings of SQ3370 previously published:
"Early data has shown that click chemistry allows for the release of doxorubicin at the tumor site to generate anti-tumor responses. Phase 1 results showing that SQ3370 is well-tolerated among a heavily pretreated patient population further validate this clinical approach and the importance of investigating SQ3370 as a potential treatment option in patients with anthracycline-sensitive- and other solid tumors," said Sant P. Chawla, M.D., FRACP, Principal Investigator, and Head, Sarcoma Oncology Center in Santa Monica, California."
Shasqi is excited to open the Phase 2 study of SQ3370 in anthracycline-naïve patients with advanced soft tissue sarcomas, relapsed or recurrent squamous-cell head and neck cancer, platinum refractory ovarian cancer recurrent and/or metastatic uterine carcinoma, or uterine sarcoma. For more information, visit www.shasqi.com
Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer with tumor-localized therapies by pioneering the use of click chemistry in humans. Click chemistry is a term that describes chemical reactions in which 2 compounds rapidly react with each other; ignoring everything else around them.
Shasqi's proprietary CAPAC platform enables precise oncology therapeutics to reach unprecedented doses at the tumor site with a strong safety profile in two steps. First, the CAPAC platform localizes a click chemistry reagent (activator) to the tumor. Then protodrugs (attenuated drugs activated by click chemistry) are infused systemically. When the protodrug reaches the activator, the payload is released at the tumor site.
The lead asset, SQ3370 has established click chemistry in humans and uses a powerful chemotherapeutic, doxorubicin, as the payload. Shasqi's CAPAC Platform, when applied to a broad range of existing and experimental cancer drugs, is designed to reach unprecedented doses and unlock novel beneficial biological effects.
View original content to download multimedia:
SOURCE Shasqi, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/shasqi-advances-sq3370-phase-2-solid-tumors/
| 2022-09-12T08:06:38Z
|
New record set for largest toy truck sentence
BOISE, Idaho, Sept. 12, 2022 /PRNewswire/ -- Truckstop set a new GUINNESS WORLD RECORDS title for the largest toy truck sentence in celebration of National Truck Driver Appreciation Week, September 11-17. National Truck Driver Appreciation Week is a time where the country celebrates and shows appreciation for the hardworking truck drivers who help keep America running. Using more than 2,000 branded big rig toy trucks, Truckstop spelled 'Truck drivers are the rockstars of the road!' at their Boise, Idaho office on September 9, 2022.
"I was excited to join the team at Truckstop for their record-breaking GUINNESS WORLD RECORDS title attempt," says Michael Empric, official adjudicator from Guinness World Records. "Seeing 2,098 toy trucks spelling out a sentence recognizing truck drivers for their crucial work was officially amazing!"
"Truck drivers are the backbone of America. We wanted to do something big to show how much we appreciate them, and there isn't anything much bigger than setting a GUINNESS WORLD RECORDS title," said Kendra Tucker, chief executive officer, Truckstop. "We appreciate the long hours and sacrifices truck drivers make. They truly are the rockstars of the road."
The GUINNESS WORLD RECORDS title for the largest toy truck sentence, officially the longest toy car sentence, stretched more than 65 feet wide and almost 14 feet tall and took more than 30 Truckstop employees to accomplish.
The toy trucks will be donated to Western Idaho Community Action Partnership (WICAP), a non-profit serving several counties in Idaho since 1965. Their programs serve community members of all ages, and the toy trucks will be donated to local children in need ahead of and during the holiday season.
For more information about how Truckstop is celebrating National Truck Driver Appreciation Week, visit https://truckstop.com/rockstars.
About Guinness World Records
What's the fastest game bird in Europe? This was the question that inspired the founding of Guinness World Records back in 1955. Starting with a single book published from a room above a gym, GWR has grown to become a global multimedia brand, with offices in London, New York, Miami, Beijing, Tokyo, and Dubai. Today, we deliver world class content, not just through Books, but via TV shows, Social Media and Live Events. Every year, our in-house consultancy helps thousands of brands, businesses, and organisations to harness the power of record-breaking and deliver award-winning campaigns and business solutions – engaging audiences, creating captivating, shareable content and telling authentic stories that generate genuine media impact. To find out more about record-breaking for businesses, visit https://www.guinnessworldrecords.com/business-marketing-solutions/
About Truckstop
Truckstop is a trusted partner for carriers, brokers, and shippers, empowering the freight community through a platform of innovative solutions for the entire freight lifecycle to increase efficiency, automate processes, and accelerate growth. As one of the industry's largest neutral freight marketplaces, Truckstop provides the customer service as well as scale of quality loads and trucks to give customers of all sizes, whether on the road or in the office, the transparency and freedom to build lasting relationships and grow their businesses. To learn how Truckstop is helping move the freight community forward, visit https://truckstop.com.
View original content to download multimedia:
SOURCE Truckstop Group LLC
|
https://www.whsv.com/prnewswire/2022/09/12/truckstop-sets-new-guinness-world-records-title-honor-national-truck-driver-appreciation-week/
| 2022-09-12T08:06:44Z
|
Public gets chance to view queen’s coffin in Edinburgh
LONDON (AP) - Queen Elizabeth II’s grandson Prince Harry hailed her Monday as a “guiding compass” and praised her “unwavering grace and dignity,” as members of the public were to get the chance to pay their respects to the monarch when her coffin lies at rest at St. Giles’ Cathedral in Edinburgh.
The personal statement, posted on Harry and his wife Meghan’s Archwell website, said he cherished their times together “from my earliest childhood memories with you, to meeting you for the first time as my Commander-in-Chief, to the first moment you met my darling wife and hugged your beloved greatgrandchildren.”
Amid acrimony in the House of Windsor, Harry quit as a senior royal and moved to the U.S. two years ago. On Saturday, there was a possible sign of a reconciliation as Harry and Meghan joined his brother Prince William and sister-in-law Catherine in meeting mourners outside Windsor Castle.
Harry’s statement came at the start of another day steeped in the historic pageantry and pomp that follows the death of a British sovereign.
King Charles III was starting the day speaking to lawmakers at Parliament in London before flying to Scotland.
Hundreds of lawmakers crowded into the 1,000-year-old Westminster Hall at the Houses of Parliament for a service in which Parliament will offer its condolences to the king, and he will reply.
On Sunday, thousands of people lined streets and roadsides as the oak coffin was borne from the late queen’s beloved Balmoral Castle summer retreat, where she died on Thursday, to Edinburgh.
The new king will fly to Edingburgh later and will walk behind his mother’s coffin as it is slowly transported from Holyroodhouse to St. Giles’ Cathedral, where the crown of Scotland will be placed on the coffin ahead of a service of prayer and reflection on the life and 70-year reign of the widely cherished monarch.
The queen’s coffin will lie at the cathedral for 24 hours, giving members of the public a chance to file past and pay their respects. On Tuesday, it will be flown to London where the coffin will lie in state at the Houses of Parliament Palace from Wednesday afternoon until the morning of the funeral on Sept. 19.
Authorities already have issued rules and guidelines for people wanting to pay their respects in London, with a long queue expected.
After visiting Scotland, Charles embarks on a tour of the other nations that make up the United Kingdom — he visits the Northern Ireland capital, Belfast, on Tuesday and Wales on Friday.
Harry’s statement ended on a poignant note alluding to the death last year of his grandfather, Prince Philip, saying that “We, too, smile knowing that you and grandpa are reunited now, and both together in peace.”
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/09/12/public-gets-chance-view-queens-coffin-edinburgh/
| 2022-09-12T09:36:44Z
|
Leading Attorneys from Two Firms Establish Baker Donelson's Second South Carolina Location
CHARLESTON, S.C., Sept. 12, 2022 /PRNewswire/ -- Baker Donelson has launched a new location in Charleston, South Carolina, with the addition of four attorneys from two well-respected firms.
Joining Baker Donelson as shareholders in the Firm's new Charleston location are corporate attorney J. Ashley Cooper and employment attorney Jennifer K. Dunlap, both previously with Parker Poe, and health law attorneys Alissa Fleming and Catherine F. Wrenn, both previously with Womble Bond Dickinson.
This is Baker Donelson's second new office in the Carolinas in less than a year. In October 2021, the Firm added a team of health care attorneys in Raleigh/Research Triangle, launching its first North Carolina location. Baker Donelson has maintained a location in Columbia, South Carolina, since 2016.
"Charleston is a vibrant and fast-growing market that is critically important to serving our clients with South Carolina operations," said Baker Donelson Chair and CEO Timothy M. Lupinacci. "Establishing a foothold there leverages our capabilities in areas such as manufacturing, global trade, health care, and energy. We're proud to have such an outstanding group of attorneys launch our Charleston office, and we look forward to working with them as we continue to build on our presence across the Carolinas."
Baker Donelson's Chief Growth Officer Mark A.B. Carlson said, "Our firm is intensely focused on recruiting leading attorneys across our footprint in an extremely competitive market for talent. This expansion is an example of the broader growth trajectory we have implemented and will continue to pursue. We look forward to partnering with these exceptional attorneys to drive client and attorney growth across South Carolina, North Carolina, and beyond."
In launching this new location, Baker Donelson has established temporary office space, but the Firm plans a larger permanent office in the coming months to accommodate further additions in Charleston.
Mr. Cooper, who will serve as managing shareholder of the Charleston office, chaired the Energy Industry Team at his previous firm. He represents companies with energy interests before the Federal Energy Regulatory Commission (FERC), the North American Electric Reliability Corporation (NERC), and state utility commissions. He counsels clients on a range of compliance, transactional, and litigation matters. He works on new and emerging energy technologies and emerging solutions. His previous experience includes serving as chief compliance officer and assistant general counsel for a Fortune 500 energy-based holding company and as legislative director and counsel to former U.S. Senator Ernest F. Hollings.
Mr. Cooper said, "I first learned of Baker Donelson's strong reputation when I worked in Washington, D.C. I am excited to offer clients the expanded resources of a national law firm that understands our market needs."
Ms. Dunlap is an employment attorney with more than 20 years of experience in handling employment and business disputes in federal and state courts for clients in the manufacturing, technology, health care, banking, and hospitality industries. She advises businesses on all issues related to employment, including drafting employment agreements, handbooks, and policies. Her litigation experience includes serving as lead counsel in lawsuits involving allegations of discrimination, harassment, and retaliation tied to race, gender, sexual orientation, national origin, age, disability, whistleblowing, and veteran status.
The addition of Ms. Fleming and Ms. Wrenn marks the latest expansion of Baker Donelson's nationally recognized Health Law practice. Beyond the addition of the six-lawyer health team in North Carolina, the Firm has made nine other health law hires across the Firm's footprint in the past year.
Ms. Fleming's practice touches on almost every aspect of health care operations, including regulatory compliance; operations and risk management; certification; reimbursement and Medicare and Medicaid repayment audits and voluntary repayments; investigations and disclosures under the CMS and OIG self-disclosure protocols involving potential violations of the Fraud and Abuse Anti-kickback Statute; confidentiality of medical information and HIPAA; facility licensing; and certification of need. In addition to her health care practice, Ms. Fleming also counsels and represents public and private employers on employment issues.
Ms. Wrenn litigates cases for businesses and health care providers, including physicians, hospitals, skilled nursing facilities, and assisted living facilities. Her practice includes advising clients on regulatory compliance and handling matters that involve Medicare fraud, wrongful death, personal injury, negligence, breach of contract, and breach of warranty. Ms. Wrenn represents clients at all stages of litigation and has significant trial and appellate experience.
Baker Donelson is a national law firm with more than 650 attorneys and public policy advisors representing more than 30 practice areas to serve a wide range of legal needs. Clients receive knowledgeable guidance from experienced, multi-disciplined industry and client service teams, all seamlessly connected across 23 offices in Alabama, Florida, Georgia, Louisiana, Maryland, Mississippi, North Carolina, South Carolina, Tennessee, Texas, Virginia, and Washington, D.C.
View original content to download multimedia:
SOURCE Baker Donelson
|
https://www.whsv.com/prnewswire/2022/09/12/baker-donelson-launches-charleston-office-with-addition-four-south-carolina-shareholders/
| 2022-09-12T09:36:50Z
|
TEL AVIV, Israel, Sept. 12, 2022 /PRNewswire/ -- Cipia (TASE: CPIA), a leading provider of AI computer vision in-cabin automotive solutions, today announced that it is collaborating with Intel India's Intel® Onboard Fleet Services, a comprehensive fleet safety SaaS solution exclusively designed for Indian commercial vehicle fleets. Cipia-FS10 will add Driver Monitoring features to the SaaS solution and initial deployments are underway in leading commercial fleets in India.
The Cipia-FS10 is a hardware and software solution that offers an advanced in-cabin video telematics and driver monitoring system as an aftermarket solution for the fleet industry. The Cipia-FS10 utilizes computer vision and artificial intelligence (AI) to monitor the driver's state behind the wheel, detecting driver ID, drowsiness, distraction and driver actions like phone and seatbelt use.
Intel® Onboard Fleet Services is a comprehensive fleet safety solution focused on Indian commercial vehicle fleets. Leveraging Artificial Intelligence, Intel® Onboard Fleet Services safeguards fleets and steps up operations efficiency to deliver true business advantage. The solution combines advanced driver assistance systems (ADAS), telematics, and driver monitoring systems (DMS) to enable safer and more efficient fleet management.
Yehuda Holtzman, CEO of Cipia, said, "Cipia's collaboration with Intel India is an important milestone for commercial vehicle safety. Together, we're deploying the most advanced technology to protect fleet companies, drivers, and other road users. We're ready to bring our solution to more Indian commercial fleets, providing a safer experience to drivers and other road users across the country."
Kishore Ramisetty, Vice President & General Manager, Vertical Solutions and Services Group at Intel Corporation, said, "Intel is happy to collaborate with Cipia to improve road safety at scale. Fleet owners are taking steps to ensure their drivers and vehicles are safe on the road. Intel® Onboard Fleet Services is a comprehensive solution that makes this commitment to road safety a reality."
Cipia and Intel are ready to bring the combined solution to more fleets in the market.
About Cipia:
Cipia is a leading provider of intelligent sensing solutions that use edge-based computer vision and AI for safer and better mobility experiences. The company focuses on the automotive in-cabin environment, offering Driver Sense – driver monitoring system, Cabin Sense – occupancy monitoring systems and Cipia-FS10 – a driver monitoring and video telematics device for fleets. Over a decade of research and development stands behind the company's proprietary market-leading computer vision technology. Cipia is constantly pushing the boundaries of what intelligent sensing solutions can see and accomplish, for better and safer mobility.
Cipia Company Contacts:
Lazer Cohen
lazer@westraycommunications.com
347-753-8256
Liat Rostock
Liat.R@cipia.com
Logo: https://mma.prnewswire.com/media/1361126/Cipia_Logo_v1.jpg
View original content:
SOURCE Cipia
|
https://www.whsv.com/prnewswire/2022/09/12/cipia-collaborates-with-intel-india-aftermarket-driver-monitoring-systems/
| 2022-09-12T09:36:56Z
|
Audited ESG Report 2022 shows accelerated progress toward industry-leading targets for 2025
GENEVA, Sept. 12, 2022 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, today releases its annual Environmental, Social and Governance (ESG) Report, tracking progress toward the group's groundbreaking sustainability targets. Fiscal Year (FY) 2022 was marked by strong sustainability performance across the Group's three key pillars, climate, nature, and people, backed by growing, best-in-class independent evaluation and reinforced ESG governance.
"I am proud that we continued to accelerate our industry-leading ESG actions despite the challenging economic climate and kept making measurable progress toward our 2025 targets, even exceeding them for renewable ingredients and Living Wage," said Gilbert Ghostine, CEO Firmenich. "Our Firmenich Inclusive Capitalism business model is gaining more traction and proving more and more relevant in today's world. Every year, new climate extremes are having a growing impact across the globe: Firmenich's bold environmental ambition is a vital business investment today and for the future."
"Firmenich ESG strategy keeps progressing across our own operations and along our supply chain," said Thomas Andro, Senior Director, Corporate Sustainability. "Furthermore, consumer demand for sustainable products is a structural growth trend in our industry and Firmenich's outstanding ESG credentials, combined with our leadership and innovation in natural and renewable ingredients, are becoming even more relevant for our customers as they progress with their own sustainability roadmaps."
FY2022 ESG Performance Highlights
- Acting on Climate Change: Firmenich was one of only two companies to receive a fourth consecutive CDP Triple A rating for climate, water, and forests. Three manufacturing sites, in Norway, Singapore and South Africa, were carbon neutral in FY22, all operating without the use of offsets. Firmenich maintained decoupling of growth in manufacturing output from its CO2 emissions: in FY22, Scope 1 and 2 emissions were reduced by 36.1% vs. 2017, and the new ingredients sites reduced Scope 1 and 2 emissions by 12.2% vs. 2020. The Group maintained 100% Renewable Electricity in its operations including in new acquisitions[1]. Firmenich aims to reach carbon neutrality in its direct operations by 2025, absolute carbon emissions reduction by 2030 in line with limiting temperature rise to 1.5˚C, as well as net-zero emissions by 2039 across its direct operations and value chain (Scopes 1, 2, and 3). Its net-zero targets were validated by the Science-Based Targets initiative (SBTi) in August 2022, making Firmenich the first company in its industry to receive SBTi approval.
- Embracing Nature: Building on UEBT validation of the Group's biodiversity strategy, work began on restoration at 15% of Firmenich sites with biodiversity risk, in line with Science-Based Targets for Nature. Implementation of 100% verified Access and Benefit Sharing (ABS) was increased. Firmenich continued to expand the proportion of ultimately or partially biodegradable ingredients in its fragrances to 96.6% on average, having surpassed its 95% target a year earlier. Firmenich reinforced green proteins in product development, enabling customers to accelerate the plant-based food revolution and contribute to climate change mitigation.
- Caring about People: Building on gender pay equity and its work to strengthen inclusion, Firmenich achieved Living Wage certification by Fairwage Network in 2022 ahead of the Group's 2025 target, a key step to ensure decent living standards for all employees and their families. The Group advanced its high global health and safety standards with an improved 0.26 Total Recordable Case (TRC) rate, and a third consecutive Gold Award from the Royal Society for the Prevention of Accidents (RoSPA). Firmenich continued to maintain zero human rights non-compliance and scaled up its effort to drive concerted business action by becoming United Nations Global Compact (UNGC) Impact Sponsor for Labor and Decent Work.
Overall, Firmenich achieved an upgraded rating from Sustainalytics with a score of 7.5, in the global top 50 of approximately 15,000 companies, that highlights the Group's low ESG risk profile. A second consecutive Platinum rating by Ecovadis with an industry-leading score of 88% placed Firmenich in the top 1% of all companies assessed worldwide. The Group was also rated for the first time as one of the "2022 World's Most Ethical Companies" by Ethisphere®, a global leader in defining and advancing the standards of ethical business practices.
Firmenich continued to work actively in alliances and partnerships, including the UN Global Compact, the Union for Ethical Biotrade (UEBT), One Planet Business for Biodiversity (OP2B), and the Science-Based Targets initiative (SBTi), to drive positive change at scale and foster effective action on climate, nature, and people in the business community.
More detailed information on Firmenich's ESG journey is available online in the ESG Report 2022.
The attached visuals from pp 9-10 of the report provide a snapshot of ESG performance highlights and progress against targets in the climate, nature and people pillars.
Disclosure
The Firmenich ESG Report 2022 is aligned with the OECD Guidelines for Multinational Enterprises, the SASB Materiality Map®, and is prepared in accordance with the Global Reporting Initiative's (GRI) standards. The ESG Report's contents also provide an update on the Group's progress with the implementation of the ten principles of the UN Global Compact, the Sustainable Development Goals (SDGs), as well as B Corp certification. The document has been independently audited, receiving a reasonable level of assurance.
About Firmenich
Firmenich, the world's largest privately-owned fragrance and taste company, was founded in Geneva, Switzerland, in 1895, and has been family-owned for 127 years. Firmenich is a leading business-to-business company specialized in the research, creation, manufacture and sale of perfumes, flavors, and ingredients. Renowned for its world-class research and creativity, as well as its leadership in sustainability, Firmenich offers its customers superior innovation in formulation, a broad and high-quality palette of ingredients, and proprietary technologies including biotechnology, encapsulation, olfactory science, and taste modulation. Firmenich had an annual turnover of 4.7 billion Swiss Francs at end June 2022. More information about Firmenich is available at www.firmenich.com.
[1] Firmenich moved to majority ownership of ArtSci in May 2022. This entity is not included in the scope of the report and will be integrated gradually in the Group's ESG framework in FY2023.
Photo - https://mma.prnewswire.com/media/1893681/Firmenich_performance.jpg
Photo - https://mma.prnewswire.com/media/1893682/Firmenich_tracker.jpg
Logo - https://mma.prnewswire.com/media/798187/Firmenich_Logo.jpg
View original content to download multimedia:
SOURCE Firmenich
|
https://www.whsv.com/prnewswire/2022/09/12/firmenich-strengthens-sustainability-performance-fy2022/
| 2022-09-12T09:37:03Z
|
New Members Spotlight Broad Base of Applications for Open Source Enterprise Blockchain Technologies
SAN FRANCISCO and DUBLIN, Sept. 12, 2022 /PRNewswire/ -- Today, Hyperledger Foundation, the open, global ecosystem for enterprise blockchain technologies, announced eight new members to kick off Hyperledger Global Forum 2022 (#HyperledgerForum, HGF). The new members include CasperLabs, Banque de France, Central Bank of Nigeria, Digital Identity Laboratory of Canada and DSR Corporation. This line-up underscores the increasingly diverse range of enterprise blockchain applications and technologies in the Hyperledger ecosystem.
A speaker from new member Banque de France will be on stage this morning for a key panel on "The CBDC Journey: Research, Live Deployments, and Policy Considerations." Other keynotes on tap today include:
- The Evolution of Ireland's Blockchain Ecosystem - Lory Kehoe, Head of EMEA Market Operations, Coinbase & Founder and Advisory Board Member, Blockchain Ireland
- The Metaverse Continuum Creates a Defining Moment for Blockchain Leaders - Melanie Cutlan, Managing Director, Metaverse Technology Capabilities Lead, Accenture
- Blockchain in Action at Allianz, DTCC and Fujitsu - Bob Crozier, Allianz Technology; Rob Palatnick, DTCC; and Christopher Pilling, Fujitsu; Moderated by Csilla Zsigri, BTP
Free live streaming of keynotes is available here.
"As we will see on stage here at Hyperledger Global Forum, the technology and market landscape for open source enterprise blockchain just continues to get more robust," said Daniela Barbosa, Executive Director, Hyperledger Foundation, and General Manager Blockchain, Healthcare and Identity at the Linux Foundation. "Hyperledger technologies are playing an outsized role in reshaping existing markets and creating new ones. Our newest members are bringing a diversity of innovation into the Hyperledger community, accelerating the development of open, decentralized technologies that will be the infrastructure for many generations of new services and applications."
Hyperledger Foundation allows organizations to create enterprise-grade, industry-specific applications, platforms and hardware systems to support their individual business transactions by offering enterprise-grade, open source distributed ledger frameworks, libraries and tools. General members joining the community are BCW Group, CasperLabs, DSR Corporation and Realto Group.
Hyperledger Foundation supports a premier global open source blockchain community that values the contributions and participation from various entities. As such, pre-approved non-profits, open source projects and government entities can join Hyperledger Foundation at no cost as associate members. Associate members joining this month include Banque de France, Central Bank of Nigeria, Digital Identity Laboratory of Canada and International Association for Trusted Blockchain Applications (INATBA).
New member quotes:
BCW Group
"BCW is committed to the success of our clients as they navigate their Web3 transformation. Across many industries, the application of hybrid public/private blockchain architectures leveraging Hyperledger Fabric is pivotal to adopting blockchain technology for enterprises," said Jeffrey Tchui, Partner, Head of BCW Consulting at BCW Group. "We look forward to collaborating with fellow Hyperledger Foundation members to build key partnerships and find innovative new use cases for Hyperledger Fabric and other Hyperledger technologies."
CasperLabs
"We are joining Hyperledger Foundation because we are committed to advancing blockchain interoperability to support enterprise operations," said Medha Parlikar, co-founder & CTO, CasperLabs. "We've already found great success working with IBM to demonstrate the first atomic cross-chain swap of fungible tokens between an instance of a Hyperledger Fabric permissioned network and the Casper Blockchain at Davos 2022. In a few months, CasperLabs will be ready with an enterprise-grade production solution for cross-chain transactions."
DSR Corporation
"Our membership in both the Linux and Hyperledger Foundations is an exciting development for DSR and our decentralized systems division as we've been working in the space for over six years," said Alexander Shcherbakov, Decentralized Systems Business Unit Manager, DSR Corporation. "This is a tremendous opportunity to bring our nearly 25 years of software development experience to the growing number of companies leveraging the Hyperledger Foundation's ecosystem. DSR is eager to make our contribution to both communities as an official member."
Realto Group
"We are excited and honored to join the Hyperledger community of DLT innovators and enterprises," said Prasanth Kalangi, Founder and CEO of Realto Group. "As a tokenization and Web3 technology provider in the global real estate industry, we have taken a leadership role in helping shape and transform the way real estate investing and capital raising is currently being done. And we look forward to collaborating with the Hyperledger community to advance blockchain education and adoption."
About Hyperledger Global Forum (#HyperledgerForum)
Hyperledger Global Forum is the biggest annual gathering of the global Hyperledger community. It is a unique opportunity for contributors, members, service providers and enterprise end users from around the world to meet, align, plan and hack together in person. The event is open to everyone involved or interested in using, developing or learning more about Hyperledger's open source enterprise blockchain technologies. Attendees will hear directly from those who are actively developing and deploying Hyperledger technologies as well as technology and business leaders who are shaping the future of enterprise blockchain. They will also have the chance to talk directly with Hyperledger project maintainers and the Technical Steering Committee, collaborate with other organizations on ideas that will directly impact the future of Hyperledger Foundation, and promote their work among the communities.
Event sponsors and partners include Accenture (Diamond and Keynote Translation), Siemens (Platinum), Digital Asset (Gold and Developer Lounge), Zeeve (Gold), AWS (Silver), BONbLOC (Silver), ConsenSys (Silver), Corsha (Silver), Espeo Blockchain (Bronze), Huawei (Bronze), Kaleido (Bronze), DTTC (Diversity Scholarship), IBM (Birds of a Feather), Black Women Blockchain Council (Community Partner), Blockchain Ireland (Community Partner), Blockchain Research Institute (Community Partner), Digital Euro Association (Community Partner), Diversity in Blockchain (Community Partner), European Blockchain Association (Community Partner), Global Blockchain Business Council (Community Partner), International Association for Trusted Blockchain Applications (Community Partner), Kerala Blockchain Academy (Community Partner), Trusted Blockchain Initiatives (Community Partner), Trust over IP Foundation (Community Partner), Wall Street Blockchain Alliance (Community Partner), Blocknews (Media Partner), BeinCrypto (Media Partner), Cointelegraph (Media Partner), CoinSpeaker (Media Partner), Forkast (Media Partner), Ledger Insights (Media Partner) and Merge by Fintech Nexus (Media Partner).
About Hyperledger Foundation
Hyperledger Foundation was founded in 2015 to bring transparency and efficiency to the enterprise market by fostering a thriving ecosystem around open source blockchain software technologies. As a project of the Linux Foundation, Hyperledger Foundation coordinates a community of member and non member organizations, individual contributors and software developers building enterprise-grade platforms, libraries, tools and solutions for multi-party systems using blockchain, distributed ledger, and related technologies. Organizations join Hyperledger Foundation to demonstrate technical leadership, collaborate and network with others, and raise awareness around their efforts in the enterprise blockchain community. Members include industry-leading organizations in finance, banking, healthcare, supply chains, manufacturing, technology and beyond. All Hyperledger code is built publicly and available under the Apache license. To learn more, visit: https://www.hyperledger.org/.
About the Linux Foundation
Founded in 2000, the Linux Foundation and its projects are supported by more than 2,950 members. The Linux Foundation is the world's leading home for collaboration on open source software, hardware, standards, and data. Linux Foundation's projects, including Linux, Kubernetes, Node.js, Hyperledger Foundation, RISC-V, and more, are critical to the world's infrastructure. The Linux Foundation's methodology focuses on leveraging best practices and addressing the needs of contributors, users, and solution providers to create sustainable models for open collaboration. For more information, please visit us at linuxfoundation.org.
Contact:
Emily Fisher
Linux Foundation/Hyperledger
PR@Hyperledger.org
View original content to download multimedia:
SOURCE Hyperledger Foundation
|
https://www.whsv.com/prnewswire/2022/09/12/hyperledger-announces-eight-new-members-including-casperlabs-banque-de-france-central-bank-nigeria-kick-off-hyperledger-global-forum/
| 2022-09-12T09:37:09Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Ideanomics (NASDAQ: IDEX), a global company focused on accelerating the commercial adoption of electric vehicles (EV), today announced that its subsidiary US Hybrid is supplying Global Environmental Products (GEP) with its proprietary electric and hybrid electric propulsion kits for use in the construction of 62 zero emission street sweepers. Once complete, GEP will provide the sweepers to New York City, California, the City of Helena, Montana, and Washington D.C.
"Together with GEP, we are providing customers across the U.S. with made-in-America zero-emission street sweepers featuring the best available technology pioneered by US Hybrid," said Ideanomics Mobility President, Robin Mackie. "This order, one of the biggest to date, reflects a simple truth – zero-emission street sweepers are better for the planet, communities, and the bottom line. Also, each order supports the growth of America's clean energy economy and green manufacturing jobs."
This is another milestone in the decades-long strategic partnership. In 2009, GEP partnered with US Hybrid to launch the first hybrid electric street sweepers in New York City and has since provided additional units to customers in Japan. In 2021, GEP and US Hybrid deployed a first-of-its-kind, fully electric, supercharged street sweeper in New York, which made a splash by cleaning up iconic Times Square after the 2022 New Year's Eve celebration.
"We care about our environment and believe in designing and building environmentally responsible products. Our long-standing relationship with US Hybrid ensures that we always have the most evolved, zero-emission technology available to us to ensure we can provide our customers state of the art zero emission technology they are looking for," stated Walter Pusic, GEP president.
GEP will provide 17 electric street sweepers to California's Department of Transportation. In addition, the company has signed a letter of intent to supply 30 plug-in hybrid electric street sweepers and seven all-electric street sweepers to New York City. Additional orders for GEP's all-electric street sweepers include two for the City of South San Francisco, three for Washington D.C., and two for the City of Helena, Montana. All sweepers will feature US Hybrid's proprietary technology.
GEP produces hybrid and fully electric street sweepers manufactured in San Bernardino, Calif. An all-electric street sweeper prevents nearly 90 metric tons of carbon emissions from entering the atmosphere over its lifetime and is significantly quieter than sweepers powered by a combustion engine.
Since acquiring US Hybrid in 2021, Ideanomics appointed automotive industry veteran Macy Neshati as interim CEO and invested more capital to enable US Hybrid to keep pace with growing demand for its industry-leading electric powertrains and fuel cell systems. Ideanomics has determined that Neshati will continue in the role of CEO, effective October 1, based on his exceptional leadership, which has enabled US Hybrid to quickly enter new markets, improve operational efficiency, and enhance the visibility of new product offerings to key market segments including a near-zero-emission natural gas-powered parallel hybrid powertrain technology for drayage and long-haul trucks.
Ideanomics is solving the complexity of fleet electrification by bringing together high-performance electric vehicles, charging infrastructure, and financing solutions under one roof. The company views US Hybrid's expertise in designing fuel cell systems and electric power trains as a competitive advantage. Ideanomics is committed to supporting the growth of US Hybrid, which includes exploring opportunities to incorporate US Hybrid technology into the design of Ideanomics' next generation of electric vehicles.
Ideanomics is a global group with a simple mission: accelerating the commercial adoption of electric vehicles. By bringing together vehicles, charging, and financing solutions under one roof, we are the one-stop partner needed to simplify the transition to and operation of any EV fleet. To keep up with Ideanomics, please follow the company on social @ideanomicshq or visit https://ideanomics.com.
Global Environmental Product is one of the world's leading producers of specialized Street Cleaning Equipment. We build Purpose Built, Heavy Duty, and simply Tough Street Sweepers. Headquartered in San Bernardino, CA, we believe in Reliable, Affordable and Innovative products. We are proud to say that our sweepers are Made in the USA.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expected timing for the filing of the Form 10-K, the Company's ability to regain compliance with the Nasdaq requirements for continued listing and related matters. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions that involve known and unknown risks and uncertainties. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the failure of the Company to file the Form 10-K on its expected timeline and other risk factors discussed from time to time in the Company's filings with the SEC. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, without limitation, the Company's most recent Form 10-K and Form 10-Q. The Company expressly disclaims any intent or obligation to update these forward-looking statements other than as required by law.
Contacts:
Ideanomics, Inc.
Tony Sklar, SVP of Investor Relations
1441 Broadway, Suite 5116, New York, NY 10018
ir@ideanomics.com
Theodore Rolfvondenbaumen, Communications Director
Trolfvondenbaumen@ideanomics.com
View original content to download multimedia:
SOURCE Ideanomics
|
https://www.whsv.com/prnewswire/2022/09/12/ideanomics-global-environmental-products-expand-partnership-produce-zero-emission-street-sweepers/
| 2022-09-12T09:37:15Z
|
Phase 1b Results Demonstrate Encouraging Median Progression-Free Survival of 5.7 Months in Difficult-to-Treat Patient Population
THOUSAND OAKS, Calif., Sept. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced updated data from its Phase 1b CodeBreaK 101 study, one of the most comprehensive global clinical development programs in patients with KRAS G12C-mutated colorectal cancer (CRC). These data show that combining LUMAKRAS®/LUMYKRAS® (sotorasib) with Vectibix® (panitumumab), Amgen's monoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody, demonstrated encouraging efficacy and safety. Overall, the confirmed objective response rate (ORR) was 30% in patients with chemo-refractory metastatic colorectal cancer (mCRC). These data were presented today during an oral session at the European Society for Medical Oncology (ESMO) Annual Meeting in Paris, France.
"We are thrilled to see these CodeBreaK 101 results, which show that LUMAKRAS plus Vectibix achieved a 30% confirmed objective response rate in patients with KRAS G12C-mutated metastatic colorectal cancer. Treatment response rates can be as low as 2% in this patient population, and the current standard of care offers a median progression-free survival benefit of two months, so developing new treatment options is critically important for patients," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "These data are encouraging as we continue to focus on combination approaches in colorectal cancer, including advancing CodeBreaK 300, the Phase 3 LUMAKRAS plus Vectibix trial in the chemotherapy-refractory patient population."
In total, 40 patients with heavily pre-treated (median of two prior lines of therapy; range 1-7) KRAS G12C-mutated chemo-refractory mCRC were enrolled in the dose expansion cohort for the combination of LUMAKRAS and Vectibix. Disease control was seen in 37 patients for a total of 92.5% with a median progression free survival (PFS) of 5.7 months. There were no apparent differences found in the efficacy between left-sided and right-sided tumors. Tumor shrinkage of any magnitude was observed in 88% of patients, based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and the median Duration of Treatment (DoT) was 5.9 months with 25% of patients remaining on treatment at the time of data cutoff. With a median follow up of 8.8 months, median overall survival (OS) was not yet reached. Treatment-related adverse events (TRAEs) reported with the combination were consistent with known safety profiles of the individual medicines, and no TRAEs resulted in discontinuation of either drug.
"These data are positive news for patients because they demonstrate encouraging efficacy and safety for sotorasib and panitumumab, as current treatments for chemo-refractory colorectal cancer provide limited survival benefits and can have notable safety issues," said Yasutoshi Kuboki, chief, Department of Experimental Therapeutics, National Cancer Center Hospital East, Japan. "There is a significant treatment gap for patients with KRAS G12C-mutated colorectal cancer and it is imperative that we continue to explore and develop precision therapies, like sotorasib, for these patients."
KRAS is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all cases, with the KRAS G12C mutation present in approximately 3-5% of colorectal cancers. These patients face a dismal prognosis and have very limited treatment options.
*LUMAKRAS is marketed as LUMYKRAS® (sotorasib) in the European Union, the United Kingdom and Switzerland.
About LUMAKRAS®/LUMYKRAS® (sotorasib)
Amgen took on one of the toughest challenges of the last 40 years in cancer research by developing LUMAKRAS/LUMYKRAS, a KRASG12C inhibitor.1 LUMAKRAS/LUMYKRAS has demonstrated a positive benefit-risk profile with rapid, deep, and durable anticancer activity in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation with a once daily oral formulation.2
Amgen is progressing the largest and broadest global KRASG12C inhibitor development program with unparalleled speed and exploring more than 10 sotorasib combination regimens, with clinical trial sites spanning five continents. To date, over 6,500 patients around the world have received LUMAKRAS/LUMYKRAS through the clinical development program and commercial use.
In May 2021, LUMAKRAS was the first KRASG12C inhibitor to receive regulatory approval with its approval in the U.S., under accelerated approval. LUMAKRAS/LUMYKRAS is also approved in the European Union, Japan, United Arab Emirates, South Korea, Hong Kong, Switzerland, Taiwan, Qatar, and in Australia, Brazil, Canada, Great Britain, Singapore, and Israel under the FDA's Project Orbis. Additionally, Amgen has submitted MAAs in Argentina, Colombia, Kuwait, Macao, Malaysia, Mexico, Russia, Saudi Arabia, Thailand and Turkey.
LUMAKRAS/LUMYKRAS is also being studied in multiple other solid tumors.3
About Advanced Colorectal Cancer and the KRAS G12C Mutation
Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide, comprising 10% of all cancer diagnoses.4 It is also the third most commonly diagnosed cancer globally.5
Patients with previously treated metastatic CRC need more effective treatment options. For patients in the third-line setting standard therapies yield median PFS times of about two months and patients' response rates are less than 2%.6,7
KRAS mutations are among the most common genetic alterations in colorectal cancers, with the KRAS G12C mutation present in approximately 3-5% of colorectal cancers. 8,9,10
About CodeBreaK
The CodeBreaK clinical development program for Amgen's drug sotorasib is designed to study patients with an advanced solid tumor with the KRAS G12C mutation and address the longstanding unmet medical need for these cancers.
CodeBreaK 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with KRAS G12C-mutant solid tumors.11 Eligible patients must have received a prior line of systemic anticancer therapy, consistent with their tumor type and stage of disease. The primary endpoint for the Phase 2 study was centrally assessed objective response rate. The Phase 2 trial in NSCLC enrolled 126 patients, 124 of whom had centrally evaluable lesions by RECIST at baseline.2 The Phase 2 trial in colorectal cancer (CRC) is fully enrolled and results have been published.12
CodeBreaK 200, the global Phase 3 randomized active-controlled study comparing sotorasib to docetaxel in KRAS G12C-mutated NSCLC completed enrollment of 345 patients. Eligible patients had previously treated, locally advanced and unresectable or metastatic KRAS G12C-mutated NSCLC. The primary endpoint is progression-free survival and key secondary endpoints include overall survival, objective response rate, and patient-reported outcomes.13
Amgen also has several Phase 1b studies investigating sotorasib monotherapy and sotorasib combination therapy across various advanced solid tumors (CodeBreaK 101) open for enrollment.14 A Phase 2 randomized study will evaluate sotorasib in patients with stage IV KRAS G12C-mutated NSCLC in need of first-line treatment (CodeBreaK 201).15
For information, please visit www.hcp.codebreaktrials.com.
LUMAKRAS® (sotorasib) U.S. Indication
LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- LUMAKRAS can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis.
- Among 357 patients who received LUMAKRAS in CodeBreaK 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). A total of 18% of patients who received LUMAKRAS had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); 6% were Grade 3 and 0.6% were Grade 4. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.
- Monitor liver function tests (ALT, AST and total bilirubin) prior to the start of LUMAKRAS every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations.
- Withhold, dose reduce or permanently discontinue LUMAKRAS based on severity of adverse reaction.
- LUMAKRAS can cause ILD/pneumonitis that can be fatal. Among 357 patients who received LUMAKRAS in CodeBreaK 100, ILD/pneumonitis occurred in 0.8% of patients, all cases were Grade 3 or 4 at onset, and 1 case was fatal. LUMAKRAS was discontinued due to ILD/pneumonitis in 0.6% of patients.
- Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold LUMAKRAS in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS if no other potential causes of ILD/pneumonitis are identified.
- The most common adverse reactions occurring in ≥ 20% were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity and cough.
- Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, dietary and herbal products.
- Inform patients to avoid proton pump inhibitors and H2 receptor antagonists while taking LUMAKRAS.
- If coadministration with an acid-reducing agent cannot be avoided, inform patients to take LUMAKRAS 4 hours before or 10 hours after a locally acting antacid.
Please see LUMAKRAS full Prescribing Information.
About Vectibix® (panitumumab)
Vectibix is the first fully human monoclonal anti-EGFR antibody approved by the FDA for the treatment of mCRC. Vectibix was approved in the U.S. in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.
In May 2014, the FDA approved Vectibix for use in combination with FOLFOX, as first-line treatment in patients with wild-type KRAS (exon 2) mCRC. With this approval, Vectibix became the first-and-only biologic therapy indicated for use with FOLFOX, one of the most commonly used chemotherapy regimens, in the first-line treatment of mCRC for patients with wild-type KRAS mCRC.
In June 2017, the FDA approved a refined indication for Vectibix for use in in patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) mCRC.
Vectibix® is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): as first-line therapy in combination with FOLFOX, and as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.
Limitation of Use: Vectibix® is not indicated for the treatment of patients with RAS mutant mCRC or for whom RAS mutation status is unknown.
Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC grade 3 and higher) in 15% of patients receiving Vectibix monotherapy [see Dosage and Administration (2.3), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].
- In Study 20020408, dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC grade 3 and higher) in 15% of patients with mCRC receiving Vectibix®. The clinical manifestations included, but were not limited to, acneiform dermatitis, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures.
- Monitor patients who develop dermatologic or soft tissue toxicities while receiving Vectibix® for the development of inflammatory or infectious sequelae. Life-threatening and fatal infectious complications including necrotizing fasciitis, abscesses, and sepsis have been observed in patients treated with Vectibix®. Life-threatening and fatal bullous mucocutaneous disease with blisters, erosions, and skin sloughing has also been observed in patients treated with Vectibix®. It could not be determined whether these mucocutaneous adverse reactions were directly related to EGFR inhibition or to idiosyncratic immune- related effects (e.g., Stevens Johnson syndrome or toxic epidermal necrolysis). Withhold or discontinue Vectibix® for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications. Dose modifications for Vectibix® concerning dermatologic toxicity are provided in the product labeling.
- Vectibix® is not indicated for the treatment of patients with colorectal cancer that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either KRAS or NRAS and hereafter is referred to as "RAS."
- Retrospective subset analyses across several randomized clinical trials were conducted to investigate the role of RAS mutations on the clinical effects of anti-EGFR-directed monoclonal antibodies (panitumumab or cetuximab). Anti-EGFR antibodies in patients with tumors containing RAS mutations resulted in exposing those patients to anti-EGFR related adverse reactions without clinical benefit from these agents. Additionally, in Study 20050203, 272 patients with RAS-mutant mCRC tumors received Vectibix® in combination with FOLFOX and 276 patients received FOLFOX alone. In an exploratory subgroup analysis, OS was shorter (HR = 1.21, 95% CI: 1.01-1.45) in patients with RAS-mutant mCRC who received Vectibix® and FOLFOX versus FOLFOX alone.
- Progressively decreasing serum magnesium levels leading to severe (grade 3-4) hypomagnesemia occurred in up to 7% (in Study 20080763) of patients across clinical trials. Monitor patients for hypomagnesemia and hypocalcemia prior to initiating Vectibix® treatment, periodically during Vectibix® treatment, and for up to 8 weeks after the completion of treatment. Other electrolyte disturbances, including hypokalemia, have also been observed. Replete magnesium and other electrolytes as appropriate.
- In Study 20020408, 4% of patients experienced infusion reactions and 1% of patients experienced severe infusion reactions (NCI-CTC grade 3-4). Infusion reactions, manifesting as fever, chills, dyspnea, bronchospasm, and hypotension, can occur following Vectibix® administration. Fatal infusion reactions occurred in postmarketing experience. Terminate the infusion for severe infusion reactions.
- Severe diarrhea and dehydration, leading to acute renal failure and other complications, have been observed in patients treated with Vectibix® in combination with chemotherapy.
- Fatal and nonfatal cases of interstitial lung disease (ILD) (1%) and pulmonary fibrosis have been observed in patients treated with Vectibix®. Pulmonary fibrosis occurred in less than 1% (2/1467) of patients enrolled in clinical studies of Vectibix®. In the event of acute onset or worsening of pulmonary symptoms interrupt Vectibix® therapy. Discontinue Vectibix® therapy if ILD is confirmed.
- In patients with a history of interstitial pneumonitis or pulmonary fibrosis, or evidence of interstitial pneumonitis or pulmonary fibrosis, the benefits of therapy with Vectibix® versus the risk of pulmonary complications must be carefully considered.
- Exposure to sunlight can exacerbate dermatologic toxicity. Advise patients to wear sunscreen and hats and limit sun exposure while receiving Vectibix®.
- Keratitis and ulcerative keratitis, known risk factors for corneal perforation, have been reported with Vectibix® use. Monitor for evidence of keratitis or ulcerative keratitis. Interrupt or discontinue Vectibix® for acute or worsening keratitis.
- In an interim analysis of an open-label, multicenter, randomized clinical trial in the first-line setting in patients with mCRC, the addition of Vectibix® to the combination of bevacizumab and chemotherapy resulted in decreased OS and increased incidence of NCI-CTC grade 3-5 (87% vs 72%) adverse reactions. NCI-CTC grade 3-4 adverse reactions occurring at a higher rate in Vectibix®-treated patients included rash/acneiform dermatitis (26% vs 1%), diarrhea (23% vs 12%), dehydration (16% vs 5%), primarily occurring in patients with diarrhea, hypokalemia (10% vs 4%), stomatitis/mucositis (4% vs < 1%), and hypomagnesemia (4% vs 0).
- NCI-CTC grade 3-5 pulmonary embolism occurred at a higher rate in Vectibix®-treated patients (7% vs 3%) and included fatal events in three (< 1%) Vectibix®-treated patients. As a result of the toxicities experienced, patients randomized to Vectibix®, bevacizumab, and chemotherapy received a lower mean relative dose intensity of each chemotherapeutic agent (oxaliplatin, irinotecan, bolus 5-FU, and/or infusional 5-FU) over the first 24 weeks on study compared with those randomized to bevacizumab and chemotherapy.
- Vectibix® can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment, and for at least 2 months after the last dose of Vectibix®.
- In monotherapy, the most commonly reported adverse reactions (≥ 20%) in patients with Vectibix® were skin rash with variable presentations, paronychia, fatigue, nausea, and diarrhea.
- The most commonly reported adverse reactions (≥ 20%) with Vectibix® + FOLFOX were diarrhea, stomatitis, mucosal inflammation, asthenia, paronychia, anorexia, hypomagnesemia, hypokalemia, rash, acneiform dermatitis, pruritus, and dry skin. The most common serious adverse reactions (≥ 2% difference between treatment arms) were diarrhea and dehydration.
To see the Vectibix® Prescribing Information, including Boxed Warning visit www.vectibix.com.
About Amgen Oncology
At Amgen Oncology, our mission to serve patients drives all that we do. That's why we're relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform lives of people with cancer.
For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.
For more information, follow us on www.twitter.com/amgenoncology.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc. acquisition, the Teneobio, Inc. acquisition, or the recently announced proposed acquisition of ChemoCentryx, Inc., as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.
CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423 (media)
Jessica Akopyan, 805-440-5721 (media)
Arvind Sood, 805-447-1060 (investors)
LUMAKRAS, LUMYKRAS, and Vectibix are trademarks of Amgen Inc.
1 Canon J, et al. Nature. 2019;575: 217–223.
2 Skoulidis F, et al. N Engl J Med. 2021;384:2371-2381.
3 Hong DS, et al. N Engl J Med. 2020;383:1207-1217.
4 Rawla, P., Sunkara, T., & Barsouk, A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Gastroenterology Review. 2019;14(2):89-103.
5 World Health Organization. 2020 Statistics. Available at: https://www.who.int/en/news-room/fact-sheets/detail/cancer. Accessed on August 26, 2021.
6 Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909-1919. doi:10.1056/NEJMoa1414325.
7 Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312. doi:10.1016/S0140-6736(12)61900-X.
8 Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205(12):858-862. doi:10.1016/j.prp.2009.07.010.
9 Jones RP, Sutton PA, Evans JP, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017;116(7):923-929. doi:10.1038/bjc.2017.37.
10 Wiesweg M, Kasper S, Worm K, et al. Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. Oncogene. 2019;38(16):2953-2966. doi:10.1038/s41388-018-0634-0.
11 ClinicalTrials.gov. CodeBreaK 100. Available at: https://clinicaltrials.gov/ct2/show/NCT03600883. Accessed on April 14, 2022.
12Fakih MG, et al. Lancet Oncol. 2022;23:115-124.
13 ClinicalTrials.gov. CodebreaK 200. Available at: https://clinicaltrials.gov/ct2/show/NCT04303780. Accessed on April 14, 2022.
14 ClinicalTrials.gov. CodeBreaK 101. Available at: https://clinicaltrials.gov/ct2/show/NCT04185883. Accessed on April 14, 2022.
15 ClinicalTrials.gov. CodeBreaK 201. Available at: https://clinicaltrials.gov/ct2/show/NCT04933695. Accessed on April 14, 2022.
View original content to download multimedia:
SOURCE Amgen
|
https://www.whsv.com/prnewswire/2022/09/12/lumakras-sotorasib-combined-with-vectibix-panitumumab-shows-confirmed-30-objective-response-rate-patients-with-kras-g12c-mutated-metastatic-colorectal-cancer/
| 2022-09-12T09:37:22Z
|
VILLANOVA DI SAN DANIELE DEL FRIULI, Udine, Italy, Sept. 12, 2022 /PRNewswire/ -- LimaCorporate, a leading global orthopedic manufacturer focused on digital innovation and patient-tailored devices, today announces that Massimo Calafiore has been appointed by the Board of Directors as the new Chief Executive Officer of the company. Massimo's appointment follows a thorough selection process that considered both internal and external candidates. Emmanuel Bonhomme, who has led the organization during the last five months as interim CEO, will take on the newly created role of Chief Commercial Officer.
Massimo has recently served as Executive Vice President and Chief Commercial Officer of NuVasive, a global leader in orthopedic spine technology. Before that, he was responsible for the Company's Product Marketing and Commercial Functions, as well as the Company's Business Units, NuVasive Specialized Orthopedics, and NuVasive Clinical Services. With more than 20 years of experience in the orthopedic field and extensive knowledge of the global orthopedic markets, he will lead the organization's patient-centric focus and continued investment in innovation and business growth.
Lars Rasmussen, Chairperson of the LimaCorporate Advisory Board, commented: "We strongly believe that Massimo is the right person to lead this new phase of our business. He brings extensive industry experience, excellent strategic and leadership skills and a track record of values-based leadership focused on improving patients' lives. I would like to thank Emmanuel Bonhomme for his dedication as interim CEO and congratulate him on his new role as Chief Commercial Officer."
Emmanuel Bonhomme commented: "It has been a pleasure and an honor to lead LimaCorporate during the last five months as interim CEO and I am very excited to carry on serving our surgeons around the world in my new role. I welcome Massimo as our new CEO and I am committed to supporting him and the Company to continue to enhance LimaCorporate's position in the industry, offering the best and most advanced solutions for our surgeons and patients."
Massimo Calafiore remarked: "I am honored to take on this role as CEO of LimaCorporate. Thanks to our internal talent, know-how, and industry-leading R&D capabilities, I will continue to focus on positioning the company as a global leader in advanced orthopedic solutions. I look forwards to working closely with all the employees and the Leadership Team to continue to serve our surgeons and patients around the globe, as we transform orthopedics, advance patient care, and most importantly, restore the eMotion of Motion in all of our patients.
"I also would like to thank Emmanuel for the passion, energy, and enthusiasm he demonstrated in leading LimaCorporate as interim CEO and the Board of Directors for giving me the opportunity to lead the organization during this new phase of growth, helping patients around the world with our innovative products."
About LimaCorporate
LimaCorporate is a global orthopedic company, focused on digital innovation and patient-tailored hardware, which advances patient-centred care. Its pioneering technological solutions are developed to empower surgeons, and to improve patient outcomes from joint replacement surgery. Its primary focus is on providing reconstructive and custom-made orthopedic solutions to surgeons, enabling them to improve the quality of life of patients by restoring the joy of movement.
Headquartered in Italy, the company operates directly in over 20 countries around the world. LimaCorporate offers products ranging from large joint revision and primary implants, to complete extremities solutions, including fixation.
For additional information on the Company, please visit www.limacorporate.com
Limacorporate spa
Via Nazionale, 52
33038 Villanova di San Daniele
Udine – Italy
t: +39 0432 945511
e.: info@limacorporate.com
View original content:
SOURCE Limacorporate S.p.A.
|
https://www.whsv.com/prnewswire/2022/09/12/massimo-calafiore-appointed-new-limacorporate-ceo/
| 2022-09-12T09:37:28Z
|
Belgium's largest insurer transforms critical business services to support their three million clients and distribution partners
BRUSSELS, Sept. 12, 2022 /PRNewswire/ -- Global digital transformation leader Micro Focus (LSE: MCRO; NYSE: MFGP) today announced the successful modernisation of AG's mission-critical business systems. By using Micro Focus solutions and services, Belgium's largest and oldest insurance provider has established a contemporary, collaborative application development environment that meets the company's current needs, while enabling continued evolution and future change.
During the significant modernisation project, critical applications comprising more than 80 million lines of code were moved from the incumbent mainframe system to new infrastructure that supports 14 million transactions per day. The project began in mid-2018 with a completion goal of four years. The efficiency of the project resulted in its completion in three years. Vitally, during the transition and since, there were no interruptions to daily business activities for AG or the services offered for its three million clients.
"The whole operation has resulted in an innovative and open environment that enables a new data-driven strategy, as well as our company enjoying a lower total cost of ownership now and far into the future," said Philippe Van Belle, Chief Information & Technology Officer of AG. The modernisation project opened the door for utilising the cloud and aligned operational systems more closely with the data analytics systems. The end result is a modern IT infrastructure that allows AG to efficiently meet its customer and distribution partners expectations and needs. We couldn't have realised this huge project without the partnership and excellent collaboration with Micro Focus."
In addition to bolstering its already excellent customer services, AG is now accelerating its own digital transformation with its modernised IT architecture. As part of this change, AG will now offer more services and conduct business operations in the cloud as they leverage new technologies in their continued digital evolution. Another advantage of the modernisation project is that AG has a cutting-edge environment for the recruitment of a new generation of developers, as well as the retention of existing talent with an uplift in development skills and program knowledge.
"The completion of this project with AG is the latest in an extensive line of successful core business system modernisation projects for Micro Focus," said Neil Fowler, Micro Focus AMC General Manager. "Our role was to enable and support AG's modernisation journey as they delivered their business outcomes through a combination of application, process and infrastructure modernisation. This has resulted in an agile platform that allows AG to leverage their core applications and continue to deliver increasing value to their customers. With Micro Focus' more than 40 years of experience in modernising business-critical applications running on the mainframe or distributed environments, we as a company are proud of the results that we were able to deliver to AG.
"AG has been a Micro Focus customer for more than ten years, and we look forward to seeing the positive impacts that this modernisation project has on the insurance services AG provides to its customers and the company's reduction in TCO for its infrastructure."
The modernisation project entailed the shift of AG's z/OS workloads to a Windows-based environment. To do so, AG utilised the Micro Focus Enterprise Developer and Enterprise Server products, as well as the expertise of the company's Professional Services group. The AG modernisation project also included collaboration from HP Enterprise as system integrator and Capgemini as the testing partner.
As a company, Micro Focus supports its customers' choice for modernising their applications, process and infrastructure. Digital transformation demands a flexible and adaptive strategy aimed at improving results and accelerating time to value. Through the Micro Focus Modernisation Maturity Model, IT leaders can quickly map their current IT environment to their future business strategy—while finding the right balance between costs, risk and speed.
"The mainframe served AG well over the years. However, more connectivity was required, as well as the integration of core systems to key business partners and the integration of data and services. We transformed our IT infrastructure to ensure that AG will continue be a leader in the insurance industry. We will begin phase two of AG's digital transformation soon with an extensive cloud integration that will enable us to easily adapt to new technologies as they emerge." Philippe Van Belle, Chief Information and Technology Officer at AG.
"One of the biggest threats during a mainframe modernisation project is business disruption. Because of the detailed and extensive planning from the Micro Focus and AG teams, there were no disruptions to AG operations or its customers. The switch to the new IT infrastructure took place during the Easter holiday weekend, with activities running normally when the following workweek began. We are pleased to have helped deliver such exceptional results for our customer and their three million clients." Stephen Murdoch, CEO of Micro Focus.
Join Micro Focus on LinkedIn and follow @MicroFocus on Twitter.
Micro Focus is one of the world's largest enterprise software providers, focused on solving the IT dilemma—how to balance today's needs with tomorrow's opportunities. We deliver mission-critical technology that helps tens of thousands of customers worldwide manage core IT elements of their business. Strengthened by our strategic services and support organisations, and an extensive partner network, our broad set of technologies for security, IT operations, application delivery, governance, modernisation, and analytics provides the innovative solutions organisations need to run and transform— at the same time.
With a share (end 2021) of 29,5% in the Life insurance market and 16.7% in Non-life, AG is the undisputed leader in the Belgian insurance market. To better tailor its offer to fulfil different customer needs, AG has a multi-channel distribution strategy that includes independent brokers and Fintro agents, bank branches (BNP Paribas Fortis, bpost bank) and collaboration with large corporate clients and sectors for their group insurance. AG employs over 4,000 specialised staff members. More information on www.ag.be
Contact: microfocus@pancomm.com
View original content to download multimedia:
SOURCE Micro Focus
|
https://www.whsv.com/prnewswire/2022/09/12/micro-focus-technology-expertise-support-successful-mainframe-modernisation-project-ag/
| 2022-09-12T09:37:35Z
|
VANCOUVER, BC, Sept. 12, 2022 /PRNewswire/ - New Pacific Metals Corp. ("New Pacific" or the "Company") (TSX: NUAG) (NYSE-A: NEWP), together with its local Bolivian partner, is pleased to announce assay results for the first drill hole from the Discovery Drill Program at the Silverstrike Project, in the Department of La Paz, Bolivia ("Silverstrike"). The drill hole intersected broad gold mineralization starting near-surface. Seven holes have been drilled to date since the start of the program in June 2022. Assay results of the remaining six holes are pending.
Drill hole DSSk0001 intersected a broader interval of 195.05 metres ("m") (from 10.22 m to 205.27 m) grading 0.96 grams per tonne ("g/t") gold ("Au") and 6 g/t silver ("Ag"), including an interval of 111.39 m (from 12.61 m to 124.00 m) grading 1.54 g/t Au and 8 g/t Ag, and a higher grade near-surface sub-interval of 36.06 m (from 12.61 m to 48.67 m) grading 3.97 g/t Au and 20 g/t Ag (Table 1).
Hole DSSk0001 was drilled to test the continuous surface chip sampling results of 42m interval grading 1.02 g/t Au and 18 g/t Ag (please refer to the Company's news release on June 14, 2022). Figures 1 & 2 show the drill hole location and geological cross section. Gold mineralization discovered is hosted in volcanic clastic sediments (breccia or ignimbrites) that extend to North and North-East with fractures dipping at high angles to the east. The ignimbrite or breccia host rock for gold is similar to the Company's gold discovery at the Carangas Project, in the Department of Oruro, Bolivia.
This discovery marks another milestone following the Company's discoveries made at Silver Sand and Carangas, displaying the Company's capability of growing its shareholders' value through careful project identification, acquisition, thorough geological study and well-planned drilling.
The Silverstrike Discovery Drill Program commenced in June 2022. To date, 2,030 m have been drilled in seven diamond drill holes (Table 2) at the Silverstrike Central Prospect.
In recent news releases, the Company has identified 1) multiple near-surface broad-zones of silver mineralization hosted in altered sandstones at Silverstrike North, similar to the mineralization style at Silver Sand, and 2) a near-surface broad silver zone near the top of a ~900 m diameter volcanic dome of ignimbrite units with the intrusion of rhyolite dyke swarm and andesite flows, and a broad gold zone half way from the top of the dome, at Silverstrike Central. The initial focus of this drilling program is to test the near surface broad gold zone and silver zone at Silverstrike Central (Figure 1).
All samples in respect of the exploration program at the Silverstrike Project, conducted by the Company and discussed in this news release, are shipped in securely-sealed bags by New Pacific staff in the Company's vehicles, directly from the field to ALS Global in Oruro, Bolivia for preparation, and ALS Global in Lima, Peru for geochemical analysis. ALS Global is an independent ISO 17025 accredited laboratory. All samples are first analyzed by a multi-element ICP package (ALS code ME-MS41) with ore grade over specified limits for silver, lead and zinc further analyzed using ALS code OG46. Further silver samples over specified limits are analyzed by gravimetric analysis (ALS code of GRA21). Gold is assayed by fire assay with AAS finish (ALS code of Au-AA25). Certified reference materials, various types of blank samples and duplicate samples are inserted to normal drill core sample sequences prior to delivery to the laboratory for preparation and analysis. The overall ratio of quality control samples in sample sequences is around twenty percent.
The scientific and technical information contained in this news release has been reviewed and approved by Alex Zhang, P. Geo., Vice President of Exploration, who is a Qualified Person for the purposes of National Instrument 43-101 — Standards of Disclosure for Mineral Projects ("NI 43- 101"). The Qualified Person has verified the information disclosed herein, including the sampling, preparation, security and analytical procedures underlying such information, and is not aware of any significant risks and uncertainties that could be expected to affect the reliability or confidence in the information discussed herein.
New Pacific is a Canadian exploration and development company with precious metal projects in Bolivia. The Company's flagship Project, the Silver Sand Silver Project, is waiting for a new Mineral Resource Estimate Update and a PEA by the end of 2022. Recently discovered Caragas Silver-Gold Project is undergoing a 40,000 m drill program. The third project, the Silverstrike Silver-Gold Project, commenced a 6,000 m discovery drill program in June 2022.
For further information, please contact:
New Pacific Metals Corp.
Phone: (604) 633-1368
U.S. & Canada toll-free: 1-877-631-0593
E-mail: invest@newpacificmetals.com
For additional information and to receive company news by e-mail, please register using New Pacific's website at www.newpacificmetals.com.
Certain of the statements and information in this news release constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian provincial securities laws. Any statements or information that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects", "is expected", "anticipates", "believes", "plans", "projects", "estimates", "assumes", "intends", "strategies", "targets", "goals", "forecasts", "objectives", "budgets", "schedules", "potential" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements or information. Such statements include, but are not limited to: statements regarding anticipated exploration, drilling, development, construction, and other activities or achievements of the Company; timing of receipt of permits and regulatory approvals; timing and content of the PEA, and estimates of the Company's revenues and capital expenditures.
Forward-looking statements or information are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those reflected in the forward-looking statements or information, including, without limitation, risks relating to: global economic and social impact of COVID-19; fluctuating equity prices, bond prices, commodity prices; calculation of resources, reserves and mineralization, general economic conditions, foreign exchange risks, interest rate risk, foreign investment risk; loss of key personnel; conflicts of interest; dependence on management, uncertainties relating to the availability and costs of financing needed in the future, environmental risks, operations and political conditions, the regulatory environment in Bolivia and Canada, risks associated with community relations and corporate social responsibility, and other factors described under the heading "Risk Factors" in the Company's Annual Information Form for the year ended June 30, 2021 and its other public filings.
This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements or information.
The forward-looking statements are necessarily based on a number of estimates, assumptions, beliefs, expectations and opinions of management as of the date of this news release that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates, assumptions, beliefs, expectations and options include, but are not limited to, those related to the Company's ability to carry on current and future operations, including: the duration and effects of COVID-19 on our operations and workforce; development and exploration activities; the timing, extent, duration and economic viability of such operations; the accuracy and reliability of estimates, projections, forecasts, studies and assessments; the Company's ability to meet or achieve estimates, projections and forecasts; the stabilization of the political climate in Bolivia; the Company's ability to obtain and maintain social license at its mineral properties; the availability and cost of inputs; the price and market for outputs; foreign exchange rates; taxation levels; the timely receipt of necessary approvals or permits, including the ratification and approval of the Mining Production Contract with COMIBOL by the Plurinational Legislative Assembly of Bolivia; the ability of the Company's Bolivian partner to convert the exploration licenses at the Carangas Project to AMC; the ability to meet current and future obligations; the ability to obtain timely financing on reasonable terms when required; the current and future social, economic and political conditions; and other assumptions and factors generally associated with the mining industry.
Although the forward-looking statements contained in this news release are based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. All forward-looking statements in this news release are qualified by these cautionary statements. Accordingly, readers should not place undue reliance on such statements. Other than specifically required by applicable laws, the Company is under no obligation and expressly disclaims any such obligation to update or alter the forward-looking statements whether as a result of new information, future events or otherwise except as may be required by law. These forward-looking statements are made as of the date of this news release.
The technical and scientific information contained herein has been prepared in accordance with NI 43-101, which differs from the standards adopted by the U.S. Securities and Exchange Commission (the "SEC"). Accordingly, the technical and scientific information contained herein, including any estimates of mineral reserves and mineral resources, may not be comparable to similar information disclosed by U.S. companies subject to the disclosure requirements of the SEC.
Additional information relating to the Company, including the Company's Annual Information form, can be obtained under the Company's profile on SEDAR at www.sedar.com, on EDGAR at www.sec.gov, and on the Company's website at www.newpacificmetals.com.
View original content to download multimedia:
SOURCE New Pacific Metals Corp.
|
https://www.whsv.com/prnewswire/2022/09/12/new-pacific-intercepts-111-metres-grading-154-grams-per-tonne-gold-near-surface-silverstrike-project/
| 2022-09-12T09:37:42Z
|
NEWINGTON, Conn., Sept. 12, 2022 /PRNewswire/ -- PCX Aerosystems ("PCX"), a market-leading producer of advanced mechanical systems for the aerospace industry, today announced the September 2, 2022 acquisition of NuSpace, Inc. ("NuSpace") from Cornerstone Capital Holdings and members of the NuSpace leadership team. With engineering and manufacturing roots going back to 1907, NuSpace has evolved from a diversified mechanical systems manufacturer into a leading-edge designer and manufacturer of proprietary propellant and high-pressure tanks for advanced satellite, launch vehicle spacecraft, and missile platforms.
"NuSpace brings a unique capability to design and produce mission critical complex assemblies for the rapidly growing space marketplace which is a fantastic addition to the growing portfolio of flight-critical components and assemblies we supply to the defense aerospace market," said PCX CEO, Tom Holzthum.
Ian Ballinger, CEO and Chief Technology Officer of NuSpace, said, "Joining the PCX team is a natural next step for NuSpace, bringing the stability and support of being part of a broader portfolio while maintaining the freedom to pursue continued growth with our customers."
Headquartered in Connecticut, PCX Aerosystems is a leading privately owned supplier of highly engineered, precision, flight critical assemblies for rotorcraft and fixed wing aerospace platforms The company produces rotorhead assemblies and control systems, landing gear assemblies, external fuel tank systems, engine and structural airframe components in addition to composite fabrications and refueling probes. The company also offers integrated special processing services such as heat treating, painting and non-destructive testing. PCX provides direct delivery of components and large assemblies to customers such as Boeing, General Electric Aircraft Engines, Bell, Sikorsky and the U.S. Government. Founded in 1900, PCX owns facilities in CT, CA and MA. PCX Aerostructures, LLC, dba PCX Aerosystems is owned by Greenbriar Equity Group, L.P. To learn more about PCX, visit www.pcxaero.com.
NuSpace is a Long Beach, California based aerospace and defense manufacturer with proprietary design and specialized fabrication capabilities, and flight-critical assembly and quality systems. Their experienced engineering and manufacturing teams excel at the design to specification and manufacture of mission critical propellant and pressure vessel solutions.
For more information:
Trevor Hartman
Vice President – Sales & Marketing
(860) 594-4388
View original content to download multimedia:
SOURCE PCX Aerosystems
|
https://www.whsv.com/prnewswire/2022/09/12/pcx-aerosystems-announces-acquisition-nuspace/
| 2022-09-12T09:37:48Z
|
63% combined pathologic response rate for neoadjuvant Libtayo monotherapy in stage II to IV resectable CSCC per primary analysis of a confirmatory Phase 2 trial
TARRYTOWN, N.Y., Sept. 12, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo® (cemiplimab) as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC). The data, from the primary analysis of a confirmatory Phase 2 trial, were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris and concurrently published in the New England Journal of Medicine (NEJM).
"Regeneron conducted the first pivotal trial of Libtayo in advanced cutaneous squamous cell carcinoma that was unlikely to be curable by surgery or radiation, and we are now studying the utility of Libtayo in earlier stages of this disease. In addition to our neoadjuvant trial, a global Phase 3 trial of Libtayo is ongoing in the adjuvant setting after surgery and radiation for patients at heightened risk for recurrence," said Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron. "In the neoadjuvant trial in stage II to IV cutaneous squamous cell carcinoma presented at ESMO and published in NEJM, Libtayo demonstrated greater than 60% response rates per both pathologic and imaging measures. Libtayo may therefore have expanded utility in earlier stages of cutaneous squamous cell carcinoma as a monotherapy to potentially help avoid surgery, and as part of a combination approach with surgery to facilitate function-preserving resections and minimize disfigurement."
In the confirmatory, multicenter, single-arm Phase 2 trial, 79 patients received up to four fixed doses of Libtayo every 3 weeks prior to surgery, with 62 receiving all 4 doses and 70 undergoing surgery. Patients experienced the following efficacy:
- 63.3% combined pathologic response rate (50 of 79 patients), with 50.6% (40 patients) achieving the primary endpoint of complete pathologic response (0% viable tumor, excluding a null hypothesis of 25%) and 12.7% (10 patients) experiencing a major pathologic response (>0% and ≤10% viable tumor cells) by independent pathologic review.
- 68% objective response rate (ORR) (54 of 79 patients; 5 complete responses [CR] and 49 partial responses [PR]) per local imaging review.
Adverse events (AE) of any grade occurred in 87% of patients, with 17% considered serious. The most common AE was fatigue (n=24). AEs that were ≥grade 3 occurred in 18% of patients. The treatment discontinuation rate due to AEs was 1%, and there was one death due to worsening congestive heart failure considered related to treatment. There were no new Libtayo safety signals.
Patient follow-up in the trial is ongoing to assess disease-free survival. A separate global Phase 3 trial investigating Libtayo in the adjuvant CSCC setting for patients at heightened risk (i.e., due to involvement of multiple lymph nodes, extension of cancer through the lymph node capsule, perineural invasion) for recurrence is enrolling patients.
The potential use of Libtayo described above is investigational, and its safety and efficacy has not been evaluated by any regulatory authority for this indication.
About Regeneron in Oncology
At Regeneron, we're applying more than three decades of scientific innovation with the goal of developing paradigm-changing therapies for patients with cancer. Our oncology portfolio is built around two foundational approaches – our approved PD-1 inhibitor Libtayo and investigational bispecific antibodies – which are being evaluated both as monotherapies and in combination with emerging therapeutic modalities. Together, they provide us with unique combinatorial flexibility to develop potentially synergistic treatments for a wide range of solid tumors and blood cancers.
If you are interested in learning more about our clinical trials, please contact us (clinicaltrials@regeneron.com or 844-734-6643) or visit our clinical trials website.
About Libtayo
Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune technology. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. In the U.S. and other countries Libtayo is indicated in certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC), as well as in advanced cervical cancer in Canada and Brazil. As of July 1, 2022, Libtayo is developed and marketed globally by Regeneron.
In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. Food and Drug Administration (FDA). Outside of the U.S. the generic name of Libtayo in its approved indication is cemiplimab.
The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Libtayo is currently being investigated in trials as a monotherapy, as well as in combination with either conventional or novel therapeutic approaches for other solid tumors and blood cancers. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.
U.S. FDA-approved Indications Libtayo is a prescription medicine used to treat people with:
- A type of skin cancer called advanced CSCC that has spread or cannot be cured by surgery or radiation.
- A type of skin cancer called BCC:
- A type of lung cancer called NSCLC. Libtayo may be used as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high "PD-L1" and your tumor does not have an abnormal "EGFR", "ALK "or "ROS1" gene.
It is not known if Libtayo is safe and effective in children.
About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create approximately one in five of all original, FDA-approved or authorized fully human monoclonal antibodies. This includes REGEN-COV® (casirivimab and imdevimab), Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb) and Inmazeb™ (atoltivimab, maftivimab and odesivimab-ebgn).
IMPORTANT SAFETY INFORMATION AND INDICATION FOR U.S. PATIENTS
What is the most important information I should know about Libtayo?
Libtayo is a medicine that may treat certain cancers by working with your immune system. Libtayo can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.
Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:
- Lung problems: cough, shortness of breath, or chest pain
- Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual, stools that are black, tarry, sticky or have blood or mucus, or severe stomach area (abdomen) pain or tenderness
- Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (tea colored), or bleeding or bruising more easily than normal
- Hormone gland problems: headache that will not go away or unusual headaches, eye sensitivity to light, eye problems, rapid heartbeat, increased sweating, extreme tiredness, weight gain or weight loss, feeling more hungry or thirsty than usual, urinating more often than usual, hair loss, feeling cold, constipation, your voice gets deeper, dizziness or fainting, or changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
- Kidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, or loss of appetite
- Skin problems: rash, itching, skin blistering or peeling, painful sores or ulcers in mouth or nose, throat, or genital area, fever or flu-like symptoms, or swollen lymph nodes
- Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with Libtayo. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: chest pain, irregular heartbeat, shortness of breath or swelling of ankles, confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs, double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight, persistent or severe muscle pain or weakness, muscle cramps, low red blood cells, or bruising
- Infusion reactions that can sometimes be severe. Signs and symptoms of infusion reactions may include: nausea, chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, back or neck pain, or facial swelling.
- Rejection of a transplanted organ. Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.
- Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with Libtayo. Your healthcare provider will monitor you for these complications.
Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with Libtayo. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with Libtayo if you have severe side effects.
Before you receive Libtayo, tell your healthcare provider about all your medical conditions, including if you:
- have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome are pregnant or plan to become pregnant. Libtayo can harm your unborn baby
Females who are able to become pregnant:
- Your healthcare provider will give you a pregnancy test before you start treatment.
- You should use an effective method of birth control during your treatment and for at least 4 months after your last dose of Libtayo. Talk with your healthcare provider about birth control methods that you can use during this time.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Libtayo.
- are breastfeeding or plan to breastfeed. It is not known if Libtayo passes into your breast milk. Do not breastfeed during treatment and for at least 4 months after the last dose of Libtayo.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of Libtayo include muscle or bone pain, tiredness, rash, and diarrhea. These are not all the possible side effects of Libtayo. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals and Sanofi at
1-877-542-8296.
Please see full Prescribing Information, including Medication Guide.
About Regeneron
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.
For more information, please visit www.Regeneron.com or follow @Regeneron on Twitter.
Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators' ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without Libtayo® (cemiplimab); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron's Products and Regeneron's Product Candidates; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Libtayo as monotherapy for resectable cutaneous squamous cell carcinoma; safety issues resulting from the administration of Regeneron's Products (such as Libtayo) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products (such as Libtayo) from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including those discussed or referenced in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials or therapeutic applications; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection, Dupixent® (dupilumab), and Praluent® (alirocumab)), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2021 and its Form 10-Q for the quarterly period ended June 30, 2022. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
View original content:
SOURCE Regeneron Pharmaceuticals, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/positive-neoadjuvant-libtayo-cemiplimab-monotherapy-data-resectable-cutaneous-squamous-cell-carcinoma-presented-esmo-published-nejm/
| 2022-09-12T09:37:55Z
|
SITA identifies four key areas for further investment in the coming year
GENEVA, Sept. 12, 2022 /PRNewswire/ -- SITA, the leading IT provider to the air transport industry, today announced the launch of a partnership program aimed at joining hands with key partners as it embarks on a new path to growth.
Through the new partner platform, Launchpad, SITA has outlined four key areas where it seeks to build new partnerships: digital identities, advanced analytics and data management, security and safety at airports, and sustainable alternative energy sources. Each of these areas is in response to the changing demands of air travel today and where SITA has already made notable strides in innovation and development.
Over the past two years, airlines and airports have faced significant challenges and changing passenger behaviors, requiring the industry to adapt how it operates. Surging fuel prices and volatility have increased sharply while passengers demand the same digital experience when traveling that dominates every aspect of their everyday life.
To meet this demand, SITA is accelerating its investment in new solutions that deliver smarter ways of working using existing and new technologies. At the same time, SITA is looking to collaborate with partners inside and outside the air transport industry to complement SITA's expertise, drive innovation, or trial new sustainable solutions within their operations.
David Lavorel, CEO of SITA, said: "We are committed to enabling the growth of the air transport industry through smart technology and solutions. We have looked carefully at the market and identified key areas where we can have a significant impact and help our customers work smarter. We have a strong investment and innovation program to support these areas which are central to the growth of SITA. To accelerate this program, we are inviting new partners working in these four areas to join us so we can reshape the air travel industry together."
To learn more about how you can partner with SITA, go to www.sita.aero/sita-launchpad
About SITA
SITA is the air transport industry's IT provider, delivering solutions for airlines, airports, aircraft and governments. Our technology powers more seamless, safe and sustainable air travel.
With around 2,500 customers, SITA's solutions drive operational efficiencies at more than 1,000 airports while delivering the promise of the connected aircraft to customers of 17,000 aircraft globally. SITA also provides technology solutions that help more than 70 governments strike the balance of secure borders and seamless travel. Our communications network connects every corner of the globe and bridges 60% of the air transport community's data exchange.
In 2021, SITA became a certified CarbonNeutral® company in accordance with The CarbonNeutral Protocol – the leading global standard for carbon neutral programs. We are reducing our greenhouse gas emissions for all our operations through our UN recognized Planet+ program, while also developing solutions to help the aviation industry meet its carbon reduction objectives, including reduced fuel burn and greater operational efficiencies. In 2022, we announced our commitment to setting science-based emission reduction targets aligned to the Science Based Targets initiative Net-Zero Standard.
SITA is 100% owned by the industry and driven by its needs. It is one of the most internationally diverse companies, providing services in over 200 countries and territories.
For further information, go to www.sita.aero
Photo - https://mma.prnewswire.com/media/1895824/SITA.jpg
Logo - https://mma.prnewswire.com/media/1839793/SITA_Logo.jpg
View original content to download multimedia:
SOURCE SITA
|
https://www.whsv.com/prnewswire/2022/09/12/sita-opens-door-new-partners-it-embarks-new-path-growth/
| 2022-09-12T09:38:02Z
|
SANTA CLARA, Calif., Sept. 12, 2022 /PRNewswire/ -- SoC.one Inc and Imagination Technologies today announced a strategic alliance to accelerate the adoption of RISC-V in the automotive design cycle.
Electrification is changing how cars are architected and built. "Software-defined vehicles" open new opportunities to redefine and package transportation and mobility as services. It also presents enormous challenges in the design, verification, and production of connected autonomous vehicles.
The RISC-V open instruction set architecture (ISA) is well positioned for the automotive market. The served addressable market (SAM) for RISC-V in automotive was 4 million cores in 2020, forecast to rise to 150 million cores in 2022, and to 2.9 billion cores by 2025 (source: Deloitte). However, uncertainties around maturity, performance, and security compared to more established automotive ISA have delayed adoption. The strategic partnership between SoC.one and Imagination Technologies aims to address those concerns and position RISC-V as a mainstream, high-performance, secured compute platform for the automotive industry.
SoC.one Cloud is an end-to-end, close-loop, mixed-reality platform that powers the needs of automotive OEMs and suppliers to explore, design, build and train / validate compute solutions critical to the future of the connected and autonomous driving cars. The SoC.one complete 'Digital Twins' approach offers a near real-time, realistic, and repeatable setting, needed to create automotive products that perform well in the stochastic and diverse real world.
"The ability to see a design from the immersive experience of the vehicles, occupants, pedestrians, motorbikes and other objects on the road offers OEMs insight and understanding that can minimize risks, improve development time, and increase safety," said Krishna Raghavan, founder of SoC.one. Raghavan added, "From integration and training for auto-pilot systems, to the fusion of in-vehicle control and infotainment, and integration with automotive edge and cloud data services, the capabilities of SoC.one Cloud will prove to be crucial component of any automotive company's process and development portfolio."
"With our longstanding track record of delivery into automotive and our diverse IP offerings, Imagination's GPU, AI, ethernet and RISC-V CPU cores are ideal for automotive grade, safety-critical applications. An integration of these IPs into SoC.one mix-reality cloud enables the designers to continuously characterize, validate, and develop software for automotive use-cases. We are delighted to be partnering with SoC.one to enable the next evolution of RISC-V automotive design," said Shreyas Derashri, Vice President of Compute at Imagination.
Automotive devices-under-x extends from onboard elements (sensors, cameras, ECUs, compute solutions) to infrastructure elements (traffic lights, smart signs, wireless communication) and vehicles (cars, trucks, motorcycles), all utilizing IPs from Imagination Technologies. SoC.one Cloud provides the means for developers and software systems to interact with the device-under-x in a close-loop context. Simulation helps the designers understand how an automotive product or device may ultimately function. SoC.one extends this capability to all phases of the product design and development, from conceptualization to stages of implementation and deployment.
Founded in 2021, SoC.one offers RISC-V developers an innovative cloud platform that includes prototyping platforms, and software debug tools to provide software developers with a unified and seamless remote experience, resulting in significant time and cost saving compared with traditional on-prem development resources and paradigm. SoC.one's custom cloud-native environment streamlines access to digital design tools and online platforms to lower adoption barriers and accelerate development time for RISC-V System-on-Chip designers.
Media Contact:
Neal Leavitt
Leavitt Communications
(760) 639-2900
neal@leavcom.com
Imagination is a UK-based company that creates silicon and software IP (intellectual property) designed to give its customers an edge in competitive global technology markets. Its GPU, CPU, and AI technologies enable outstanding power, performance, and area (PPA), fast time-to-market, and lower total cost of ownership. Products based on Imagination IP are used by billions of people across the globe in their smartphones, cars, homes, and workplaces. See https://www.imaginationtech.com/
Follow Imagination on Twitter, YouTube, LinkedIn, Facebook and Blog.
Imagination, PowerVR, and the Imagination Technologies logo are trademarks of Imagination Technologies Limited and/or its affiliated group companies in the United Kingdom and/or other countries. All other logos, products, trademarks, and registered trademarks are the property of their respective owners.
References:
View original content to download multimedia:
SOURCE SoC.one
|
https://www.whsv.com/prnewswire/2022/09/12/socone-imagination-technologies-partner-enable-adoption-risc-v-automotive-design/
| 2022-09-12T09:38:08Z
|
...HIGH SURF ADVISORY IN EFFECT FOR SOUTH FACING SHORES OF ALL
ISLANDS BEGINNING MONDAY MORNING...
.A south swell (190 degrees) will build tonight and bring surf
heights to advisory level for south facing shores by Monday
morning. The large surf will continue Monday night and decline
Tuesday.
...HIGH SURF ADVISORY IN EFFECT FROM 6 AM MONDAY TO 6 AM HST
TUESDAY...
* WHAT...Surf 7 to 10 feet.
* WHERE...South facing shores of all Hawaiian Islands.
* WHEN...From 6 AM Monday to 6 AM HST Tuesday.
* IMPACTS...Moderate. Expect strong breaking waves, shore break,
and strong longshore and rip currents making swimming
difficult and dangerous.
PRECAUTIONARY/PREPAREDNESS ACTIONS...
Beachgoers, swimmers, and surfers should heed all advice given by
ocean safety officials and exercise caution.
&&
HONOLULU (KITV)- Sunday marked 21 years since 9-11 terrorist attacks. Nearly 3,000 people lost their lives that day. In Honolulu, local leaders, firefighters, and residents commemorated those who were killed during the annual Remembrance Walk.
One step after the other, one person after another taking part in Honolulu's Remembrance Walk in Honolulu.
“Quite honestly I feel emotional about this,” said Honolulu Mayor Rick Blangiardi. Honolulu's mayor isn't the only one thinking about the nearly 3,000 people who died in the terrorist attacks over two decades ago.
The streets are packed with people for this walk, the first since 2019 because of COVID. “This is wonderful. Because of the tragedy that our nation went through, it should be remembered. We're not the type to be a violent nation. But I think the remembrance is good,” said Lester Chao who is honoring those who died in the 9-11 attacks.
343 firefighters and 60 law enforcement officers lost their lives rushing to the aid of those inside buildings hit by the attacks. Honolulu firefighters remember... and honor those killed.
“It's just about serving the community. They lost their lives. And it’s something we would not want to see again on our soil. But again, this is a great opportunity to remember their sacrifices and the heroes they are,” said Honolulu Fire Department Fire Chief Sheldon Hao.
This day, there are moments of silence at the police station and fire station. To get to each location. the public and first responders travel together. The journey ends, with a memorial at city hall with an everlasting flame, a cultural tribute, and a laying of flower lei. All in the honor of those who died.
“We just have to remind our young generation what happened over 20 years ago. So any time we can remember those sacrifices, it’s a good opportunity,” said Chief Hao.
Many first responders also died from health complications related to saving people from the buildings damaged by the attacks.
Do you have a story idea? Email news tips to news@kitv.com
Jefferson Tyler joined KITV after a lengthy stint in Reno, Nev. where he covered a variety of subjects. From wildfires to presidential elections, Jefferson takes pride in creating balanced stories that keep viewers’ attentions.
|
https://www.kitv.com/news/crime/remembrance-walk-for-9-11-returns/article_5ae77152-3274-11ed-abb7-7312e514856c.html
| 2022-09-12T09:56:50Z
|
Ukraine keeps initiative, claims it reached Russian border
KHARKIV, Ukraine (AP) - Ukraine kept the counteroffensive momentum in its war against Russia going Monday, saying it liberated one village after another and claiming that in one region it pushed the invaders back right up to the border in a lightning military move that stunned many.
“In some areas of the front, our defenders reached the state border with the Russian Federation,” said the regional governor of the northeastern Kharkiv region, Oleh Syniehubov. Russian troops crossed the border in the region on Feb. 24, the first day of the invasion.
Russia acknowledged the military developments by saying it was regrouping. As throughout the war, military claims were hard to verify independently.
After Sunday’s attacks by Russia on power stations and other infrastructure that knocked out electricity in many place across Ukraine, Kyiv authorities also said that electric power and water supplies have been restored to some 80 percent in the Kharkiv region.
“You are heroes!!!” wrote Kharkiv mayor Ihor Terekhov early in the morning on Telegram, highlighting the ebullient mood in the nation that has endured more than 200 days of war and occupation. “Thanks to everyone who did everything possible on this most difficult night for Kharkiv to normalize the life of the city as soon as possible.”
The General Staff of the Armed Forces of Ukraine said that its troops had liberated more than 20 settlements within the past day.
The buoyant mood was also captured by a defiant President Volodymyr Zelenskyy on social media late Sunday, comments that immediately went viral.
“Do you still think you can intimidate, break us, force us to make concessions? Did you really not understand anything? Don’t understand who we are? What we stand for? What we are talking about,” Zelenskyy exhorted.
“Read my lips,” he continued. “Cold, hunger, darkness and thirst for us are not as scary and deadly as your ‘friendship’ and brotherhood.’”
He added: “We will be with gas, lights, water and food… and WITHOUT you!”
Yet even amid the ebullience, the casualties kept mounting. Ukraine’s presidential office said Monday that at least four civilians were killed and 11 others were wounded in a series of Russian attacks in nine regions of the country. The U.N. Human Rights Office said last week that 5,767 civilians were killed so far.
The Russians continued shelling Nikopol across the Dnieper from the Zaporizhzhia power plant, damaging several buildings there and leaving Europe’s largest nuclear facility in a precarious position.
The turn of events and all-important reversal of initiative was backed up by international observers who warned of dire times ahead for Russian troops. It stood in sharp contrast to the first days of the war when Russian troops were moving toward Kyiv’s doorstep.
“In the face of Ukrainian advances, Russia has likely ordered the withdrawal of its troops from the entirety of occupied Kharkiv Oblast west of the Oskil River,” the British defense ministry said Monday, signifying a major advance by Kyiv. “Ukraine has recaptured territory at least twice the size of Greater London,” it said.
The British said that likely will further deteriorate the trust Russian forces have in their commanders. Ukraine’s initial move on the southern Kherson area, drawing the attention of enemy troops there, before pouncing on more depleted Russian lines in the northeast beyond Kharkiv has been seen as a great military move so far.
Even around Kherson, Russia is struggling to bring forces across the Dnipro River to stop the Ukrainian offensive there, the British military said.
It added: “The rapid Ukrainian successes have significant implications for Russia’s overall operational design. The majority of the force in Ukraine is highly likely being forced to prioritize emergency defensive actions.”
The Washington-based Institute for the Study of War said Monday that Russia likely lacks the reserve forces it needs to bolster its defenses in Ukraine.
While the war likely will stretch into next year, the institute believes that “Ukraine has turned the tide of this war in its favor” by effectively using Western-supplied weapons like the long-range HIMARS missile system and strong battlefield tactics. “Kyiv will likely increasingly dictate the location and nature of the major fighting.”
Seeking to contain its loss of momentum, Russia fired missiles at power plants and other critical infrastructure, immediately meeting with Ukrainian and U.S. criticism for centering on civilian targets.
The bombardment ignited a massive fire at a power station on Kharkiv’s western outskirts and killed at least one person. Zelenskyy denounced the “deliberate and cynical missile strikes” against civilian targets as acts of terrorism.
“Russia’s apparent response to Ukraine liberating cities and villages in the east: sending missiles to attempt to destroy critical civilian infrastructure,” U.S. Ambassador to Ukraine Bridget A. Brink wrote.
Separately, the Zaporizhzhia Nuclear Power Plant in the Russia-occupied south completely shut down in a bid to prevent a radiation disaster as fighting raged nearby.
___
Arhirova reported from Kyiv.
____
Follow AP war coverage at https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/09/12/ukraine-keeps-initiative-claims-it-reached-russian-border/
| 2022-09-12T10:24:35Z
|
The Primetime Emmy Awards will be held Monday night in Los Angeles and broadcast live on NBC and its streaming service Peacock. Keenan Thompson, of Saturday Night Live, will emcee the ceremony.
Copyright 2022 NPR
The Primetime Emmy Awards will be held Monday night in Los Angeles and broadcast live on NBC and its streaming service Peacock. Keenan Thompson, of Saturday Night Live, will emcee the ceremony.
Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/a-preview-of-some-of-the-top-contenders-to-walk-away-with-an-emmy
| 2022-09-12T10:34:30Z
|
After decades in Queen Elizabeth's shadow, her son Charles is now Britain's king Published September 12, 2022 at 4:07 AM CDT Facebook Twitter LinkedIn Email Listen • 5:17 NPR's Steve Inskeep and British journalist Tina Brown discuss the challenges facing King Charles III as he begins his reign. Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/after-decades-in-queen-elizabeths-shadow-her-son-charles-is-now-britains-king
| 2022-09-12T10:34:31Z
|
NPR's A Martinez talks to Cynt Marshall about her memoir: You've Been Chosen. She discusses surviving colon cancer, her rise in corporate America and other events that helped shape who she is today.
Copyright 2022 NPR
NPR's A Martinez talks to Cynt Marshall about her memoir: You've Been Chosen. She discusses surviving colon cancer, her rise in corporate America and other events that helped shape who she is today.
Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/dallas-mavericks-ceo-talks-about-beating-the-odds-in-her-new-memoir
| 2022-09-12T10:34:32Z
|
NPR's A Martínez talks to former U.S. Attorney Chuck Rosenberg about what a judge will consider when choosing who to appoint as a special master in the Mar-a-Lago documents case.
Copyright 2022 NPR
NPR's A Martínez talks to former U.S. Attorney Chuck Rosenberg about what a judge will consider when choosing who to appoint as a special master in the Mar-a-Lago documents case.
Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/doj-and-trump-attorneys-offer-names-for-an-outside-arbiter-in-fbi-search-case
| 2022-09-12T10:34:33Z
|
Community Forklift in Maryland is a beloved shopping spot for deals on architectural salvage, but like many such businesses, it's struggling with rising prices for warehouse space.
Copyright 2022 WAMU 88.5
Community Forklift in Maryland is a beloved shopping spot for deals on architectural salvage, but like many such businesses, it's struggling with rising prices for warehouse space.
Copyright 2022 WAMU 88.5
|
https://www.keranews.org/2022-09-12/e-commerce-gains-push-warehouse-vacancies-to-a-low-rents-to-a-record-high
| 2022-09-12T10:34:34Z
|
ALBANY, Ga. – Johnnie Armstrong says he has voted in Albany since 1955, so he remembers an era when local officials tried to keep Black voters like him from the ballot box.
"They'd give you a bottle, a big thing with a lot of marbles in it," he says. "You guess how many marbles, then you can vote."
Armstrong says it felt remarkable that about 65 years later he got to help elect Georgia's first Black U.S. senator, Democrat Raphael Warnock.
Even better, Armstrong says, is Warnock spending a muggy August morning taking selfies with voters on Albany's Ray Charles Plaza as he campaigns for a full term in Washington.
Until recently, a statewide candidate spending significant time in this thinly-populated, substantially Black, southwest corner of Georgia was virtually unheard of.
For years, Democrats failed to win statewide in Georgia. The ground began to shift about four years ago when Stacey Abrams made her first bid for governor.
"Atlanta cannot live without Albany, and Albany cannot live without the investments that come from Atlanta," Abrams said in 2017, launching her campaign, not in Atlanta, but in Albany. "We need to talk to those forgotten voters, the ones who are rarely talked about. I am running for governor because we need a governor who comes from a town like Albany. Where we begin does not dictate what we become."
Instead of bending over backward to court more conservative voters, Abrams focused on activating non-voters and irregular voters, especially people of color in overlooked parts of the state.
"I know everybody looks at Atlanta as the African American mecca," says Albany Commissioner Demetrius Young. "But if you follow this blue wave in Georgia, it came right through Albany down into Southwest Georgia. We need to hold the ground that we've gained."
Abrams' strategy got her within 55,000 votes of the governor's mansion in 2018, losing to Republican Brian Kemp. Two years later, it helped deliver Georgia for Joe Biden and flip two Senate seats, giving Democrats control of the U.S. Senate.
Voters want change
Young is glad candidates come to southwest Georgia now, but he says they also need to deliver on their promises for a region that's not benefited as much from the state's economic growth.
"With the pandemic, it ripped wide open the disparities we knew were already there," he says.
Roughly a quarter of Southwest Georgians live below the poverty line, early double the rate in the U.S. For a time, Albany had the country's worst per-capita death rate from COVID.
After several grueling election cycles, many voters are tired and organizers are trying to combat that.
On a drizzly Monday, Shayla Jackson, an Albany native with the non-partisan New Georgia Project, canvasses a block of small homes, where backyard chickens roam freely. After striking out at a dozen or so addresses, Lavasha Hooks opens her door for Jackson, with a toddler hiding behind her legs.
Hooks says the economy, racial justice and the pandemic are all on her mind. She plans to vote but she hasn't thought much about the midterms yet. She says she doesn't think politicians have done much to improve life in her corner of Georgia.
"The wages are too low in my current job," Hooks says. "And everything is more expensive."
Jackson walks Hooks through finding her polling location and asks if she will need a ride to the polls. The New Georgia Project, which does not canvas for candidates or parties, was founded by Abrams in 2014 as part of her strategy to expand Georgia's electorate. Abrams is no longer affiliated with the organization.
More than 50,000 people have registered in Southwest Georgia since 2018. The majority are non-white, the New Georgia Project says.
"Look, for the most part, the rural characterization is true," says Dante Chinni, a researcher with the American Communities Project who has studied rural African American counties in the South. "Rural America tends to vote for Trump, tends to be Republican. But when you divide the vote further, you see these subtleties and nuances."
Nearly a quarter of rural Americans were people of color in 2020, according to an analysis by the Brookings Institution. And while the country's rural population is shrinking overall, its diversity is growing.
Still, the biggest shifts from red to blue in 2020 were in the suburbs of metro Atlanta, where newcomers have poured in from out of state and where then-President Donald Trump repelled many moderate voters.
And even while Democrats in racially diverse rural communities in the South turned out more voters in the 2020 presidential election than in 2016, turnout for Trump soared even more in these same counties, driven by white, rural voters.
"This is a both/and strategy. I think some people want to use it as an either/or," says Andra Gillespie, a professor of political science at Emory University.
"Even though Democrats expect to lose in rural parts of the state, they can't underperform there. Because if they underperform there, they end up losing the election."
Life and death challenges
Outside Albany, city blocks give way to acres of cotton and peanut crops. An hour up US-82 is the town of Cuthbert, Ga.
Its only hospital closed a few years ago.
"When the hospital closed, it became like a sudden death to us," says Rhonda Jones-Johnson, who used to work as a nurse there. "It broke some of our lives."
This spring, Jones-Johnson spoke alongside Abrams, who held her first formal campaign stop in front of the shuttered hospital. At the event, Jones-Johnson described how her aunt died waiting to access care.
"We had only one ambulance in the county," Jones-Johnson said. "No emergency care. If only we had a hospital open here, I truly believe her life could have been saved."
Both parties are trying to convince voters far from metro Atlanta that they're listening. Republicans, like Gov. Brian Kemp and Senate candidate Herschel Walker, are regularly barnstorming whiter rural counties, rallying their most reliable voters.
Democrats hope to slice into the GOP's margins, particularly in racially-diverse rural counties. Warnock has emphasized the plight of rural Black farmers. Abrams prominently highlights rural hospital closures as she pitches her plan to expand Medicaid.
Elections may hinge on the suburbs, but candidates need every vote
Youth organizer Maggie Bell appreciates the specific challenges this region faces. She also says the rural South is more diverse and vibrant than outsiders may imagine.
Bell graduated in the spring from Albany State University, a historically Black college.
"When people think of rural voters, they think of farmers, white people," Bell says, as Albany State's Marching Rams band parades by. "But really, there are Black people down here – Black people who want to be part of the election process, but they don't get a knock at their door."
Bell feels the weight of history in Albany, too. In 1961, Black residents in Albany launched what's considered the country's first mass civil rights movement to desegregate an entire city.
Bell says she's optimistic about what can happen as voters in this stretch of Georgia harness their power. And she says campaigns in other states should take note, as Democrats nationwide have struggled to win rural voters.
"Pay attention to these counties," she says. "Because once you engage and mobilize Black and brown people in these counties, you will actually see your work come to fruition."
This fall will be another test. Two months out, Abrams is trailing Kemp in polls. Warnock is slightly ahead of Walker in averages.
Both races are extremely tight.
On Election Night, cable TV anchors will spend a lot of time zooming in on their touch-screen maps on metro Atlanta, picking apart the returns from counties like Fulton, Cobb, Gwinnett and DeKalb.
But Bell still believes organizers have to work for every vote, especially in counties like hers, and especially in a state where election outcomes have become famously close.
Copyright 2022 90.1 WABE
|
https://www.keranews.org/2022-09-12/georgias-rural-black-voters-helped-propel-democrats-before-will-they-do-it-again
| 2022-09-12T10:34:50Z
|
Anti-abortion rights groups say they've been preparing to help women facing unplanned pregnancies through a network of volunteer organizations. Critics say those services come with strings attached.
Copyright 2022 NPR
Anti-abortion rights groups say they've been preparing to help women facing unplanned pregnancies through a network of volunteer organizations. Critics say those services come with strings attached.
Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/groups-opposing-abortion-are-getting-more-calls-for-help-with-unplanned-pregnancies
| 2022-09-12T10:34:56Z
|
Drug price reforms passed as part of the Inflation Reduction Act did not solve the problem of skyrocketing costs of insulin. States are taking their own action.
Copyright 2022 NPR
Drug price reforms passed as part of the Inflation Reduction Act did not solve the problem of skyrocketing costs of insulin. States are taking their own action.
Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/insulin-costs-increased-600-over-the-last-20-years-states-aim-to-curb-the-price
| 2022-09-12T10:35:02Z
|
Ukrainian forces reclaimed a wide swath of territory in the northeast. China's president will make his first trip out of China in over two years. U.S. states aim to lower the high cost of insulin.
Copyright 2022 NPR
Ukrainian forces reclaimed a wide swath of territory in the northeast. China's president will make his first trip out of China in over two years. U.S. states aim to lower the high cost of insulin.
Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/news-brief-ukraine-recaptures-key-territory-xi-putin-meeting-insulin-prices
| 2022-09-12T10:35:08Z
|
NPR's Bob Boilen and Stephen Thompson were straining to hear folk singer Laura Gibson. They invited her to perform at NPR's headquarters at Boilen's desk. The 1,000 Tiny Desk Concert is out Monday.
Copyright 2022 NPR
NPR's Bob Boilen and Stephen Thompson were straining to hear folk singer Laura Gibson. They invited her to perform at NPR's headquarters at Boilen's desk. The 1,000 Tiny Desk Concert is out Monday.
Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/npr-musics-tiny-desk-concerts-followed-a-visit-to-a-noisy-bar-at-sxsw-in-austin
| 2022-09-12T10:35:14Z
|
The tiny Lac La Croix pony, also known as the Ojibwe horse, faced extinction decades ago, but on-going efforts aim to help the breed survive.
Copyright 2022 MPR News
The tiny Lac La Croix pony, also known as the Ojibwe horse, faced extinction decades ago, but on-going efforts aim to help the breed survive.
Copyright 2022 MPR News
|
https://www.keranews.org/2022-09-12/the-story-of-a-breed-of-tiny-horses-is-one-of-those-greatest-stories-rarely-told
| 2022-09-12T10:35:21Z
|
Native Americans say they're "sad, betrayed and exhausted" after the University of North Dakota recently found human remains of their ancestors in its possession.
Copyright 2022 MPR News
Native Americans say they're "sad, betrayed and exhausted" after the University of North Dakota recently found human remains of their ancestors in its possession.
Copyright 2022 MPR News
|
https://www.keranews.org/2022-09-12/the-university-of-north-dakota-will-return-native-american-remains-to-tribal-homes
| 2022-09-12T10:35:27Z
|
The tennis tournament saw players on both the women's and men's side winning the championship for the first time, and Serena Williams may have played in her final tournament.
Copyright 2022 NPR
The tennis tournament saw players on both the women's and men's side winning the championship for the first time, and Serena Williams may have played in her final tournament.
Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/this-years-u-s-open-is-in-the-books-and-many-call-it-one-of-the-greatest
| 2022-09-12T10:35:33Z
|
President Xi Jinping is traveling outside China for the first time since the start of the pandemic. He'll meet with Russia's President Vladimir Putin at a security forum meeting in Uzbekistan.
Copyright 2022 NPR
President Xi Jinping is traveling outside China for the first time since the start of the pandemic. He'll meet with Russia's President Vladimir Putin at a security forum meeting in Uzbekistan.
Copyright 2022 NPR
|
https://www.keranews.org/2022-09-12/xi-putin-meeting-marks-a-closer-relationship-between-the-2-global-powers
| 2022-09-12T10:35:39Z
|
Why did you decide to look at arteries in studying long COVID?
Usually, when normal people exercise or move around, their heart needs more blood. The arteries dilate so you can get enough blood to the heart, so your heart can function and provide enough blood to the entire body and muscles.
We noted in this study that among those patients with prior COVID infection, there was a nearly 20% decrease in the amount of blood that is supplied to the heart muscle. This may potentially in part explain why these patients continue to have chest pain or shortness of breath. When their heart needs more blood there not getting it fully.
40 to 50% of these patients actually had this decreased blood flow to the heart. And we know from prior studies that this decrease in blood flow to the heart is not a benign condition and if persists, that is associated with a worse outcome.
This study pointed to endothelial cells as a sign of how COVID affects the heart. What are endothelial cells?
The cells that are possible for dilating your arteries when you are exercising. Your endothelial cells signal to the arteries that it's time to dilate because Sam is exercising, and he needs more blood delivered to his heart. So, let's relax and open the arteries so more blood is delivered.
You're finding that COVID gets in the way?
Yes. We have some work from our basic science colleagues here at Houston Methodist that shows that COVID affects the endothelial cells and makes them less active.
So, we know from other disease states that patients with diabetes and other conditions have their endothelial cells not fully functional, and that's why their arteries don't dilate. And what we noted here is that these patients here with COVID have kind of this similar situation.
How or why would COVID do that?
There might be some biomarkers that it really is whether the virus is attacking these cells directly or not. We don't have these assets yet.
Is there a specific type of COVID patient who develops this? Older patients, younger patients, maybe people with preexisting heart conditions? What have you seen so far?
We found this across the board. So that's kind of probably more related to the infection itself rather than preexisting conditions these patients had.
What could damaged endothelial cells ultimately do to someone with long COVID or to someone period?
We know this condition from before the days of COVID. That's called coronary microvascular dysfunction because there are a whole subset of patients who continue to have chest pain and shortness of breath. And these patients have no blockages in their arteries. It’s just that endothelial cells are not working fine.
What is new in this study is that linking this and some patients report that initially it was linked more often to diabetes, high cholesterol, obesity, renal, kidney problems, things like that. But what we found here is that probably COVID is giving us something that is similar.
Since we know of this particular problem with damaged endothelial cells anyway. Is there a treatment for it?
Before the days of COVID, we primarily focused on statins, aspirin, and calcium channel blockers in some patients. That is not the definitive therapy.
And I would say risk factor modification is actually a very important and helpful treatment in these patients. Specifically controlling blood pressure, controlling sugar, controlling cholesterol, exercising, quitting smoking, and weight loss. All of these have been shown before to be very helpful in the treatment of this condition.
RESOURCES:
Heart Problems Among Consistent Symptoms For COVID Long Haulers, New Research Finds
COVID-19: UTSW Rehab Program Offers Help For Long Haulers
What's ailing long COVID patients? A new federal study looks for clues
|
https://www.keranews.org/health-wellness/2022-09-12/houston-researchers-find-your-heart-arteries-may-play-a-role-in-long-covid
| 2022-09-12T10:35:45Z
|
Under the Trump administration, applying for Medicaid or the Supplemental Nutrition Assistance Program could affect an immigrant’s eligibility for a green card.
But the Biden Administration’s decision last week to finalize a rule that undoes Trump’s policy is welcome news for advocates, who say such restrictions were harmful to immigrants going through the immigration process.
Adriana Cadena, director of Protecting Immigrant Families Coalition, called the revised so-called public charge rule a win for immigrant communities.
"Programs like SNAP, WIC, the Child Tax Credit, Section 8 Housing and other non-cash federal programs and also any similar programs at a local or state level will never affect a person's immigration status,” Cadena said. “The important thing here is that immigrant communities who need to use these services can do so without fear of affecting their immigration status."
The newly finalized rule largely resembles the policy in place before the Trump administration. The concept has been around since the late 1880s and is used to determine if a noncitizen could become a “public charge” or likely dependent on government assistance. If so, then the person could be denied a green card, or lawful permanent residence.
Despite the Biden’s administration decision to undo Trump’s policy, some organizations are still concerned. The Migration Policy Institute said recent interviews conducted by its researchers revealed that some individuals are still confused or afraid of accessing benefits and social services for fear of hurting their immigration status.
The Department of Homeland Security has said it noticed a decline in enrollment in certain programs by U.S. citizen children after Trump’s policy took effect even though they weren’t subject to that policy.
“What’s really important is that DHS is not going to look at only the use of those services — those particular two programs (long-term institutional care or cash assistance) — but they’re going to ensure that they look at the totality of the person and ensure that they look at the person’s age, education, health, income and if they have enough to be able to support.”
Although someone could use these services and possibly be considered a public charge, Cadena said the federal government won’t automatically consider them a public charge.
Got a tip? Email Stella M. Chávez at schavez@kera.org. You can follow Stella on Twitter @stellamchavez.
KERA News is made possible through the generosity of our members. If you find this reporting valuable, consider making a tax-deductible gift today. Thank you.
|
https://www.keranews.org/news/2022-09-12/new-immigration-rules-shouldnt-discourage-green-card-applicants-from-seeking-help-advocates-say
| 2022-09-12T10:35:51Z
|
Biden to announce new support for US biotech production
WASHINGTON (AP) — President Joe Biden is launching a new initiative to encourage biotech production and research in the U.S., the latest move by the White House to boost domestic industry.
Biden on Monday signed an executive order implementing the initiative and later, in remarks at the John F. Kennedy Presidential Library in Boston, will address how biotech can help fight cancer. On Wednesday, the Democratic president’s administration will host a summit and announce new investments from several federal agencies, according to a White House fact sheet.
The initiative will seek to boost biomanufacturing in pharmaceuticals but also in other industries such as agriculture, plastics and energy. A senior administration official wouldn’t say how much funding will be announced Wednesday.
Biomanufacturing processes can program microbes to make specialty chemicals and compounds, the fact sheet said. Biomanufacturing can be used to make alternatives to oil-based chemicals, plastics and textiles.
The executive order follows bipartisan legislation Biden signed last month that provided $52 billion to subsidize the production of semiconductors, construction of new chip plants and research and development in the United States.
That legislation was intended to reduce the U.S. economy’s reliance on semiconductors made overseas, particularly in Taiwan, and to respond to greater efforts by China to develop its own chip industry.
Biden touted the benefits of the semiconductor law on Friday, in a stop in Columbus, Ohio, where chip giant Intel has broken ground on a new $20 billion factory.
The administration official, who wasn’t authorized to speak publicly and insisted on anonymity, said the White House wants to support manufacturing biotech products that are developed in the U.S., rather than seeing American innovations produced abroad.
The official said that the administration was aiming to expand domestic biomanufacturing capacity and that other countries, especially China, have been aggressively investing in the sector, posing risks to U.S. leadership and competitiveness.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/09/12/biden-announce-new-support-us-biotech-production/
| 2022-09-12T11:08:06Z
|
Report Finds 88% of Current Internet-Connected Risks Driven By Misconfigurations and Exposures
ANN ARBOR, Mich., Sept. 12, 2022 /PRNewswire/ -- Today, Censys, the leader in Attack Surface Management (ASM), launched its inaugural State of the Internet Report, a holistic view into Internet risks and organizations' exposure to them. This first-of-its-kind report also provides perspective on how security practitioners addressed several vulnerabilities over the last eighteen months, while offering organizations guidance for how to prioritize and evaluate the security maintenance of their Internet-connected business assets.
The inaugural report compiled by the Censys research team is informed by the firm's technology, which maintains the most comprehensive view of assets on the Internet by continuously scanning the public IPv4 address space across the 3,600+ most popular ports. The Censys research team's mission is to conduct timely and critical research of Internet exposures and enable the broader cybersecurity community to take quick actions that mitigate future issues.
Through careful examination of which ports, services, and software are most prevalent on the Internet and the systems and regions where they run, Censys' research team discovered that misconfigurations and exposures represent 88% of the risks and vulnerabilities across the Internet. Using Censys' Internet-wide scan capabilities and risk detection fingerprints, the State of the Internet Report provides visibility of the assets and weaknesses across an organization's Internet infrastructure in three sections: the Internet as a Whole, the Attack Surface of the Internet, and the Attack Surfaces of Organizations.
"Assessing the state of the Internet is crucial in understanding an organization's own risks and exposures," said Zakir Durumeric, Co-Founder and Chief Scientist of Censys. "Censys' unique perspective of the Internet provides a holistic look into the potential consequences of misconfigurations, while outlining security teams' crucial need for expanded visibility and understanding to make smart security decisions."
Censys' 2022 State of the Internet Report found that:
- Misconfigurations – including unencrypted services, weak or missing security controls and self-signed certificates – make up roughly 60% of observed risks. When analyzing the risk profile of organizations across industries, missing common security headers accounted for the primary security error.
- Exposures of services, devices, and information represent 28% of observed risks. This includes everything from accidental database to device exposures.
- Critical vulnerabilities and advanced exploits only represent 12% of observed risks. When analyzing organizations by industry, the Computer and Information Technology industry had the widest spread of different risks, while Freight Shipment and Postal Services had the second widest.
Censys' researchers also conducted a holistic assessment of the Internet's response to three major vulnerabilities – Log4j, GitLab and Confluence – to understand mitigation strategies based on how a vulnerability is perceived. From this analysis, Censys learned how the Internet responds differently to vulnerability disclosures.
Censys observed three distinct types of behavior in response to vulnerability disclosures:
- Near-immediate upgrading: Systems vulnerable to Log4j acted quickly based on the widespread coverage of the vulnerability. By March 2022, Censys observed only 36% of potential vulnerable services were left unpatched.
- Upgrading only after the vulnerability is being actively and widely exploited: While the GitLab vulnerability was being exploited, the remediation process acted slower than others until researchers discovered a botnet composed of thousands of compromised GitLab servers participating in DDoS campaigns.
- Near-immediate response by taking the vulnerable instance off the Internet entirely: Rather than upgrading, users chose to remove assets entirely from the Internet after Confluence's vulnerability became public between June 2021 and March 2022.
The Internet constantly evolves as new technologies emerge, vulnerabilities are discovered, and organizations expand their operations that interact with the Internet. Security teams have the responsibility to protect their organizations' digital assets and need proper visibility into the entire landscape to do so. Although vulnerabilities often garner the bigger headlines, it's undetected misconfigurations and exposures that create the most risk for an organization, making it important to regularly assess any new hosts or services that appear in your infrastructure. Regardless of vulnerability type, providing organizations with the visibility and tools needed to strengthen their security posture introduces a proactive, more vigilant approach to digital risk management.
To download the full report, visit: https://censys.io/state-of-the-internet-report/
To learn more about Censys' approach to organizational visibility, visit: https://www.censys.io.
About Censys
Censys, Inc.™ is the leading provider of continuous attack surface management. Founded in 2013 in Ann Arbor, Michigan, Censys gives organizations the world's most comprehensive real-time view of global networks and devices. Customers like FireEye, Google, NATO, Swiss Armed Forces, the U.S. Department of Homeland Security, and over 10% of the Fortune 500 rely on the company's Internet-wide continuous visibility platform to discover and prevent cybersecurity threats. At Censys, you can be yourself. We like it that way. Diversity fuels our mission, and we are committed to inclusion across race, gender, age and identity. To learn more, visit censys.io and follow Censys on Twitter.
View original content to download multimedia:
SOURCE Censys
|
https://www.whsv.com/prnewswire/2022/09/12/censys-launches-inaugural-state-internet-report/
| 2022-09-12T11:08:13Z
|
SINGAPORE, Sept. 12, 2022 /PRNewswire/ -- China Yuchai International Limited (NYSE: CYD) ("China Yuchai" or "the Company"), a leading automotive manufacturer and distributor of engines for on- and off-road applications in China through its main operating subsidiary, Guangxi Yuchai Machinery Company Limited ("GYMCL"), announced today that its subsidiary, Guangxi Yuchai Machinery Monopoly Development Co., Ltd. has deregistered and ceased operations of the Vietnam Yuchai Machinery Services Co., Ltd. due to the restructuring of the Company's overseas business through resource optimization. Sales into the Vietnamese market are being conducted through the GYMCL headquarters.
About China Yuchai International
China Yuchai International Limited, through its subsidiary, Guangxi Yuchai Machinery Company Limited ("GYMCL"), engages in the manufacture, assembly, and sale of a wide variety of light-, medium- and heavy-duty engines for trucks, buses, passenger vehicles, construction equipment, marine and agriculture applications in China. GYMCL also produces diesel power generators. The engines produced by GYMCL range from diesel to natural gas and hybrid engines. Through its regional sales offices and authorized customer service centers, GYMCL distributes its engines directly to auto OEMs and retailers and provides maintenance and retrofitting services throughout China. Founded in 1951, GYMCL has established a reputable brand name, strong research and development team and significant market share in China with high-quality products and reliable after-sales support. In 2021, GYMCL sold 456,791 engines and is recognized as a leading manufacturer and distributor of engines in China. For more information, please visit http://www.cyilimited.com.
Safe Harbor Statement:
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe", "expect", "anticipate", "project", "targets", "optimistic", "confident that", "continue to", "predict", "intend", "aim", "will" or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that may be deemed forward-looking statements. These forward-looking statements including, but not limited to, statements concerning China Yuchai's and the joint venture's operations, financial performance and condition are based on current expectations, beliefs and assumptions which are subject to change at any time. China Yuchai cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world and in China including those discussed in China Yuchai's Form 20-Fs under the headings "Risk Factors", "Results of Operations" and "Business Overview" and other reports filed with the Securities and Exchange Commission from time to time. Among others, if the COVID-19 pandemic is not effectively and timely controlled, our business operations and financial condition may be materially and adversely affected due to a deteriorating market for automotive sales, an economic slowdown in China and abroad, a potential weakening of the financial condition of our customers, or other factors that we cannot foresee. All forward-looking statements are applicable only as of the date it is made and China Yuchai specifically disclaims any obligation to maintain or update the forward-looking information, whether of the nature contained in this release or otherwise, in the future.
For more information:
Investor Relations
Tel: +1-212-521-4050
Email: cyd@bluefocus.com
View original content:
SOURCE China Yuchai International Limited
|
https://www.whsv.com/prnewswire/2022/09/12/china-yuchai-announces-dissolution-vietnam-subsidiary/
| 2022-09-12T11:08:20Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention 17 Education & Technology Group Inc. ("17EdTech") (NASDAQ: YQ) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded 17EdTech securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with 17EdTech's December 2020 initial public offering.
If you suffered a loss on your investment in 17EdTech, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against 17EdTech includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) 17EdTech's K-12 Academic AST Services would end less than a year after the Company's initial public offering; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech's core business; and (3) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
DEADLINE: September 19, 2022
Aggrieved 17EdTech investors only have until September 19, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-17edtech-investors-lead-plaintiff-deadline-september-19-2022/
| 2022-09-12T11:08:27Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Abbott Laboratories ("Abbott") (NYSE: ABT) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all persons or entities who purchased or otherwise acquired shares of Abbott common stock during the period from February 19, 2021, to June 8, 2022, inclusive.
If you suffered a loss on your investment in Abbott, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: According to the filed complaint, defendants touted the strength of Abbott's infant formula brands and their contribution to the Company's sales and revenue growth, despite knowing that the facility that manufactured those products was in flagrant violations of United States Food and Drug Administration ("FDA") health, safety, and manufacturing regulations. The complaint further alleges that defendants willfully or recklessly concealed these violations from investors, even though the violations put Abbott's infant formula business in dire jeopardy and left the Company exposed to a risk of severe regulatory action, including the recall of its products and closure of the Sturgis facility. Indeed, according to the complaint, defendants received direct warnings, communications, FDA inspection reports, and consumer complaints identifying in detail the safety and regulatory violations that were rampant at the Sturgis facility.
Aggrieved Abbott investors only have until October 31, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-abbott-investors-lead-plaintiff-deadline-october-31-2022/
| 2022-09-12T11:08:34Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Azure Power Global Limited ("Azure") (NYSE: AZRE) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 15, 2021 and August 26, 2022.
If you suffered a loss on your investment in Azure, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Azure includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) there were procedural irregularities, including deviations from safety and quality standards, at one of Azure's plants; (2) certain project data was manipulated; (3) as a result of the foregoing, the Company's internal controls and procedures were not effective; (4) Azure had received a credible whistleblower report alleging such misconduct; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: October 31, 2022
Aggrieved Azure investors only have until October 31, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-azure-investors-lead-plaintiff-deadline-october-31-2022/
| 2022-09-12T11:08:41Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Carvana Co. ("Carvana") (NYSE: CVNA) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 6, 2020 and June 24, 2022.
If you suffered a loss on your investment in Carvana, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/cvna-carvana-loss-submission-form?prid=31515&wire=4
ABOUT THE ACTION: The class action against Carvana includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Carvana faced serious, ongoing issues with documentation, registration, and title with many of its vehicles; (2) as a result, Carvana was issuing unusually frequent temporary plates; (3) as a result of the foregoing, Carvana was violating laws and regulations in many existing markets; (4) as a result of the foregoing, Carvana risked its ability to continue business and/or expand its business in existing markets; (5) as a result of the foregoing, Carvana was at an increased risk of governmental investigation and action; (6) Carvana was in discussion with state and local authorities regarding the above-stated business tactics and issues; (7) Carvana was facing imminent and ongoing regulatory actions including license suspensions, business cessation, and probation in several states and counties including in Arizona, Illinois, Pennsylvania, Michigan, and North Carolina; and (8) as a result, Defendants' statements about Carvana's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
DEADLINE: October 3, 2022
Aggrieved Carvana investors only have until October 3, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-carvana-investors-lead-plaintiff-deadline-october-3-2022/
| 2022-09-12T11:08:47Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Co-Diagnostics, Inc. ("Co-Dx") (NASDAQ: CODX) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m. ET).
If you suffered a loss on your investment in Co-Dx, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Co-Dx includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) demand for the Company's Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants' positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.
DEADLINE: October 17, 2022
Aggrieved Co-Dx investors only have until October 17, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-co-dx-investors-lead-plaintiff-deadline-october-17-2022/
| 2022-09-12T11:08:53Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Dingdong (Cayman) Ltd. ("Dingdong") (NYSE: DDL) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of persons who purchased, or otherwise acquired, Dingdong American Depository Shares pursuant or traceable to the F-1 registration statements and related prospectus on Form 424B4 issued in connection with Dingdong's June 2021 initial public stock offering.
If you suffered a loss on your investment in Dingdong, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: According to the filed complaint, the registration statement and prospectus used to effectuate the Company's initial public offering misstated and/or omitted facts concerning Dingdong's so-called commitment to ensuring the safety and quality of the food it distributes to the market. For example, despite claiming that it applies "stringent quality control across [its] entire supply chain to ensure product quality to [its] users," Dingdong sold food past its sell-by date. Consequently, Dingdong was, in fact, no better at providing or assuring access to "fresh" groceries than the supermarkets, traditional Chinese wet markets, or traditional e-commerce platforms it repeatedly claimed to be displacing. Moreover, the foregoing conduct subjected Dingdong to an increased risk of regulatory and/or governmental scrutiny and enforcement, all of which, once revealed, were likely to negatively impact Dingdong's business, operations, and reputation.
Aggrieved Dingdong investors only have until October 24, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-dingdong-investors-lead-plaintiff-deadline-october-24-2022/
| 2022-09-12T11:08:59Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Enochian BioSciences, Inc. ("Enochian") (NASDAQ: ENOB) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 17, 2018 and June 27, 2022.
If you suffered a loss on your investment in Enochian, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Enochian includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Aggrieved Enochian investors only have until September 26, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-enochian-investors-lead-plaintiff-deadline-september-26-2022/
| 2022-09-12T11:09:06Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Humanigen, Inc. ("Humanigen") (NASDAQ: HGEN) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 28, 2021 and July 12, 2022.
If you suffered a loss on your investment in Humanigen, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Humanigen includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Humanigen's lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab's clinical and commercial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Aggrieved Humanigen investors only have until October 25, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-humanigen-investors-lead-plaintiff-deadline-october-25-2022/
| 2022-09-12T11:09:13Z
|
The Primetime Emmy Awards will be held Monday night in Los Angeles and broadcast live on NBC and its streaming service Peacock. Keenan Thompson, of Saturday Night Live, will emcee the ceremony.
Copyright 2022 NPR
The Primetime Emmy Awards will be held Monday night in Los Angeles and broadcast live on NBC and its streaming service Peacock. Keenan Thompson, of Saturday Night Live, will emcee the ceremony.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/a-preview-of-some-of-the-top-contenders-to-walk-away-with-an-emmy
| 2022-09-12T11:09:15Z
|
NPR's Steve Inskeep and British journalist Tina Brown discuss the challenges facing King Charles III as he begins his reign.
Copyright 2022 NPR
NPR's Steve Inskeep and British journalist Tina Brown discuss the challenges facing King Charles III as he begins his reign.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/after-decades-in-queen-elizabeths-shadow-her-son-charles-is-now-britains-king
| 2022-09-12T11:09:17Z
|
NPR's A Martinez talks to Cynt Marshall about her memoir: You've Been Chosen. She discusses surviving colon cancer, her rise in corporate America and other events that helped shape who she is today.
Copyright 2022 NPR
NPR's A Martinez talks to Cynt Marshall about her memoir: You've Been Chosen. She discusses surviving colon cancer, her rise in corporate America and other events that helped shape who she is today.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/dallas-mavericks-ceo-talks-about-beating-the-odds-in-her-new-memoir
| 2022-09-12T11:09:19Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.
If you suffered a loss on your investment in Kiromic, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the "Offering Documents") failed to disclose that the Food and Drug Administration ("FDA") had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ("IND") applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.
Aggrieved Kiromic investors only have until October 4, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-kiromic-investors-lead-plaintiff-deadline-october-4-2022/
| 2022-09-12T11:09:19Z
|
NPR's A Martínez talks to former U.S. Attorney Chuck Rosenberg about what a judge will consider when choosing who to appoint as a special master in the Mar-a-Lago documents case.
Copyright 2022 NPR
NPR's A Martínez talks to former U.S. Attorney Chuck Rosenberg about what a judge will consider when choosing who to appoint as a special master in the Mar-a-Lago documents case.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/doj-and-trump-attorneys-offer-names-for-an-outside-arbiter-in-fbi-search-case
| 2022-09-12T11:09:25Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Kohl's Corporation ("Kohl's") (NYSE: KSS) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between October 20, 2020 and May 19, 2022.
If you suffered a loss on your investment in Kohl's, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Kohl's includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Kohl's new strategic framework to "drive top-line growth," "expand operating margin," and become "the most trusted retailer of choice for the active and casual lifestyle" (the "Strategic Plan") was not well tailored to achieving the Company's stated goals; (ii) the defendants had likewise overstated the Company's success in executing its Strategic Plan; (iii) Kohl's had deficient disclosure controls and procedures, internal control over financial reporting, and corporate governance mechanisms; (iv) as a result, the Company's board of directors was able to and did withhold material information from shareholders about the state of Kohl's in the lead-up to the Company's annual meeting; (v) all the foregoing, once revealed, was likely to have a material negative impact on Kohl's financial condition and reputation; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Aggrieved Kohl's investors only have until November 1, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-kohls-investors-lead-plaintiff-deadline-november-1-2022/
| 2022-09-12T11:09:26Z
|
Community Forklift in Maryland is a beloved shopping spot for deals on architectural salvage, but like many such businesses, it's struggling with rising prices for warehouse space.
Copyright 2022 WAMU 88.5
Community Forklift in Maryland is a beloved shopping spot for deals on architectural salvage, but like many such businesses, it's struggling with rising prices for warehouse space.
Copyright 2022 WAMU 88.5
|
https://www.wyomingpublicmedia.org/2022-09-12/e-commerce-gains-push-warehouse-vacancies-to-a-low-rents-to-a-record-high
| 2022-09-12T11:09:32Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Latch, Inc. f/k/a TS Innovation Acquisitions Corp. ("Latch") (NASDAQ: LTCH) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 13, 2021 and August 25, 2022.
If you suffered a loss on your investment in Latch, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Latch includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) there were unreported sales arrangements related to hardware devices; (2) as a result, the Company had improperly recognized revenue throughout fiscal 2021 and first quarter 2022; (3) there were material weaknesses in Latch's internal control over financial reporting related to revenue recognition; (4) as a result of the foregoing, Latch would restate financial statements for fiscal 2021 and first quarter 2022; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: October 31, 2022
Aggrieved Latch investors only have until October 31, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-latch-investors-lead-plaintiff-deadline-october-31-2022/
| 2022-09-12T11:09:33Z
|
The death of Queen Elizabeth II closes a chapter in British history that lasted seven decades. But beyond the years, there's another way to mark her reign: in her lifetime, the queen met with a procession of 13 different U.S. presidents. The names and faces of the American head of state kept changing — while the queen and her crown remained a constant.
Her title was still Princess Elizabeth when she arrived in America for the first time in October 1951. Dignitaries on hand to meet the future queen on the crowded tarmac at Washington National Airport included President Harry Truman.
"It certainly is a very great pleasure for me as president of the United States to welcome you to the capital of our country," Truman said, adding, "I think your visit will improve — if that is possible — the cordial relations that exist between our two great countries, and I hope that while you are here you will have a very enjoyable time."
The 25-year-old Elizabeth — with husband Philip by her side — was there to represent her ailing father, King George VI.
Just months later, she'd be crowned queen.
Her next trip to America came in 1957 when President Dwight D. Eisenhower hosted her at a state dinner at the White House.
Eisenhower — dressed in white-tie and tails for the formal event — also wore a medal around his neck that the late King George VI had awarded him in recognition of his role as commander of allied forces in Europe during World War II.
John F. Kennedy was the first president Elizabeth hosted
News footage from 1961 shows the young president and first lady riding through London streets in an open top limousine. Crowds can be seen pressing forward, trying to get a closer look.
The Kennedys were invited to Buckingham Palace for dinner. Photos show the queen, Prince Philip and the Kennedys posing, all dressed in formal wear. But the visit has long been reported to have been more than a bit awkward.
There are stories of a queen jealous of the glamourous Jacqueline Kennedy. In fact, the encounter inspired the story-line for an episode of the Netflix Series, The Crown in 2017 — with the drama enhanced to be sure.
The series showed the queen getting word from a friend and confidant, Baron Patrick Plunket, of dismissive comments uttered later by Jackie Kennedy. In the series, Plunket tells the queen, "She found Buckingham Palace second-rate, dilapidated and sad, a much neglected provincial hotel. And that one came away with a sense of a tired institution without a place in the modern world."
The next president — Lyndon Johnson — was the only one Elizabeth did not meet. There's no definitive explanation as to why, but the meetings resumed with Richard Nixon.
President Gerald Ford would welcome the queen in a ceremony on White House South Lawn on the occasion of America's bicentennial, marking its break with the crown.
"Your Majesty, the wounds of our parting in 1776 healed long ago. Americans admire the United Kingdom as one of our truest allies and best friends," Ford said.
For her part, the queen described that past as long buried.
"History is not a fairy tale," she said in a toast at a state dinner that evening. "What is more important is that our shared language and traditions and history have given us a common vision of what is right and just."
President Jimmy Carter visited Elizabeth at Buckingham Palace in London a year later.
Then it was Ronald Reagan, the president with whom the queen seemed most comfortable. They went horseback riding together outside Windsor Castle and held long conversations with one another. Reagan later welcomed the queen to his home state of California, including a dinner in her honor in San Francisco.
President George H.W. Bush entertained the queen on her next U.S. visit, and he decided it was time that she got a look at America's pastime. Bush took the queen and Prince Philip her to a Major League Baseball game in Baltimore. She even held a receiving line with players in the Orioles dugout.
Such moments are symbolic and more. While presidents discuss policy with British prime ministers, with the monarch it's more about friendship and shared national values.
Elizabeth met Bill Clinton three times while he was president, including at ceremonies to mark the 50th anniversary of the D-Day landings on the European continent during WWII.
When George W. Bush was at the palace in 2003, the niceties of that visit were overshadowed by huge street demonstrations over the war in Iraq. Security was so tight during that trip, Bush's itinerary in London included no contact with the British people.
Four years later, Bush would host Elizabeth at the White House. During the welcome ceremony, Bush started to tell the audience that the queen had previously been there for the bicentennial in 1976 — but he misspoke and started to say she'd visited in 1776. He caught himself, paused, then looked over at the queen.
"She gave me a look that only a mother could give a child," Bush quipped.
The rest of the visit went smoothly, including a state dinner with a performance by the legendary violinist Itzhak Perlman afterward.
Proper etiquette is always paramount with the royals, but missteps do happen
When President and Michelle Obama were at the palace in 2009, at one point the first lady put her arm around the Queen. An affectionate gesture, but hugging the monarch is not something you're supposed to do.
Then there was President Trump's inspection of the Royal Guard on the palace grounds in 2018. It's an important ceremonial moment, but Trump suddenly cut right in front of the queen, blocking her path. It took a moment for them to sort it out and for Elizabeth to get herself into proper position to resume the inspection.
British tabloids took great notice. But in the case of both Trump and with Mrs. Obama, the queen appeared not to take offense.
In 2021, an economic summit brought President Biden to the UK. It's worth noting that every president before him who had met the queen had also met Prince Philip, who died two months prior to Biden's visit. As he began a major speech to the summit, Biden used the moment to first pay tribute to the queen's husband of 73 years.
'Today would have been Prince Philip's 100th birthday," Biden said, "I know there are a lot of people feeling his absence today."
Days later, the queen had the president and the first lady to the castle for tea.
Afterward, Biden told reporters that she had been gracious and that she reminded him a bit of his own mother.
He was the thirteenth sitting U.S. president Elizabeth would meet.
Copyright 2022 NPR. To see more, visit https://www.npr.org.
|
https://www.wyomingpublicmedia.org/2022-09-12/from-truman-to-biden-the-queens-meetings-with-presidents-were-formal-fun-or-awkward
| 2022-09-12T11:09:35Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention LifeStance Health Group, Inc. ("LifeStance") (NASDAQ: LFST) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all purchasers of LifeStance common stock pursuant and/or traceable to the documents issued in connection with LifeStance's June 10, 2021 initial public stock offering.
If you suffered a loss on your investment in LifeStance, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against LifeStance includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the number of virtual visits clients were undertaking utilizing LifeStance Health was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining LifeStance Health's out-patient/virtual revenue growth; (ii) the percentage of in-person visits clients were undertaking utilizing LifeStance Health was increasing as the COVID-19 lockdowns were being lifted, thereby causing LifeStance Health's operating expenses to increase substantially; (iii) LifeStance Health had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the initial public offering's registration statement, and LifeStance Health had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (iv) as a result, LifeStance Health's business metrics and financial prospects were not as strong as the initial public offering's registration statement represented.
Aggrieved LifeStance investors only have until October 11, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-lifestance-investors-lead-plaintiff-deadline-october-11-2022/
| 2022-09-12T11:09:39Z
|
ALBANY, Ga. – Johnnie Armstrong says he has voted in Albany since 1955, so he remembers an era when local officials tried to keep Black voters like him from the ballot box.
"They'd give you a bottle, a big thing with a lot of marbles in it," he says. "You guess how many marbles, then you can vote."
Armstrong says it felt remarkable that about 65 years later he got to help elect Georgia's first Black U.S. senator, Democrat Raphael Warnock.
Even better, Armstrong says, is Warnock spending a muggy August morning taking selfies with voters on Albany's Ray Charles Plaza as he campaigns for a full term in Washington.
Until recently, a statewide candidate spending significant time in this thinly-populated, substantially Black, southwest corner of Georgia was virtually unheard of.
For years, Democrats failed to win statewide in Georgia. The ground began to shift about four years ago when Stacey Abrams made her first bid for governor.
"Atlanta cannot live without Albany, and Albany cannot live without the investments that come from Atlanta," Abrams said in 2017, launching her campaign, not in Atlanta, but in Albany. "We need to talk to those forgotten voters, the ones who are rarely talked about. I am running for governor because we need a governor who comes from a town like Albany. Where we begin does not dictate what we become."
Instead of bending over backward to court more conservative voters, Abrams focused on activating non-voters and irregular voters, especially people of color in overlooked parts of the state.
"I know everybody looks at Atlanta as the African American mecca," says Albany Commissioner Demetrius Young. "But if you follow this blue wave in Georgia, it came right through Albany down into Southwest Georgia. We need to hold the ground that we've gained."
Abrams' strategy got her within 55,000 votes of the governor's mansion in 2018, losing to Republican Brian Kemp. Two years later, it helped deliver Georgia for Joe Biden and flip two Senate seats, giving Democrats control of the U.S. Senate.
Voters want change
Young is glad candidates come to southwest Georgia now, but he says they also need to deliver on their promises for a region that's not benefited as much from the state's economic growth.
"With the pandemic, it ripped wide open the disparities we knew were already there," he says.
Roughly a quarter of Southwest Georgians live below the poverty line, early double the rate in the U.S. For a time, Albany had the country's worst per-capita death rate from COVID.
After several grueling election cycles, many voters are tired and organizers are trying to combat that.
On a drizzly Monday, Shayla Jackson, an Albany native with the non-partisan New Georgia Project, canvasses a block of small homes, where backyard chickens roam freely. After striking out at a dozen or so addresses, Lavasha Hooks opens her door for Jackson, with a toddler hiding behind her legs.
Hooks says the economy, racial justice and the pandemic are all on her mind. She plans to vote but she hasn't thought much about the midterms yet. She says she doesn't think politicians have done much to improve life in her corner of Georgia.
"The wages are too low in my current job," Hooks says. "And everything is more expensive."
Jackson walks Hooks through finding her polling location and asks if she will need a ride to the polls. The New Georgia Project, which does not canvas for candidates or parties, was founded by Abrams in 2014 as part of her strategy to expand Georgia's electorate. Abrams is no longer affiliated with the organization.
More than 50,000 people have registered in Southwest Georgia since 2018. The majority are non-white, the New Georgia Project says.
"Look, for the most part, the rural characterization is true," says Dante Chinni, a researcher with the American Communities Project who has studied rural African American counties in the South. "Rural America tends to vote for Trump, tends to be Republican. But when you divide the vote further, you see these subtleties and nuances."
Nearly a quarter of rural Americans were people of color in 2020, according to an analysis by the Brookings Institution. And while the country's rural population is shrinking overall, its diversity is growing.
Still, the biggest shifts from red to blue in 2020 were in the suburbs of metro Atlanta, where newcomers have poured in from out of state and where then-President Donald Trump repelled many moderate voters.
And even while Democrats in racially diverse rural communities in the South turned out more voters in the 2020 presidential election than in 2016, turnout for Trump soared even more in these same counties, driven by white, rural voters.
"This is a both/and strategy. I think some people want to use it as an either/or," says Andra Gillespie, a professor of political science at Emory University.
"Even though Democrats expect to lose in rural parts of the state, they can't underperform there. Because if they underperform there, they end up losing the election."
Life and death challenges
Outside Albany, city blocks give way to acres of cotton and peanut crops. An hour up US-82 is the town of Cuthbert, Ga.
Its only hospital closed a few years ago.
"When the hospital closed, it became like a sudden death to us," says Rhonda Jones-Johnson, who used to work as a nurse there. "It broke some of our lives."
This spring, Jones-Johnson spoke alongside Abrams, who held her first formal campaign stop in front of the shuttered hospital. At the event, Jones-Johnson described how her aunt died waiting to access care.
"We had only one ambulance in the county," Jones-Johnson said. "No emergency care. If only we had a hospital open here, I truly believe her life could have been saved."
Both parties are trying to convince voters far from metro Atlanta that they're listening. Republicans, like Gov. Brian Kemp and Senate candidate Herschel Walker, are regularly barnstorming whiter rural counties, rallying their most reliable voters.
Democrats hope to slice into the GOP's margins, particularly in racially-diverse rural counties. Warnock has emphasized the plight of rural Black farmers. Abrams prominently highlights rural hospital closures as she pitches her plan to expand Medicaid.
Elections may hinge on the suburbs, but candidates need every vote
Youth organizer Maggie Bell appreciates the specific challenges this region faces. She also says the rural South is more diverse and vibrant than outsiders may imagine.
Bell graduated in the spring from Albany State University, a historically Black college.
"When people think of rural voters, they think of farmers, white people," Bell says, as Albany State's Marching Rams band parades by. "But really, there are Black people down here – Black people who want to be part of the election process, but they don't get a knock at their door."
Bell feels the weight of history in Albany, too. In 1961, Black residents in Albany launched what's considered the country's first mass civil rights movement to desegregate an entire city.
Bell says she's optimistic about what can happen as voters in this stretch of Georgia harness their power. And she says campaigns in other states should take note, as Democrats nationwide have struggled to win rural voters.
"Pay attention to these counties," she says. "Because once you engage and mobilize Black and brown people in these counties, you will actually see your work come to fruition."
This fall will be another test. Two months out, Abrams is trailing Kemp in polls. Warnock is slightly ahead of Walker in averages.
Both races are extremely tight.
On Election Night, cable TV anchors will spend a lot of time zooming in on their touch-screen maps on metro Atlanta, picking apart the returns from counties like Fulton, Cobb, Gwinnett and DeKalb.
But Bell still believes organizers have to work for every vote, especially in counties like hers, and especially in a state where election outcomes have become famously close.
Copyright 2022 90.1 WABE
|
https://www.wyomingpublicmedia.org/2022-09-12/georgias-rural-black-voters-helped-propel-democrats-before-will-they-do-it-again
| 2022-09-12T11:09:42Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention MINISO Group Holding Limited ("MINISO") (NYSE: MNSO) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded MINISO securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with MINISO's October 2020 initial public offering.
If you suffered a loss on your investment in MINISO, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/miniso-mnso-lawsuit-loss-submission-form?prid=31519&wire=4
ABOUT THE ACTION: The class action against MINISO includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) defendants and other undisclosed related parties owned and controlled a much larger amount of MINISO stores than previously stated; (2) as a result, MINISO concealed its true costs; (3) the Company did not represent its true business model; (4) defendants, including the Company and its chairman, engaged in planned unusual and unclear transactions; (5) as a result of at least one of these transactions, the Company is at risk of breaching contracts with People's Republic of China authorities; (6) the Company would imminently and drastically drop its franchise fees; and (7) as a result, defendant's statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
DEADLINE: October 17, 2022
Aggrieved MINISO investors only have until October 17, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-miniso-investors-lead-plaintiff-deadline-october-17-2022/
| 2022-09-12T11:09:46Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Missfresh Limited ("Missfresh") (NASDAQ: MF) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of persons who purchased or otherwise acquired Missfresh securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Missfresh's June 2021 initial public offering.
If you suffered a loss on your investment in Missfresh, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Missfresh includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Missfresh provided false financial figures in its registration statement and related prospectus issued in connection with the Company's June 2021 initial public offering; (2) Missfresh would need to amend its financial figures; (3) Missfresh, among other things, had lesser net revenues for the quarter ended March 31, 2021; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared.
DEADLINE: September 12, 2022
Aggrieved Missfresh investors only have until September 12, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-missfresh-investors-lead-plaintiff-deadline-september-12-2022/
| 2022-09-12T11:09:47Z
|
Anti-abortion rights groups say they've been preparing to help women facing unplanned pregnancies through a network of volunteer organizations. Critics say those services come with strings attached.
Copyright 2022 NPR
Anti-abortion rights groups say they've been preparing to help women facing unplanned pregnancies through a network of volunteer organizations. Critics say those services come with strings attached.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/groups-opposing-abortion-are-getting-more-calls-for-help-with-unplanned-pregnancies
| 2022-09-12T11:09:48Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Molecular Partners AG ("Molecular Partners") (NASDAQ: MOLN) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022.
If you suffered a loss on your investment in Molecular Partners, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Molecular Partners includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration ("FDA") was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization ("EUA"); (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) another of the Company's product candidates, MP0310, was less attractive to Molecular Partners' collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company's initial public offer and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
DEADLINE: September 12, 2022
Aggrieved Molecular Partners investors only have until September 12, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-molecular-partners-investors-lead-plaintiff-deadline-september-12-2022/
| 2022-09-12T11:09:54Z
|
A growing number of Republican politicians are moving to penalize Wall Street investors who consider environmental, social and governance (ESG) issues when they decide where to put clients' money.
In Florida, a state board chaired by Gov. Ron DeSantis recently barred investment fund managers and advisors from considering "social, political, or ideological interests" when making decisions for Florida's retirement system. In Texas and West Virginia, GOP leaders say they will block investors from state business who they claim "boycott" the fossil fuel industry. Fifteen other states are considering similar measures. And Republicans have said that if they retake Congress in the midterms, they plan to push federal legislation to curtail investment decisions they attack as "woke."
Anti-ESG Republicans say big financial firms are abusing their power to advance a liberal agenda on issues like diversity, social justice and, especially, climate change.
Many experts disagree, saying Republicans are distorting the goals and strategies of ESG investing.
It's hard for most people to get a clear read of what ESG is amid the overheated rhetoric. Is the idea to bring about social changes that couldn't be achieved at the ballot box? And what does it mean for things like your 401K when investors follow ESG principles?
This FAQ is for anyone who wants to better understand an investing trend that is becoming core to global financial markets and a new battlefront in American politics — including, possibly, in your own state.
What is ESG?
It's probably easiest to think of this as a set of considerations that investors are using to try to understand risks and opportunities that aren't accounted for in traditional financial models.
Climate change is one of the simplest examples: Investors are trying to find out how physical risks from things like rising sea levels and worsening drought could impact a company's operations. For example, does a company rely on water to operate its factories, or to move goods in places like Europe or China where rivers have dried to a trickle this summer?
Investors also want information about "transition risk" — how companies will fare as governments enact policies aimed at cutting emissions and demand grows for things like renewable energy and batteries.
"It's about looking at a business and saying, 'Are they prepared for the climate transition that's coming?'" says Witold Henisz, faculty director of the ESG Initiative at The Wharton School of Business at the University of Pennsylvania. "Some companies are, and some companies aren't. And that tilts your portfolio, it shifts your investment strategy."
ESG is different from impact investing, where the goal is to make money by investing in companies that are trying to achieve certain social or environmental outcomes.
"In our view, ESG is more of a sort of defensive framework," says Kunal Shah, a managing director at iCapital, a financial technology company. "Whereas impact investing ... is focused on investing in companies with a clear mission to make a change to the positive."
Are ESG investors boycotting fossil fuels?
It doesn't look that way. Big banks continue to provide hundreds of billions of dollars in financing to the fossil fuel industry every year. BlackRock, the world's largest asset manager and a favorite target of anti-ESG Republicans, is one of the top shareholders in many leading oil and gas companies.
"ESG isn't about a boycott," says Henisz of the Wharton School. "It's a question of which fossil fuel company do you hold? And how long do you hold them?"
In fact, BlackRock's CEO, Larry Fink, has said he thinks selling off fossil fuel stocks — or divestment — is an ineffective way to fight climate change. Instead, Fink has advocated for engagement, urging shareholders to press fossil fuel executives to be transparent about their plans for the future.
That said, it has gotten more expensive for fossil fuel companies to borrow money in recent years, reflecting the risks those companies face from climate change, says Tensie Whelan, director of New York University's Stern Center for Sustainable Business.
"It's not so much that [lenders are] punishing the companies. They're just saying, 'Hey, there's risk. And just like we would with any other products, we need to financially assess those risks and build them into the cost of credit,'" Whalen says.
Is ESG hurting the financial performance of companies or investors?
It doesn't appear to be.
NYU's Whalen co-authored a report examining the relationship between ESG and financial performance. After reviewing more than 1,000 research papers published between 2015 and 2020, Whalen's team found that corporate sustainability initiatives often seemed to drive better financial performance. They also found that in many cases, using ESG investment strategies appeared to deliver similar or better financial results compared to conventional approaches.
That doesn't mean proponents of ESG investing think it's being done perfectly. ESG disclosures vary from company to company. Ratings agencies that assess the data use proprietary methods, making it hard for investors to know how firms reach their conclusions. And there is growing concern that some asset managers are slapping ESG labels on funds that don't deserve them.
"The problem is we don't have good data," says Henisz of the Wharton School. "And so we struggle to measure whether companies are delivering."
Why is ESG becoming a political fight now?
Observers point to two potential factors, which aren't mutually exclusive.
One is that ESG — and climate considerations more broadly — are becoming ingrained deeply enough in corporate America and financial markets to begin changing the way some industries operate, says Mindy Lubber, CEO of Ceres, a sustainability nonprofit.
Hundreds of companies and investment firms, for example, have now promised to eliminate or offset their greenhouse gas emissions. Only a few years ago, there were hardly any.
The other explanation is that Republicans are trying to score political points ahead of elections.
"Taking climate risk as investment risk is just good business," says Henisz of the Wharton School. "Now, we can argue about how we do it and who does it well and who does it poorly. That's a legitimate argument. [But] the idea that ESG is ideological and not economics is a political argument."
Copyright 2022 NPR. To see more, visit https://www.npr.org.
|
https://www.wyomingpublicmedia.org/2022-09-12/how-esg-investing-got-tangled-up-in-americas-culture-wars
| 2022-09-12T11:09:55Z
|
Drug price reforms passed as part of the Inflation Reduction Act did not solve the problem of skyrocketing costs of insulin. States are taking their own action.
Copyright 2022 NPR
Drug price reforms passed as part of the Inflation Reduction Act did not solve the problem of skyrocketing costs of insulin. States are taking their own action.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/insulin-costs-increased-600-over-the-last-20-years-states-aim-to-curb-the-price
| 2022-09-12T11:09:55Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention NIO Inc. ("NIO") (NYSE: NIO) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 1, 2021 and July 11, 2022.
If you suffered a loss on your investment in NIO, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against NIO includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) NIO pulled forward revenue by selling batteries to a related party, which owned the batteries and managed users' subscriptions; (2) through the related party, NIO also recognized enormous depreciation savings; (3) as a result of the foregoing, the Company's revenue and net loss were overstated; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: October 24, 2022
Aggrieved NIO investors only have until October 24, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-nio-investors-lead-plaintiff-deadline-october-24-2022/
| 2022-09-12T11:10:00Z
|
Outside a dive bar advertising topless dancers on a recent Friday night in North Hollywood, a dancer who goes by her stage name, Reagan, sees her cue.
Before a car full of patrons can enter the parking lot of Star Garden, she cozies up to the driver's side window. She tells the group of four men why the bar — her former workplace — doesn't deserve their business.
"We do want to dance. We love it in there," Reagan tells the friends. But, turning on the flirt, she encourages them to instead dance with her co-workers on the sidewalk. "We're fighting for safer working conditions."
Reagan is among a group of former Star Garden employees who began striking outside the club six months ago. Since then, the dancers have taken their performances outside — picketing, putting on costumed runway shows and deterring customers from entering a space that they say failed to protect them.
They allege that security fails to intervene when belligerent customers threaten and physically assault dancers, that dancers are filmed without consent and that arbitrary rules and quotas govern their job security. After two dancers asked management to take basic measures to address their safety concerns, the dancers say, they were fired in retaliation. Those firings were the final push that drove the group of Star Garden dancers to take the first leap in an effort to unionize.
On March 18, 15 of the club's 23 employees at the time delivered a petition to Star Garden's owners stating their demands. When they attempted to meet with their bosses at the club the next day to discuss their grievances, the dancers said, they were locked out.
NPR spoke to eight dancers for this story, all of whom said that they were contract employees and that they were unfairly terminated for raising safety and privacy concerns with management. They spoke to NPR on the condition that they be identified by only their stage names to protect their safety and privacy. All the dancers said they use the term "stripper" to describe their work and often use the label interchangeably with "dancer."
All the dancers NPR spoke to said conditions are the same if not worse at other clubs. But they describe Star Garden as special in that it's a Lynchian dive bar full of personality and dancer camaraderie. They say that's why they're willing to fight so hard for better working conditions there.
Their approach is a novel one. In August, after several months of striking, the dancers filed for a union election through the Actors' Equity Association, a union that represents actors and stage managers on Broadway and at prominent theater venues. To start the unionization process, Actors' Equity lawyers will have to convince the National Labor Relations Board that the locked-out dancers were employees who were wrongfully terminated.
Andrea Hoeschen, the union's general counsel, said it's clear that strippers need the protections afforded by a union for the same host of reasons as do actors and stage managers.
"Safety onstage, safe backstage areas, sanitary backstage areas, having the employer take some responsibility for the behavior of audience members, making sure people aren't filmed or harassed by audience members, and that when any of those problems arise, that there is accountability on the part of the employer," Hoeschen told NPR.
If the dancers are successful, the Star Garden workers will become the only strippers in the U.S. to be represented by a union, according to Actors' Equity, which represents more than 51,000 workers.
They're not the first group of strippers to take the union path. The Star Garden dancers take direct inspiration from a unionization effort 25 years ago led by strippers at the Lusty Lady, a defunct peep show in San Francisco that unionized when the strippers joined the Service Employees International Union.
Many of the Star Garden dancers say a strip club run as a co-op is the ultimate goal — which is just what the Lusty Lady strippers did when they bought out the venue in 2003. But rising rent prices and the lure of online pornography made it difficult to keep the lights on, forcing the club to shut down in 2013.
The Star Garden dancers' effort is part of a larger movement in recent months by workers who are seeking unionization for better labor protections.
"I definitely see it as an aftershock of COVID," Reagan said. "People going back to work are just realizing what they're worth and realizing what they deserve."
The club's owners, Stepan "Steve" Kazaryan and Yevgenya "Jenny" Kazaryan, have not responded to multiple calls from NPR about the allegations described by the dancers. Joshua Kaplan, a lawyer reportedly representing the club, has not responded to multiple contact attempts.
For now, the dancers will be out on the sidewalk, trying to upset the club's bottom line.
More often than not, the dancers say, their deterrence tactics work to turn away business. But that one car of friends ended up going into the club that night.
Reagan shrugged: "Everyone needs a different touch," she said.
Reagan (she/her)
When the COVID-19 pandemic forced Star Garden to close in 2020, Reagan, like many workers, took her business online. She and her fellow dancers started hosting virtual shows.
"It was like a revelation," Reagan said. "We realized that we have the know-how, the tools to create a community and an environment that we feel safe in and that we can perform and make money."
Online, she said, the talent ran the show. The performers could block a customer if they were being harassed, instead of waiting around for security to step in.
The time spent away from the club, she said, was a "wake-up call" to the pervasive safety issues that she said came into sharper focus when she returned.
Reagan said she was fired after standing up for herself to a manager who was joking about a customer killing her.
Now, to stay afloat emotionally and financially, she's continuing to host the virtual performances.
Reagan has been stripping for over a decade. For her, it hasn't been difficult to draw a separation between her private and public-performer lives. That distinction is now becoming muddier, however, as her public profile as an activist melds with her performer persona in the spotlight of the strike.
Outside of stripping, Reagan is a theater performer who is already represented by Actors' Equity. It's serendipitous, she said, that those two worlds are forming one, and it validates her belief that strippers are stage performers.
Wicked (she/her)
Wicked is a self-described theater kid — a performer.
"You are a one-woman show when you're out there to make your money," she said.
And for a while, she truly was. Star Garden hired her in July 2021, and for her first eight weeks, she said, she danced in the club alone. As more strippers got brought on board, she held out hope that club conditions would improve.
The conditions, she said, included holes in the stage, a broken pole, shattered glass on the ground and a general lack of cleanliness. Star Garden owners and managers, who she said also took shifts as bartenders and security guards, didn't rush to address her concerns.
"They filled a lot of roles and cut a lot of corners doing that," Wicked said. "And in cutting so many corners, they made us less safe."
Week by week, month after month, working conditions deteriorated, she said.
"You could tell security, 'This guy just tried to shove his finger in me,' and you'd be met with a blank stare," Wicked said. "That happened to me multiple times."
Feeling that they couldn't rely on security, the dancers warned and protected each other from customers and management.
After two dancers were fired in the span of a couple of days, the Star Garden strippers felt they were running out of options. They presented their petition to management and took to the picket line when barred from reentering the club.
The support of the nonprofit Strippers United and, now, Actors' Equity has been critical to keeping their momentum going, Wicked said.
"We made it five months, which in labor terms is colossal," she said in August. "It's a very long time to continue picketing and continue staying strong on these lines."
Selena (she/her) and Tess (she/they)
When she wears her hair down, Selena often gets compared to the late Tejano pop star Selena Quintanilla, so choosing a stage name to "represent the queen herself" was an obvious choice.
Selena started dancing two years ago. A difficult financial situation had left her living out of her car, and she felt like stripping could offer the flexibility to pay her bills and still go to school.
"I could take a week off dancing because I was focused on [finals] week, and I've never had any job do that before," she said.
Her new job also allowed her to explore different sides of herself.
"I'm very masc outside of being a stripper," she explained. "As soon as I step into the strip club, I can be as femme as I want. It's really liberating and really beautiful to be in an environment where that's appreciated."
Selena landed at Star Garden in January, becoming its only Latina dancer. That didn't immediately raise red flags — it meant good money. But the more she talked to her Star Garden co-workers, most of whom were white, the more she felt uncomfortable with how her new employers seemed to be tokenizing her.
And slowly, she said, the things she valued most about her career as a stripper — the freedom, the independence, the self-expression — started eroding. In March, Selena hit a breaking point.
She said she was fired, with no clear explanation why, after asking a customer to stop filming one of her co-workers.
Striking and organizing takes a huge toll, especially as one of the few people of color on the team, she said.
Tess is no stranger to these feelings and financial hardship. Tess started dancing at Star Garden years ago, when it was under different ownership. Then, after a three-year hiatus from the stripping scene, she returned last August.
"The money was good," they said. "But then, weird things started happening."
For example, she said, Jenny Kazaryan would close down the stage show if the strippers were not selling enough lap dances. When you do that at a stage club, Tess explained, part of the clientele is going to get up and leave.
In February, they fell off the pole during a performance — a combination of circumstances, they said, that included an unkempt stage and a lack of rags to clean off the pole between dancers. Jenny's son drove Tess to the hospital, but she never received any sort of compensation or financial support. Tess said management didn't give her a copy of the contract she signed at hiring, so she didn't know whether she was entitled to any benefits or protections.
A few weeks later, they showed up in a sling to sign the petition for improved safety.
Now, Tess financially supports her family through several streams of income. But they make it out to the picket line as much as possible and take pride in producing and performing in stripper co-op shows. She also runs the strike's Twitter account.
Like Selena, Tess, who is of Asian descent, is one of a few people of color in their movement. That's because nearly all the Star Garden dancers are white and none are Black — a fact that has resulted in a backlash against the strippers' unionization effort,
The dancers say they saw Black dancers being turned away and allege that Star Garden's management engaged in racist hiring practices.
"That wasn't up to us. It's not our fault that the club hired light-skinned and white women, because that's what they wanted," Tess said.
She said she is dedicated to centering Black voices in the Star Garden unionization effort. That could be achieved in part, she says, by including anti-racist hiring language in their union contract so that Star Garden would hire Black dancers. She says it would also include listening to Black strippers and sex-work activists who have criticized the unionization effort, and then taking those concerns into consideration moving forward.
At the end of the day, Selena said, she enjoys being a stripper — and wants to do it safely at Star Garden. Stripping has taught her to take better care of herself, physically and mentally, and she's proud to wear the title.
"It's a way to take out the stigma, and it seems like people are so afraid to say 'stripper' because it feels like there is a negative connotation or a cynical meaning to it," she said. "But this is what a stripper looks like, you know? And the more that we say it, the more normalized it will become."
Charlie (she/they)
Charlie started working at Star Garden in January. Though it wasn't Charlie's first strip club, bar managers assumed she was a "baby stripper" — and soon she started navigating what she calls "arbitrary rules and quotas" that she said she'd never experienced at other workplaces.
To get scheduled on weekend shifts, which made the most money, she said club owners required that she work on weeknights too. This meant wrapping up her 9-to-5, rushing to the club by 6 p.m. and dancing until close at 2 a.m.
"It did awful things to my brain and my body," they explained. "And I would go to work in the morning and just do it all again because they told me I had to, and I didn't want to lose my job."
When the club locked out the dancers, Charlie once again found herself bouncing between gigs to stay afloat. She said stripping helps her find her voice, to speak up for herself and communicate with her clients about their physical and emotional needs.
"[Stripping] is so incredibly multifaceted. It's a performance from all parties, not just us," they said. "The men that come in here, they get to be a different version of themselves."
It's not just Star Garden that's riddled with workplace safety concerns, they said. There aren't better options in the industry — the only solution she sees, for now, is to unionize, she added.
Copyright 2022 NPR. To see more, visit https://www.npr.org.
|
https://www.wyomingpublicmedia.org/2022-09-12/meet-the-strippers-working-to-unionize-a-los-angeles-dive-bar
| 2022-09-12T11:10:01Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Stitch Fix, Inc. ("Stitch Fix") (NASDAQ: SFIX) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of purchasers of Stitch Fix Class A common stock between December 8, 2020, and March 8, 2022, inclusive.
If you suffered a loss on your investment in Stitch Fix, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: According to the filed complaint, Stitch Fix made numerous false and misleading statements to investors concerning the synergy between the Company's Fix and Freestyle programs, and repeatedly denied claims that the Freestyle program could cannibalize the Company's legacy Fix business. Specifically, Stitch Fix repeatedly assured investors that the Company's Freestyle business was "an additive experience" and "complementary" to the Fix business, that "the combination of those two things will allow us to address many more types of clients," and that "we see solid growth in both sides of the business." In truth, Stitch Fix concealed that these programs were not complementary or additive. Stitch Fix knew that the Freestyle program would be much preferred to the Company's original Fix model and that the Freestyle program would inevitably cannibalize the Company's legacy Fix business.
Aggrieved Stitch Fix investors only have until October 25, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-stitch-fix-investors-lead-plaintiff-deadline-october-25-2022/
| 2022-09-12T11:10:07Z
|
Ukrainian forces reclaimed a wide swath of territory in the northeast. China's president will make his first trip out of China in over two years. U.S. states aim to lower the high cost of insulin.
Copyright 2022 NPR
Ukrainian forces reclaimed a wide swath of territory in the northeast. China's president will make his first trip out of China in over two years. U.S. states aim to lower the high cost of insulin.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/news-brief-ukraine-recaptures-key-territory-xi-putin-meeting-insulin-prices
| 2022-09-12T11:10:08Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention TG Therapeutics, Inc. ("TG Therapeutics") (NASDAQ: TGTX) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 15, 2020 and May 31, 2022.
If you suffered a loss on your investment in TG Therapeutics, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against TG Therapeutics includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.
Aggrieved TG Therapeutics investors only have until September 16, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-tg-therapeutics-investors-lead-plaintiff-deadline-september-16-2022/
| 2022-09-12T11:10:14Z
|
NPR's Bob Boilen and Stephen Thompson were straining to hear folk singer Laura Gibson. They invited her to perform at NPR's headquarters at Boilen's desk. The 1,000 Tiny Desk Concert is out Monday.
Copyright 2022 NPR
NPR's Bob Boilen and Stephen Thompson were straining to hear folk singer Laura Gibson. They invited her to perform at NPR's headquarters at Boilen's desk. The 1,000 Tiny Desk Concert is out Monday.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/npr-musics-tiny-desk-concerts-followed-a-visit-to-a-noisy-bar-at-sxsw-in-austin
| 2022-09-12T11:10:14Z
|
Count me among those who rely on NPR reporter Nina Totenberg's crystalline explanations for all things legal, especially Supreme Court arcana — no one is clearer and more incisive.
Now comes Totenberg with Dinners with Ruth, a memoir ostensibly about her long friendship with the late Justice Ruth Bader Ginsburg.
"Ostensibly" because this book is not quite about dinners with Ruth; it is a memoir about Nina Totenberg, a jaunt through her captivating life and career, nose for the jugular, and forthrightness about her joys and sorrows. The book opens a window into the history of professional women in the workplace, as well as the trajectory of the Supreme Court over the last 50 years. Above all, Totenberg's book is about the abiding importance of friendship.
Totenberg, born in 1944, came of age as a journalist in the early days of NPR, and together with her radio "sisters" Linda Wertheimer, and the late Cokie Roberts, formed a formidable reporting triumvirate. They breached a man's world in a time when it was not the norm to become friends with fellow women at work. But they did; they needed each other both personally and professionally.
Without graduating college, Totenberg developed singular legal expertise through her dogged efforts to get to know the people who make law. Her lengthy in-person interviews — obtained through grit and perseverance — are core to her strategy: forming bonds with everyone in the legal workplace, including elevator operators and receptionists, who are often invaluable sources.
A foodie acquainted with great home cooks — many of them men — Totenberg attends and gives parties, lunches, and dinners with anyone who's anyone in the nation's capital. Her star-studded social life is germane to the way she transacts business, and she partakes gleefully. As she namedrops her way through the politically well-connected and influential, Totenberg brings the charm and self-deprecation to keep us turning pages.
For Totenberg, friendship is a skill she had to learn. This book shows how and from whom she learned it. True friendship, she believes, is "sustained by a certain level of humility." A detached retina she suffered as a young reporter in 1976 sobered Totenberg to the necessity of foul weather friends. As she embarks on her friendship education, Totenberg becomes more deeply engaged with those in her circle who require tending — Cokie Roberts as she fought terminal breast cancer over long years, Ruth Ginsburg whose bouts of cancer plagued her for decades until her death in 2020, and the wrenching series of health crises that embattled Totenberg's first husband, former Colo. Sen. Floyd Haskell, over the last four years of his life.
Totenberg "met" Ruth Bader Ginsburg in 1971, when Ginsburg was a Rutgers law professor who had just authored the ACLU brief arguing that women were entitled to the same equal protection guarantees as men under the 14th Amendment. This winning argument, "which may seem obvious today," was anything but. Totenberg phoned to ask Ginsburg to explain her legal theory, and Ginsburg spent an hour walking Totenberg through the intricate framework of her argument. Totenberg emerged from the conversation "like a goose that had just been stuffed in preparation for foie gras."
Their relationship became closer when Ginsburg was appointed to the U.S. Court of Appeals for the D.C. Circuit in 1980 and she and her husband, Marty, moved to Washington. Totenberg had recently married her first husband, former Sen. Haskell. Marty Ginsburg was a marvelous cook; Totenberg remembers what the two couples ate and where they ate it over many years. Not only was Ginsburg an engaging dinner companion, she was also a critical legal source, a wise personal counselor, and a fashion consultant. "Shopping with Ruth was a humbling experience. She was petite and beautiful and could wear almost anything."
Totenberg became a household name during the now infamous hearings for Justice Clarence Thomas' nomination to the Supreme Court. She broke the story of accusations that Thomas had sexually harassed law professor Anita Hill while she was in his employ. In light of the tsunami of criticism and threats, Totenberg insisted that NPR retain the legendary First Amendment lawyer Floyd Abrams to ensure that she could protect her sources. For a time, Totenberg was the story, "Nothing I'd ever done in my life, good, bad, or indifferent, went unexamined."
Totenberg takes readers inside her romance and second marriage to surgeon David Reines — Justice Ginsburg officiated — and explores the impact on the justice (not much) of Ginsburg's anomalous rise to pop stardom as RBG. Although Reines was a critical medical advisor to Ginsburg's family, Totenberg says he kept related knowledge and advice confidential from his wife.
Also in the book, Justice Ginsburg goes to the opera with her ideological opponent Justice Antonin Scalia — and Totenberg dines with Supreme Court justices even as, or because, she covers them. If all of this triggers uncomfortable ethical questions, Totenberg doesn't agree; as an equal-opportunity-reporter and social animal, she'll sit down with anyone, no matter their political or ideological persuasion.
In Dinners with Ruth, readers will learn about the critical role Ginsburg played in expanding women's rights before and after she was on the bench. Totenberg's look behind Ginsburg's legendary reserve is of special interest. But let's face it, this memoir is a romp through Washington's glitterati — Republican and Democrat alike — penned by a reporter who thrives on it. What's not to enjoy about being in Totenberg's sparkling company for an entire book?
Martha Anne Toll is a DC based writer and reviewer. Her debut novel, Three Muses, won the Petrichor Prize for Finely Crafted Fiction and is forthcoming from Regal House Publishing in September.
Copyright 2022 NPR. To see more, visit https://www.npr.org.
|
https://www.wyomingpublicmedia.org/2022-09-12/nprs-nina-totenberg-offers-a-window-into-her-world-in-dinners-with-ruth
| 2022-09-12T11:10:15Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention TuSimple Holdings Inc. ("TuSimple") (NASDAQ: TSP) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all persons who: (a) purchased or otherwise acquired TuSimple common stock pursuant and/or traceable to documents issued in connection with TuSimple's April 15, 2021 initial public offering; and/or (b) that purchased or otherwise acquired TuSimple securities between April 15, 2021 and August 1, 2022, both dates inclusive.
If you suffered a loss on your investment in TuSimple, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against TuSimple includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) TuSimple's commitment to safety was significantly overstated and defendants concealed fundamental problems with the Company's technology; (ii) TuSimple was rushing the testing of its autonomous driving technology in order to deliver driverless trucks to the market ahead of its more safety-conscious competitors; (iii) there was a corporate culture within TuSimple that suppressed or ignored safety concerns in favor of unrealistically ambitious testing and delivery schedules; (iv) the aforementioned conduct made accidents involving the Company's autonomous driving technology more likely; (v) the aforementioned conduct invited enhanced regulatory scrutiny and investigatory action toward the Company; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: October 31, 2022
Aggrieved TuSimple investors only have until October 31, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-tusimple-investors-lead-plaintiff-deadline-october-31-2022/
| 2022-09-12T11:10:20Z
|
The U.S. Open tennis tournament ended Sunday and history was made, as several competitors broke ground as the firsts, while 27-year veteran Serena Williams punctuated her career by participating in what is thought to be her last match.
Serena Williams may bid the sport farewell
Williams, a 23-time Grand Slam winner, said in August that she will likely be "evolving away" from tennis after this year's U.S. Open, but stopped short of saying she would retire. On Sep. 2, she was defeated by Ajla Tomljanovic 7-5, 6-7 (4), 6-1 in the third round.
"Clearly, I'm still capable. ... (But) I'm ready to be a mom, explore a different version of Serena," she said. "Technically, in the world, I'm still super young, so I want to have a little bit of a life while I'm still walking."
When asked if she would consider coming back to the sport, she said, "I don't think so, but you never know."
Carlos Alcaraz is the youngest to be ranked No. 1 in men's tennis
Carlos Alcaraz, of Spain, defeated Casper Rudd 6-4, 2-6, 7-6 (1), 6-3 in the final round of the U.S. Open Sunday, earning his first Grand Slam title and becoming the youngest man to be ranked No. 1 in the world at 19 years old.
This year's U.S. Open is Alcaraz's eighth major tournament appearance.
Frances Tiafoe is the first American man to reach the semifinals in years
Frances Tiafoe, from Maryland, became the first American man to make it to the semifinals of the U.S. Open in 16 years.
He defeated veteran Rafael Nadal in the fourth round before beating Andrey Rublev 7-6 (3), 7-6 (0) last Wednesday. Though Tiafoe was eliminated by Alcaraz Friday.
The last American man to reach the U.S. Open semifinals was Andy Roddick, who was eliminated by Roger Federer in 2006. Roddick is also the last American man to win a Grand Slam singles tournament since winning the U.S. Open in 2003.
Ons Jabeur is the first African and Arab woman to reach the finals
Ons Jabeur of Tunisia became the first African and Arab woman to reach the finals at the U.S. Open.
She beat Caroline Garcia 6-1, 6-3 on Sept. 9, marking her second consecutive appearance at a Grand Slam title match. She was also a finalist at Wimbledon two months ago.
Automation could replace humans in deciding out-of-bounds balls
While human officiants are typically used to determine if a ball was inbounds or not, computers could now be up for the job.
Optical technology made the decision in some of the U.S. Open matches.
Immediately after impact, a recorded voice shouts out the call: "FAULT!" for a wayward serve; "OUT!" for a ball that lands long or wide in a rally.
By replacing human line judges with the optical system called Hawk-Eye Live, "we're providing the players a fairer playing field with a lot more integrity, a much higher accuracy call," says Sean Cary, who oversees officiating for the United States Tennis Association (USTA), which runs the U.S. Open.
Copyright 2022 NPR. To see more, visit https://www.npr.org.
|
https://www.wyomingpublicmedia.org/2022-09-12/serena-and-a-tournament-of-firsts-how-this-years-u-s-open-made-history
| 2022-09-12T11:10:22Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Tuya Inc. ("Tuya") (NYSE: TUYA) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all persons or entities who purchased Tuya American Depositary Shares in or traceable to the Company's March 2021 initial public offering.
If you suffered a loss on your investment in Tuya, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Tuya includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (a) a material portion of Tuya's China-based customers were engaged in the widespread and systematic manipulation of reviews and product offerings in violation of Amazon.com's terms of use; (b) prior to the initial public offering, a consumer investigation and data breach had exposed an illicit fake review scheme being perpetrated by many of Tuya's clients, among others, which included, inter alia, the exposure of 13 million records of organized fake review scams linked to over 200,000 Amazon account profiles; (c) as a result of (a) and (b) above, there was a substantial risk that a material portion of Tuya's significant customers would be barred from using Amazon.com's platform, negatively impacting Tuya's business, revenue, earnings, and prospects; and (d) as a result of (a)-(c) above, the registration statement's representations regarding Tuya's historical financial and operational metrics and purported market opportunities and expected growth did not accurately reflect the actual business, operations, financial results, and trajectory of the Company at the time of the initial public offering, and such statements were materially false and misleading and lacked a reasonable factual basis.
DEADLINE: October 11, 2022
Aggrieved Tuya investors only have until October 11, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-tuya-investors-lead-plaintiff-deadline-october-11-2022/
| 2022-09-12T11:10:26Z
|
With two months to go until the midterms, tech companies are getting ready: rolling out fact checks, labeling misleading claims and setting up voting guides.
The election playbooks being used by Facebook, Twitter, Google-owned YouTube and TikTok are largely in line with those they used in 2020, when they warned that both foreign and domestic actors were seeking to undermine confidence in the results.
But the wave of falsehoods in the wake of that election – including the "big lie" that Donald Trump won – has continued to spread, espoused by hundreds of Republican candidates on ballots this fall.
That's left experts who study social media wondering what lessons tech companies have learned from 2020 – and whether they are doing enough this year.
The host of election-related announcements in recent weeks add up to a "business as usual" approach, said Katie Harbath, a former elections policy director at Facebook who's now a fellow at the Bipartisan Policy Center.
The return of familiar playbooks
The platforms are largely taking a two-pronged approach: tamping down misleading or outright false claims, and boosting authoritative information from local election officials and reputable news sources.
In the first case, all four major platforms are leaning on labels to flag falsehoods and, in many cases, direct users to fact checks or accurate information. In some cases, users won't be able to share labeled posts and the platforms themselves won't recommend them. YouTube, Facebook and TikTok also say they will remove some specific false claims about voting and threats of violence.
Platforms are often hesitant to spell out exactly how they enforce their policies to avoid giving bad actors a roadmap. The range of approaches to labeling and removal also illustrates the fraught balance the companies try to strike between letting users express themselves and protecting their platforms from being weaponized – all while facing scrutiny from politicians on both sides of the aisle.
Policies diverge most when it comes to political ads. Twitter and TikTok have banned ads for candidates and about political issues. Google and Facebook both allow them, requiring disclosure of who pays for them. Facebook is once again freezing all new political ads in the week before Election Day but will allow existing ads to continue running.
But defining when an ad or issue qualifies as political isn't straightforward, leaving gaps that experts worry could be exploited.
"It's actually a quite confusing landscape because there is no regulation, there are no standards these companies have to follow," Harbath said. "Everyone is just making the choices that they feel are best for them and their company."
On the flip side, all four platforms are highlighting features that aim to put more reliable information in users' feeds, such as providing information about candidates, voter registration and when and where to cast ballots. That information will also be available in Spanish across platforms.
Branching out beyond English is an important step towards addressing a "glaring omission" in previous elections, said Zeve Sanderson, executive director of New York University's Center for Media and Politics.
In the final days of the 2020 election, Latino voters were targeted with social media posts discouraging them from voting, according to voting rights activists and disinformation experts.
Evidence is mixed on how well platform policies work
Even as social media companies double down on their 2020 tactics, researchers say it's not always clear how effective their interventions are.
In the case of labels, there is mixed evidence about whether they help dispel false impressions, or if, in some cases, they may inadvertently encourage people to double down on those beliefs.
Last year, researchers at NYU analyzed what happened after Twitter labeled some of Trump's tweets before and after the 2020 election as containing misinformation. They found the labeled messages spread even further on Twitter, and also took off on other platforms including Facebook, Instagram and Reddit.
The platforms have given small peeks into what they know about how well their tools work. Twitter has said after it redesigned its misleading information labels last year, more people clicked through to read accurate information.
Facebook, meanwhile, says it will be more choosy about what it labels, after users said labels were "over-used" in 2020. "In the event that we do need to deploy them this time round our intention is to do so in a targeted and strategic way," Nick Clegg, president of global affairs at Facebook parent Meta, wrote in a blog post.
But for NYU's Sanderson, that raised more questions the company has not answered.
"What was the feedback? From which users? What do the words 'targeted' and 'strategic' mean?" he said. "It would be really helpful for them to contextualize it within actual details of what their internal research has found."
Moving beyond misinformation "Whac-A-Mole"
What's more, it's hard to know how well the companies enforce their policies – which Harbath, the former Facebook official, described as a "huge gap."
"The companies are like, 'These are our policies, these are all the things that we're going to do.' But they don't talk enough about, 'Okay, but humans are fallible. The technology is not 100% perfect,'" she said.
In the hours after polls closed in 2020, Trump supporters began rallying online under the slogan "Stop the Steal," Facebook removed the first Stop the Steal group on its platform quickly, under its rules against casting doubt on the legitimacy of the election and calling for violence. But more groups kept popping up – and Facebook was unable to keep up.
Researchers warn that the 2020 approach to election falsehoods doesn't address the reality of 2022. Tech companies approach elections as discrete events, typically putting policies in place and then turning them off when the voting is over – even though false claims don't end when the ballots are counted.
"The companies should be doing a lot more to have an always-on policy, because clearly these topics around the integrity of elections are certainly staying in the lexicon and the conversation well beyond Election Day," Harbath said.
The big challenge is for companies to move beyond being reactive and find ways to prevent their platforms from being used to spread these kinds of falsehoods so widely in the first place.
"When it comes to election misinformation and disinformation, platforms are kind of just playing Whac-A-Mole – trying to get on top of something before something else arises," said Spandi Singh, a policy analyst at the Open Technology Institute at the think tank New America.
Editor's note: Facebook parent Meta pays NPR to license NPR content.
Copyright 2022 NPR. To see more, visit https://www.npr.org.
|
https://www.wyomingpublicmedia.org/2022-09-12/social-media-firms-are-prepping-for-the-midterms-experts-say-it-may-not-be-enough
| 2022-09-12T11:10:28Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Attention Weber Inc. ("Weber") (NYSE: WEBR) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Weber Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's August 2021 initial public offering.
If you suffered a loss on your investment in Weber, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Weber includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Weber was reasonably likely to implement price increases; (2) as a result, consumer demand for Weber's products was reasonably likely to decrease; (3) due to the resulting inventory buildup, Weber was reasonably likely to run promotions to "enhance retail sell through"; (4) the foregoing would adversely impact Weber's financial results; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
DEADLINE: September 27, 2022
Aggrieved Weber investors only have until September 27, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong
|
https://www.whsv.com/prnewswire/2022/09/12/class-action-alert-law-offices-vincent-wong-remind-weber-investors-lead-plaintiff-deadline-september-27-2022/
| 2022-09-12T11:10:33Z
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.